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1. Summary 
Tumor formation can be linked to the misregulation of the developmentally important 
Hedgehog (Hh) signaling pathway. In general, Hh signaling is initiated by the secretion of Hh 
ligands. This is followed by the binding of Hh to the 12-pass transmembrane protein Patched 
(Ptch). Ptch normally represses the activity of the 7-pass transmembrane protein Smoothened 
(Smo). Binding of Hh to Ptch inhibits Ptch, thereby relieving the inhibition of Smo. Smo 
translocates into the primary cilium and mediates the activation of the members of the Glioma 
associated (Gli) family of transcription factors, leading to the transcription of target genes. 
The Smo protein harbors two domains important for its regulation by small-molecules, the 
seven-transmembraneous domain (7TM) and the N-terminal, extracellular cysteine-rich-
domain (CRD). The mechanism by which Ptch inhibits Smo is not completely understood. A 
direct interaction of Ptch and Smo has been excluded and the inhibition is rather based on a 
catalytic mechanism involving small-molecule signal transmitters that are secreted in a Ptch-
mediated manner. Indeed, recent data suggested that Ptch may secrete Smo inhibiting sterol-
derivatives. 
Our recent data demonstrated that the secosteroid and hormonally active form of 
vitamin D3 (vitD3), calcitriol, inhibits Hh signaling at the level of Smo and reduces tumor 
growth in murine models for basal cell carcinoma (BCC) and rhabdomyosarcoma (RMS). In 
the present study we aimed to enhance the calcitriol-mediated antitumoral effects on BCC 
with antifungal azoles. Indeed, itraconazole (ITZ) but not the well-known Smo inhibitor 
cyclopamine (CP) strongly enhances calcitriol-mediated antitumoral response of the murine 
BCC cell line ASZ001. Furthermore, the combined effects of ITZ and calcitriol were not 
mediated by an enhanced bio-availability of calcitriol but by a synergistic inhibition of Hh 
signaling. Despite these promising in vitro data, no cooperative antitumoral effects of 
calcitriol and ITZ were achieved in two mouse models for BCC.  
Based on the findings that calcitriol inhibits Hh signaling at the level of Smo we next 
hypothesized that calcitriol is secreted by Ptch and investigated if calcitriol plays a key role in 
the physiological regulation of Hh signaling. Media transfer experiments and mass 
spectrometric analyses show that Ptch is indispensable for calcitriol release from the cells, but 
not for its synthesis. Second, generation of concentration-response curves, direct-competition 
assays and analyses of mutant Smo variants revealed that calcitriol does neither bind to the 
7TM nor the CRD of Smo. This is in line with the current opinion that Ptch-mediated 
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inhibition of Smo is unlikely to occur at the 7TM or the CRD. Taken together, our results 








Cancer is one of the most leading causes of death in humans. In 2012 approximately 
14 million people diseased and 8 million patients died due to cancer-related diseases (WHO 
2015). Most cancer types are characterized by malignant growth and spreading of metastases, 
which finally lead to organ failure and the death of the patients.  
Throughout all cancers the group of the non-melanoma skin cancers (NMSC) or 
“white skin cancers” has the highest incidence. The majority of NMSC are basal cell 
carcinomas (BCC) and squamous cell carcinoma (SCC). BCC is the most commonly 
diagnosed cancer among Caucasians (reviewed in (Berking et al. 2014; Lomas et al. 2012)) 
with a lifetime risk of about 30 %. Yearly incidence rates differ from 70-80 new cases per 
100,000 people in Germany, 115 per 100,000 in the UK and up to 2 per 100 in Australia, 
(Basset-Seguin et al. 2015; Roewert-Huber et al. 2007) with an estimated 2-3 fold increase 
throughout the last three decades. BCCs metastasize only in 0.0028 % to 0.55 % of all cases 
(Berking et al. 2014; Walling et al. 2004). But the fact that the tumors usually develop at sun-
exposed skin like the head and neck region, especially the face, often complicates the surgical 
removal of those tumors (Roewert-Huber et al. 2007). Intermittent UV exposure, fair skin, 
male gender as well as geographically high UV radiation (e.g. Australia) significantly 
enhance the risk for BCC development (Roewert-Huber et al. 2007; Walling et al. 2004). 
Apart from epidemiological risk factors, patients who suffer from the rare heritable, 
autosomal-dominant basal cell nevus syndrome or Gorlin-Goltz-syndrome develop multiple 
BCCs throughout their lifetime (Epstein 2008; Gorlin and Goltz 1960). Genetically, this 
syndrome is caused by mutations in the Patched1 gene (PTCH) located on the human 
chromosome 9q22 (Hahn et al. 1996; Johnson et al. 1996). Since the PTCH protein negatively 
regulates the activity of the Hedgehog (HH) signaling pathway, mutations in PTCH result in 
excessive HH pathway activation (Epstein 2008; Goodrich et al. 1997). Upon this discovery it 
was revealed that the majority of sporadic BCCs (90 %) display PTCH mutations and 
frequently show biallelic loss of PTCH (reviewed in (Albert and Hahn 2014; Epstein 2008)). 
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2.2. Hedgehog	signaling	
The Hh signaling pathway was initially described by the two Nobel laureates 
Nüsslein-Volhard and Wieschaus (Nusslein-Volhard and Wieschaus 1980). They showed that 
this pathway is implicated in body patterning, since the loss of the Hh gene led to a hedgehog-
like appearance of the mutant Drosophila melanogaster (D. melanogaster) larvae (Nusslein-
Volhard and Wieschaus 1980). Additional screens revealed other components of this pathway, 
like the Hh receptor Ptch, its interacting partner Smo, the kinase Fused (Fu) and the 
transcription factor cubitus interruptus (Ci) (reviewed in (Albert and Hahn 2014; van den 
Brink 2007)).  
In mammals, Hh signaling also regulates embryonic development and its 
misregulation leads to congenital malformations like cyclopia or holoprosencephaly (Briscoe 
and Therond 2013; Hooper and Scott 2005). In the adult organism, the pathway is mainly 
silenced except for its implication in cell differentiation and proliferation, stem cell 
maintenance and regenerative responses after injury (Hooper and Scott 2005; Machold et al. 
2003; Shin et al. 2011). Recently, Teperino et al. showed that Hh signaling is also involved in 
the control of metabolism (Teperino et al. 2014). Although the Hh pathway is evolutionary 
conserved (Roberg-Larsen et al. 2014), it displays a far more complex picture in mammals. In 
contrast to D. melanogaster three Hh genes and proteins are known in vertebrates: Sonic 
(Shh), Indian (Ihh) and Dessert hedgehog (Dhh) (Echelard et al. 1993; Varjosalo and Taipale 
2008) of which Shh is the best characterized and most broadly expressed (Varjosalo and 
Taipale 2008). Furthermore, two Ptch homologues, Ptch and Patched2 (Ptch2), are known in 
vertebrates. Of those, Ptch is better characterized and considered to be the key player in Hh 
signaling regulation. Finally, the D. melanogaster transcription factor Ci has three 
orthologues in mammals: glioma-associated oncogene family members 1, 2 and 3 (Gli1, Gli2 
and Gli3 (see below)).  
Although the exact interplay of the pathway components still contains many gaps, it is 
established that in the absence of Shh, the receptor Ptch inhibits its interacting partner Smo by 
a hitherto unidentified, indirect mechanism (Fig. 1 A). Upon binding of Shh to Ptch, the Hh 
pathway is activated by internalization of the Ptch protein (Denef et al. 2000) which leads to a 
loss of Smo inhibition (Fig. 1 B). Subsequently, Smo facilitates the translocation of the Gli 
transcription factors into the nucleus where they induce the expression of Hh signaling target 
genes (Fig. 1B) (Hooper and Scott 2005). Known target genes include the proto-oncogene N-
Myc (Kenney et al. 2003) and the cell-cycle regulators Cyclin D1 and Cyclin D2 (Kenney and 
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Rowitch 2000). Additionally, activation of Hh signaling leads to the expression of the 
pathway components Ptch (Marigo and Tabin 1996) and Gli1 (Lee et al. 1997). This results in 
a negative and positive feedback loop, respectively. Constitutively active Hh signaling can 
lead to or is observed in a variety of cancers. This overactivation can be caused by many 
different mechanisms like overexpression of the Hh ligands (Oro et al. 1997), mutational 
inactivation of the tumor suppressor Ptch (Goodrich et al. 1997; Hahn et al. 1996), activating 
mutations of Smo (Lam et al. 1999) or overexpression of the Gli transcription factors (Gli 
TFs) (Nilsson et al. 2000) (Fig. 1C). 
 
 
Figure 1: Schematic representation of the Hh signaling pathway. The figure shows a simplified model of the 
Hh pathway, displaying the four key components Patched (Ptch), Smoothened (Smo), Glioma-associated 
oncogene (Gli) and Sonic Hedgehog (Shh). (A) In the absence of its ligand Shh, the Ptch receptor inhibits its 
interaction partner Smo by an unknown, catalytic mechanism. This results in the inactivation or proteolytic 
cleavage of the Gli transcription factors (Gli TF) resulting in the formation of the Gli repressor forms (Glirep), 
which repress target gene expression. (B) Shh binding inhibits Ptch, which suspends the inhibition of Smo. Smo 
then activates a signaling cascade finally resulting in the activation or inhibition of the proteolytic cleavage of 
the Gli TF leading to the stabilization of Gli activator forms (Gliact). This terminally leads to the translocation of 
the Gli TFs into the nucleus, where they induce target gene expression. (C) In cancer, Hh signaling can be 
misregulated by several mechanisms, including overexpression of Shh, inactivating mutations in Ptch, activating 
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2.2.1. The Ptch/Smo-Axis 
A direct interaction of Ptch and Smo during Hh signaling has been excluded because a 
1:45 ratio of Ptch to Smo expression constructs resulted in a nearly 80 % reduction of Smo 
activity, despite a great excess of Smo protein (Taipale et al. 2002). Thus, the Ptch/Smo 
interplay is rather based on a catalytic mechanism (Taipale et al. 2002) by which small-
molecule signal transmitters are secreted in a Ptch-mediated manner that regulate Smo action 
(Bijlsma et al. 2006; Nachtergaele et al. 2012; Taipale et al. 2002). This hypothesis is 
strengthened by the structures of both proteins and the finding that several small molecules 
can bind to and modulate Smo action (see below). 
The 12-transmembrane protein Ptch consists of two intracellular regions at the C- and 
N-terminus, two extracellular loops for Hh ligand binding (Briscoe et al. 2001) as well as a 
sterol-sensing-domain (SSD) in the transmembraneous region (Strutt et al. 2001). 
Interestingly, SSDs are usually found in proteins that are involved in sterol-level sensing 
(Kuwabara and Labouesse 2002) such as bacterial transporters of the resistance-nodulation-
division (RND) family (Taipale et al. 2002) and the Niemann-Pick C1 disease protein (NP-
C1) (Carstea et al. 1997; Loftus et al. 1997). In accordance with other proteins of the RND 
family Ptch also forms stable trimers (Lu et al. 2006). Moreover, Ptch is involved in 
cholesterol transport (Bidet et al. 2011). Thus, a function of Ptch as a small-molecule 
transporter seems reasonable. Nevertheless a distinct molecule that is released by Ptch and 
exerts Smo-modulating function has not been discovered so far.  
The Ptch-interacting partner Smo (Fig. 2) belongs to the superfamily of G-protein 
coupled receptors (GPCR) (Wang et al. 2013) and contains a 7 transmembrane domain 
(7TM), an intracellular C-terminal tail (CTD, C-terminal domain) and an extracellular N-
terminal region harboring a cysteine-rich-domain (CRD) (Nachtergaele et al. 2013; Nedelcu 
et al. 2013). 
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Figure 2: Schematic structure of Smo. The Smo protein consists of a C-terminal tail, a 7-transmembrane 
domain (7TM) and an N-terminal cysteine-rich domain (CRD). The 7TM contains the binding pocket for the 
majority of modulators like cyclopamine, the Smo agonist SAG, the Smo antagonist SANT1 or the FDA-
approved drug for advanced BCC vismodegib (Chen et al. 2002a; Chen et al. 2002b; Wang et al. 2014). The 
CRD harbors the binding pocket for oxysterols like 20(S)-hydroxy cholesterol (McCabe and Leahy 2015; 
Nachtergaele et al. 2012; Nachtergaele et al. 2013; Nedelcu et al. 2013). 
Several small-molecule modulators of Smo have been identified in the last years. The 
first discovered was the plant alkaloid cyclopamine (CP), a teratogen derived from the corn 
lily that inhibits Smo by binding to its 7TM (Chen et al. 2002a). This binding mechanism is 
employed by the majority of other Smo-modulators, which often are structurally related to 
sterols (reviewed in (Briscoe and Therond 2013)) such as the antagonists SANT-1 and SANT-
2 (Ali et al. 2013), the FDA-approved drug for the treatment of advanced BCC vismodegib 
(Sekulic et al. 2012) and the Smo agonist SAG (Ali et al. 2013). Interestingly, the recent 
crystallization of the Smo heptahelical bundle with 5 modulators bound, including the above-
mentioned drugs CP, SAG and SANT-1, showed that they all act on the same site (McCabe 
and Leahy 2015; Wang et al. 2014).  
Additionally, the antifungal drug itraconazole (ITZ) inhibits Hh signaling at the level 
of Smo by a mechanism distinct from that of CP (Kim et al. 2010). It also has been published 
that it does not interact with the 7TM (Kim et al. 2010) or the CRD of Smo (Nachtergaele et 
al. 2012). In contrast, oxysterols, oxidized derivatives of cholesterol like 25-hydroxy 
cholesterol or 20(S)-hydroxycholesterol (20S)OHC, exclusively bind to the CRD of Smo and 
activate Hh signaling (Corcoran and Scott 2006; Dwyer et al. 2007; Michoel and 
Nachtergaele 2012; Nachtergaele et al. 2013; Nedelcu et al. 2013).  
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A recent study suggests that Ptch mediates the secretion of Smo-inhibitory 3β-
hydroxysteroids, like 7-dehydrocholesterol (7-DHC) and vitamin D3 (vitD3). Interestingly,  
7-DHC is the immediate precursor of vitD3 (Bijlsma et al. 2006)(reviewed in (Albert and 
Hahn 2014; Roberg-Larsen et al. 2014)). Furthermore, vitD3 effectively inhibits Hh signaling 
at the level of Smo, apparently by binding to the 7TM (Bijlsma et al. 2006; Tang et al. 2011). 
Recently, we showed that the secosteroid and hormonally active form of vitD3, calcitriol 
(1α,25(OH)2-vitamin D3), also inhibits Hh signaling in vitro and acts anti-tumorigenic in vivo 
by inhibiting Hh signaling also at level of Smo (Uhmann et al. 2011a; Uhmann et al. 2012). 
Importantly, calcitriol is active in the nanomolar range, whereas its progenitor vitD3 is needed 
at a 100-1,000-fold higher concentration (Bijlsma et al. 2006; Tang et al. 2011; Uhmann et al. 
2011a). 
 
2.2.2. The Gli-transcription factors 
Structurally, all three mammalian Gli proteins contain a conserved DNA binding 
domain that recognizes the same Gli binding site (GliBS) (5’-GACCACCCA-3’ (Hallikas et 
al. 2006; Winklmayr et al. 2010)), a C-terminal activation domain, and an N-terminal 
repressor domain in case of Gli2 and Gli3 (Briscoe and Therond 2013). In the inactive state of 
the Hh pathway Gli2 and Gli3 are proteolytically processed into N-terminal-truncated 
transcriptional repressors (Gli2rep and Gli3rep) (Aberger et al. 2012; Roberg-Larsen et al. 
2014). Upon Hh signaling activation (e.g. Shh binding to Ptch) Smo, probably indirectly, 
resolves the Gli-inhibitory complex, which results in accumulation of the Gli2 and Gli3 
activator forms (Gli2act and Gli3act) (Roberg-Larsen et al. 2014) and the transcription of target 
genes, including Gli1 and Ptch (Ruiz i Altaba et al. 2007). Although the Gli proteins 
apparently have overlapping functions it is generally acknowledged that Gli2 mainly acts as a 
transcriptional activator whereas Gli3 mainly represses target gene expression (Briscoe and 
Therond 2013). The major target of the Hh pathway Gli1 seems to have only minor influence 
on the direct regulation of Hh target gene expression. It rather enhances the responses of the 
other Gli proteins (Briscoe and Therond 2013). Furthermore, it has been reported that Gli1 
can regulate its own expression by activating Gli3act that is only a weak transcriptional 
activator by itself (Roberg-Larsen et al. 2014). Nevertheless, the balance of Gliact/Glirep, 
referred to as the “Gli code”, seems to be highly dependent on the cellular and species-
specific context (Aberger and Ruiz 2014; Ruiz i Altaba et al. 2007) and can also be controlled 
independently of Smo by non-canonical regulation (Aberger and Ruiz 2014). 
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VitD3 is a steroidal hormone that is synthesized by keratinocytes in the skin via UV-B-
mediated photo conversion of 7-DHC. Alternatively, it can be absorbed from dietary sources 
(e.g. fatty fish, liver cod oil), although this only accounts for a small amount (DeLuca 2004). 
Bound to vitamin D binding proteins (DBP) vitD3 circulates through the body and is delivered 
to the liver where it is hydroxylated by the enzyme 25-hydroxylase (encoded by the gene 
CYP27A1) resulting in the formation of the major circulating form 25-hydroxy vitamin D3 
(25(OH)D3) (Christakos et al. 2010). DBP-bound 25(OH)D3 is transported to the kidney 
where it is hydroxylated to calcitriol by the 1α-hydroxylase (encoded by the gene CYP27B1) 
(Chen et al. 2012; Christakos et al. 2010). Aside from the kidney, the 1α-hydroxylase is also 
present in a plethora of other tissues, including keratinocytes of the skin (Vantieghem et al. 
2006). Therefore calcitriol-synthesis from its direct precursor 25(OH)D3 is not only possible 
in the kidney, but throughout most tissues of the body. The degradation of 25(OH)D3 and 
calcitriol is catalyzed by the 24-hydroxylase (encoded by the gene CYP24A1). Thus, the 
amount of calcitriol is limited by both calcitriol catabolism and decreased amounts of 
25(OH)D3 available for calcitriol synthesis (Christakos et al. 2010; Deeb et al. 2007)(Fig. 3).  
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Figure 3: Schematic representation of the metabolism of calcitriol. Calcitriol (1α,25(OH)2 vitamin D3), the 
hormonally active form of vitamin D3 (vitD3) is synthesized from its progenitor 25-hydroxy vitamin D3 
(25(OH)D3) by the enzyme 1α-hydroxylase, which is transcribed from the Cyp27b1 gene. Upon binding of 
calcitriol to the vitamin D receptor (Vdr), the Vdr forms heterodimers with the retinoid-X-receptor α (RXRα) 
and the complex translocates into the nucleus (not depicted) and regulates gene expression. One negatively 
regulated target is the Cyp27b1 gene, thus representing a negative feedback loop. One positively regulated target 
is the Cyp24a1 gene. This gene encodes for the enzyme 24-hydroxylase, which can add a hydroxyl-group at the 
C24-position of both 25(OH)D3 and calcitriol. This leads to the degradation of both compounds, thus, offering 
another negative feedback loop. 
Calcitriol acts via the genomic and the non-genomic signaling pathways. The activity 
of both pathways is mediated by binding of calcitriol to the vitamin D receptor (Vdr). Non-
genomic calcitriol signaling is mediated by a membrane-bound Vdr that leads, among others, 
to the accumulation of Ca2+ in the cells (Bikle 2011b). In contrast, genomic calcitriol 
signaling is mediated by an intracellular Vdr that form heterodimers with the retinoid X 
receptor α (RXRα) (MacDonald et al. 1993). This complex translocates to the nucleus and 
regulates target gene expression by binding to specific vitamin D response elements (VDRE) 
(Campbell et al. 2010; Haussler et al. 1998). VDREs can activate or inhibit target gene 
expression. Active genomic Vdr signaling inhibits the expression of genes for calcitriol 
synthesis (e.g. CYP27B1, (Takeyama et al. 1997)) and activates Vdr expression (Costa and 
Feldman 1987; Wiese et al. 1992) as well as the expression of genes responsible for calcitriol 
degradation such as CYP24A1 (Ohyama et al. 1994). Thus, CYP24A1 expression is widely 
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used as a surrogate marker for active Vdr signaling (Deeb et al. 2007; Haussler et al. 1998). 
The activation of genomic Vdr signaling also induces anti-tumorigenic effects, like inhibition 
of proliferation and stimulation of differentiation processes and apoptosis (Bikle 2011a; Bikle 
2011b). Known target genes are cell cycle inhibitors like CDKN1A (encoding for cyclin-
dependent kinase (CDK) inhibitor p21) or growth inhibitors like transforming growth factor β 
(TGF-β) (Bikle 2012; Deeb et al. 2007; Yang et al. 2001).  
In fact, the anti-tumorigenic effects of vitD3 are known for several decades. The first 
evidence came from a study in 1980, showing that increased sunlight exposure reduces the 
risk of colon cancer (Garland and Garland 1980). Subsequent studies revealed that low 
25(OH)D3 serum levels are associated with increased cancer risk and mortality (Deeb et al. 
2007) and that calcitriol inhibits proliferation and induces differentiation of keratinocytes by 
changing the expression levels of Vdr target genes (Trump et al. 2010). Moreover Vdr-/- mice 
are prone to chemically induced tumorigenesis (Zinser et al. 2005; Zinser et al. 2002) 
indicating a tumor-preventive function of Vdr signaling. Interestingly, human BCCs as well 
as other human tumors frequently overexpress the VDR (Majewski et al. 1994; Shabahang et 
al. 1996) or the CYP24A1 gene (Albertson et al. 2000).  
Up to date several studies were conducted to analyze the anti-tumoral effects of 
calcitriol or synthetic derivatives. Indeed, calcitriol or synthetic derivatives can stimulate 
differentiation of leukemia cell lines (Munker et al. 1996; Tanaka et al. 1982). Additionally it 
can inhibit proliferation and induce cell cycle arrest of SCC cell lines in vitro and in vivo 
(Akutsu et al. 2001; Prudencio et al. 2001).  
 
2.4. Crosstalk	between	Hh	and	Vdr	Signaling	
As mentioned above Vdr-/-mice are prone to chemically induced carcinogenesis 
(Zinser et al. 2005; Zinser et al. 2002). Remarkably, the induced tumors overexpress key 
components of active Hh signaling like Ptch and Gli1 (Teichert et al. 2011). Furthermore, 
human BCCs, which are characterized by constitutively active HH signaling, overexpress the 
VDR and CYP24A1 genes (Mitschele et al. 2004)(reviewed in (Albert and Hahn 2014)). These 
findings are suggestive for a potential crosstalk between Hh and Vdr signaling. Other hints for 
a crosstalk of the two pathways came from the hereditary diseases Smith-Lemli-Opitz 
syndrome (SLOS), and the SLOS-like diseases lathosterolosis and desmosterolosis, which are 
caused by a defective cholesterol metabolism. SLOS is caused by mutations of the 7-
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dehydrocholesterolreductase (DHCR7), which catalyzes the synthesis of 7-DHC, the direct 
precursor of vitD3 (Cunniff et al. 1997; Opitz et al. 1987; Tint et al. 1994; Wassif et al. 1998), 
whereas lathosterolosis and desmosterolosis are caused by mutations in 3β-Hydroxysteroid-
δ5-desaturase (SC5D) (Brunetti-Pierri et al. 2002) and 3β-Hydroxysterol-δ24-reductase 
(DHCR24) (FitzPatrick et al. 1998; Waterham et al. 2001), respectively. These enzymes are 
involved in cholesterol metabolism that can also lead to the synthesis of vitD3 (Bijlsma et al. 
2006; Porter and Herman 2011). Analyses of Dhcr7-/- and Sc5d-/- mice, SLOS-like disease 
models , demonstrated low cholesterol levels and/or accumulation of different metabolites in 
these animals in tissues and structures, which require functional Hh signaling (Bijlsma et al. 
2006; Cooper et al. 2003; Cunniff et al. 1997; Opitz et al. 1987; Porter and Herman 2011; 
Tint et al. 1994; Wassif et al. 1998). Accordingly, mutations in the Hh signaling pathway lead 
to similar symptoms (Cooper et al. 2003; Porter 2006). 
However, the exact crosstalk between Hh and Vdr signaling is still a topic with many 
open questions. Recently it has been demonstrated that Hh signaling is enhanced by 
cholesterol and that inhibition of Ptch upon Hh binding decreased the cellular cholesterol 
efflux (Bidet et al. 2011). Furthermore, oxysterols can mediate Smo activity by binding to its 
CRD (Corcoran and Scott 2006; Dwyer et al. 2007; Nachtergaele et al. 2012; Nachtergaele et 
al. 2013; Nedelcu et al. 2013). This led to the hypothesis that the Ptch/Smo interaction might 
involve oxysterols or sterol-like compounds. Moreover, 7-DHC and vitD3 seem to be released 
from the cell in a Ptch-dependent manner and, strikingly, these molecules efficiently inhibit 
Hh signaling (Bijlsma et al. 2006). Accordingly, our lab showed that calcitriol also inhibits 
Hh signaling in murine mouse models for BCC and RMS (Uhmann et al. 2011a; Uhmann et 
al. 2012) and that this inhibition occurs independently of the Vdr and supposedly at the level 
of Smo (Uhmann et al. 2011a)(reviewed in(Albert and Hahn 2014)).  
Due to the facts that a) Ptch shows similarities to oxysterol transporters (Carstea et al. 
1997; Loftus et al. 1997), b) Ptch-/-cells are unable to secrete Hh-inhibitory factors (Bijlsma et 
al. 2006; Uhmann et al. 2011a), c) Smo activity is controllable by oxysterols (Corcoran and 
Scott 2006; Dwyer et al. 2007; Nachtergaele et al. 2012) and that d) the natural occurring 
cholersterol-derivative calcitriol efficiently inhibits Hh signaling (this work and (Uhmann et 
al. 2011a; Uhmann et al. 2012)) we have speculated that calcitriol might be an endogenous 
mediator of the Ptch/Smo interaction and Smo inhibition.  
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3. Aim of the study 
The main aim of this study was to unravel the interaction of the Hh and Vdr signaling 
pathways, to validate calcitriol-based therapies for the treatment of Ptch-associated BCCs in 
mouse models and to investigate the molecular basis for calcitriol-mediated Smo inhibition.  
Based on the findings that the VDR is frequently upregulated in human BCCs the first 
goal was to investigate if Vdr expression is regulated by Hh signaling. Hence, Gli3 was 
overexpressed in wt Ptch and Ptch-/- cells as well as in Gli1/Gli2 double knockout cells  
(Gli1-/-/Gli2-/-) and the expression of the Vdr was quantified by real-time PCR. Additionally, 
luciferase reporter assays were performed to analyze if the Gli TFs regulate the expression of 
the Vdr promoter. 
Previous data from our lab showed that calcitriol exhibits antitumoral potential and 
inhibits Hh signaling and tumor growth of Ptch-associated BCC and RMS. Thus, the second 
project focused on the enhancement of calcitriol-mediated anti-tumorigenic potential by 
combining calcitriol with the previously described Smo inhibitor family of azoles. As model 
systems the BCC cell line ASZ001, murine BCC-bearing skin biopsies and transgenic BCC-
bearing mice were used. 
Finally, we investigated whether calcitriol might represent a potential endogenous 
inhibitor of Hh signaling and analyzed the potential role of Ptch in calcitriol release and/or 
metabolism of calcitriol in wt Ptch, Ptch-/- and a Ptch-deficient BCC cell line from vitD3 and 
25(OH)D3. Experimental procedures covered medium transfer experiments using reporter 
assays and mass spectrometry. Furthermore, the mode of action of calcitriol on Smo was 
investigated by performing functional and direct competition assay using other Smo 
modulators and mutant Smo variants. 
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4. Materials 
4.1. Technical equipment 
Table 1: List of laboratory equipment 
Equipment Supplier 
(CO2-) Incubator (6000, BBD 6220) Kendro Laboratory Products GmbH, Hanau 
1260 HPLC System Agilent Technologies, Santa Clara, CA, USA 
-80 °C Freezer (MDF-U71V) Sanyo Electric Co., Ltd., Japan 
8-well pipette Costar, Corning Incorporated, Corning, USA 
96-Well Tabless Tube Holder Phenomenex Inc., Aschaffenburg 
Accu-jet Brand GmbH & Co. KG, Wertheim 
Agarose gel electrophoresis chamber Peqlab Biotechnology GmbH, Erlangen 
Arium® 611 VF water purification system Sartorius, Göttingen 
Autoclave (sanoclav) W. Krannich GmbH & Co. KG, Göttingen 
Biophotometer (6131) Eppendorf AG, Hamburg 
Bunsen burner (Gasprofi 2 scs) WLD-TEC GmbH, Göttingen 
Centrifuges (Biofuge pico, fresco, primo, Multifuge 3LR)  
Kendro Laboratory Products GmbH, Hanau, 
Germany 
Clean bench (Euroflow Class IIA) Clean Air Techniek bv, Woerden, Netherlands 
Cold light source (KL 200) Schott Glas, Mainz 
Cryolys temperature controller BERTIN Corp, MD, USA 
Digital Monochrome Printer P91D Mitsubishi, Ratingen 
Digital Photocamera (PowerShot G2) Canon Deutschland GmbH, Krefeld 
FACScalibur BD Biosciences GmbH, Heidelberg 
Fluorchem Q Fisher Scientific GmbH, Schwerte 
Freezer (-20 °C) Liebherr GmbH, Ochshausen 
Fridge (4 °C) Robert Bosch GmbH, Stuttgart 
Heating block (Thermomixer) Eppendorf AG, Hamburg 
Heating stirrer (MR 3000/3001) Heidolph Instruments, Schwabach 
High-precision scales (Sartorius Basic plus) Sartorius AG, Göttingen 
Homogenizer (Miccra D-1) 
ART Prozess- & Labortechnik GmbH & Co. 
KG, Müllheim 
HTC-xt autosampler CTC Analytics AG, Zwingen, Switzerland 
Hybridization oven (HB-1000 Hybridizer) UVP, Inc., Upland, USA 
Inverse microscope with fluorescence filter (Axiovert 25, 
FilterSet 43, 01, 09) 
Carl Zeiss Jena GmbH, Jena 
Liquid nitrogen tank L’air liquid S.A., Paris, France 
LSR II BD Biosciences GmbH, Heidelberg 
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Equipment Supplier 
Luminometer (Synergy Mx) BioTek Instruments, Inc., Bad Friedrichshall 
Mastercycler ep gradient S Eppendorf AG, Hamburg 
Mercury-short-arc lamp (HBO 50W/AC) OSRAM AG, Munich 
Microtome (HN 40) 
New Brunswick Scientific GmbH, Nürtingen, 
Germany 
MilliQ-Devices Sartorius Stedim Biotech GmbH, Göttingen 
Mini centrifuge Carl Roth GmbH & Co. KG, Karlsruhe 
Mr. FrostyTM Freezing Container  Thermo Fisher Scientific GmbH, Schwerte 
Multipette Eppendorf AG, Hamburg 
Nitrogen-driven Positive Pressure-96 Processor  Water GmbH, Eschborn 
One-channel pipettes Eppendorf AG, Hamburg 
Paraffin dispenser (Dispenser PAG 12) MEDITE GmbH, Burgdorf 
pH-meter (inoLab pH Level 1) WTW GmbH, Vienna, Austria 
PCR machine Eppendorf, Hamburg 
PCR-machine (PrimusHT) MWG AG Biotech, Ebersberg 
PCR-machine (Robocycler Gradient 96 Combo) Stratagene, Amsterdam Zuidoost, Netherlands 
Power supply for electrophoresis Peqlab Biotechnology GmbH, Erlangen 
Precellys 24 tissue homogenizer BERTIN Corp, MD, USA 
Qtrap5500 mass spectrometer  AB SCIEX, Framingham, MA, USA 
Sequencer (ABI 3500 XL) Life Technologies GmbH, Darmstadt 
Shaking incubator New Brunswick Scientific GmbH, Nürtingen 
Shaking waterbath (1083) GFL mbH, Burgwedel 
Stereo microscope (Stemi 2000) Carl Zeiss Jena GmbH, Jena 
Sterile bench (Euroflow class IIA) Clean Air Techniek bv, Woerden, Netherlands 
Tank for liquid nitrogen L’air liquid S.A., Paris Cedax, France 
TaqMan (ABI Prism 7900HT) Life Technologies GmbH, Darmstadt 
Thermoprinter (DPU-414) Eppendorf AG, Hamburg 
Tissue embedding and rehydrating machine (TP 1020) Leica Microsystems GmbH, Bensheim 
Trans-Blot SD semi-dry transfer cell Bio-Rad Laboratories GmbH, Munich 
UV transilluminator 
Intas Science Imaging Instruments GmbH, 
Göttingen 
Vacuum pump Schütt Labortechnik, Göttingen, Germany 
Vortexer-Genie 2 Scientific Industries, Inc., Woburn, USA 
Weighing scale (Sartorius Basic plus) Sartorius AG, Göttingen 
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4.2. Consumables 
Table 2: List of consumable materials 
Consumer good Supplier 
1.5 ml reaction tubes Ochs GmbH, Bovenden/Lenglern 
1.5 ml Safeseal Microtubes Sarstedt AG & Co., Nürnberg 
13 ml tubes Sarstedt AG & Co., Nürnberg 
15 ml tubes Greiner Bio-One GmbH, Frickenhausen 
2.0 ml reaction tubes Sarstedt AG & Co., Nürnberg 
384-well Optical Reaction Plate Life Technologies GmbH, Darmstadt 
50 ml tubes Greiner Bio-One GmbH, Frickenhausen 
96-Well Assay Plate Costar, Corning Incorporated, Corning, USA 
96-Well Optical Reaction Plate Life Technologies GmbH, Darmstadt 
Balance oeco multi-function paper inapa tecno, Hamburg 
BD DiscarditTM II (2, 10, 20 ml) BD Biosciences GmbH, Heidelberg 
BD Microfine + Demi BD Biosciences GmbH, Heidelberg 
BD Plastipak BD Biosciences GmbH, Heidelberg 
BD Plastipak 1 ml Sub-Q BD Biosciences GmbH, Heidelberg 
Blotting paper (GB 33 B003) Heinemann Labortechnik GmbH, Duderstadt 
Cell culture dishes, 35 mm, 50 mm, 100 mm (Nunclon 
Surface) 
Nunc GmbH & Co.KG, Wiesbaden 
Cell scraper Sarstedt AG & Co., Nürnberg 
Coverslips Menzel GmbH & Co.KG, Braunschweig 
Cryo Pure Sarstedt AG & Co., Nürnberg 
Cuvettes (UVette) Carl Roth GmbH & Co. KG, Karlsruhe 
Disposable needles (Sterican Ø 0,45 x 12 mm) B. Braun Medical AG, Emmenbrücke, Germany 
Eppendorf Combitips Plus/Advanced (0.2, 0.5, 2.5, 5, 
10, 25, 50 ml) 
Eppendorf AG, Hamburg 
Filter tips (10 μl) Sarstedt AG & Co., Nürnberg 
Filter tips (100 μl, 200 μl, 1000 μl) Kisker Biotech GmbH & Co. KG, Steinfurt 
Flow Cytometry Tube Sarstedt AG & Co., Nürnberg 
Fluted filters Sartorius AG, Göttingen 
Framestar 384 4titude Ltd., Berlin 
Glassware Schott AG, Mainz 
Hyperfilm ECL Amersham Biosciences Europe GmbH, Freiburg 
Milliporefilter (Nuclepore Track-Etch Membran) Whatman GmbH, Dassel 
Miscroscope slides (SuperFrost Plus) Menzel GmbH & Co.KG, Braunschweig 
MultiScreenHTS-HV plate Millipore GmbH, Schwalbach am Taunus 
Neubauer counting chamber Brand GmbH & Co KG, Wertheim 
Nitrocellulose membrane(Hybond ECL) GE Healthcare Europe GmbH, Freiburg 
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Consumer good Supplier 
NuPAGE Novex 4 – 12 % Bis-Tris Midi Gel Invitrogen GmbH, Karlsruhe 
Pasteur pipettes Brand GmbH & Co.KG, Wertheim 
PCR-Reaction tubes (ThermoFast 96, nonskirted, natural 
domed cap strips) 
Sarstedt AG & Co., Nürnberg 
Petri dishes Ochs GmbH, Bovenden/Lenglern 
Pipette tips (10 μl, 200 μl) Ochs GmbH, Bovenden/Lenglern 
Pipette tips (1000 μl) Sarstedt AG & Co., Nürnberg 
Pipette tips (20 µl) Sarstedt AG & Co., Nürnberg 
Precellys ceramic kit 1.4/2.8 mm 2.0 ml tubes  BERTIN Corp, MD, USA 
QPCR Adhesive Clear Seal 4titude Ltd., Berlin 
Scalpel blade #10, #24 Aesculap AG & Co.KG, Tuttlingen 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml, 50 ml) Sarstedt AG & Co., Nürnberg 
SOC Medium Invitrogen GmbH, Karlsruhe 
Strata-X 33 µm polymeric reversed phase (30 mg/ml) 
tubes 
Phenomenex, Aschaffenburg 
Sterile filter Omnilab-Krannich, Göttingen 
Terumo Syringe 30, 50 ml Terumo Medical Corp., Elkton, MD, USA 
Tissue Culture Plate 24-Well Sarstedt AG & Co., Nürnberg 
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4.3. Reagents and chemicals 
The chemicals not listed below were purchased from AppliChem GmbH, Darmstadt, 
Carl Roth GmbH & Co. KG, Karlsruhe, or from Sigma-Aldrich Chemistry GmbH, Steinheim. 
Table 3: List of used reagents and chemicals 
Chemicals and reagnets  Supplier 
0.9 % NaCl Solution B. Braun Melsungen AG, Melsungen 
25-hydroxy vitamin D2 [25,26,27-
13C3] Cambridge Isotope Laboratories, Andover, MA, USA 
50 bp, 100 bp plus and 1 kb DNA Ladder Fermentas GmbH, St. Leon-Rot 
Agarose Bio-Budget Technologies GmbH, Krefeld 
Ampuwa Fresenius Kabi Deutschland GmbH, Bad Homburg, 
Boric acid MP Biomedicals LLC, Illkirch, France 
Deoxyribonucleotide triphosphate (dNTP) Roche Diagnostics GmbH, Mannheim 
Dithiotreitol, 100mM (DTT) Invitrogen GmbH, Karlsruhe 
DNase/Rnase-free water GIBCO Invitrogen GmbH, Karlsruhe 
Ethidium bromide (0.07 %) inna-TRAIN-Diagnostics, Kronberg 
EtOH 99 % J.T. Baker B.V., Deventer, Netherlands 
EtOH 99 % denatured CVH Chemie-Vertrieb GmbH & Co. Hannover KG, Hannover 
Formamide Acros Organics b.v.b.a, Geel, Belgium 
Glycergel mounting medium Dako GmbH, Hamburg 
Hematoxiline MAYER Medite GmbH, Burgdorf 
Ketanest S Pfizer Pharma GmbH, Karlsruhe 
Matrigel BD Biosciences GmbH, Heidelberg 
NBT/BCIP Roche Diagnostics GmbH, Mannheim 
NuPAGE MES SDS Running Buffer, 20 x Invitrogen GmbH, Karlsruhe 
PBS-Tablets GIBCO Invitrogen GmbH, Karlsruhe 
Pertex mounting medium Medite Medizintechnik GmbH, Burgdorf 
Ringer Lactate B. Braun Melsungen AG, Melsungen 
RNase-, DNase free destilled water GIBCO Invitrogen GmbH, Karlsruhe 
Rompun (Xylazin 2 %) Bayer AG, Leverkusen 
SeeBlue® Plus2 Pre-Stained Standard Invitrogen GmbH, Karlsruhe 
Sporanox Sporanox, Eurim-Pharm Arzneimittel GmbH 
TRIzol Reagent Invitrogen GmbH, Karlsruhe 
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4.4. Kits and ready-to-use reaction Systems 
Unless stated otherwise, all kits and ready-to-use reaction systems were used as 
described in manufacturer’s instructions. 
Table 4: List of kits and ready-to-use reaction systems 
Reaction system Supplier 
Amersham ECL Plus™ Western Blotting Detection Reagents GE Healthcare Europe GmbH, Freiburg 
BigDye Terminator v3.1 Cycle Sequencing kit Life Technologies GmbH, Darmstadt 
Cell Proliferation ELISA, BrdU (chemiluminscent) Roche Diagnostics GmbH, Mannheim 
Dual-Luciferase® Reporter Assay System Promega GmbH, Mannheim 
Pierce BCA Protein Assay kit Fisher Scientific GmbH, Schwerte 
Platinum SYBR Green qPCR SuperMix-UDG with ROX Invitrogen GmbH, Karlsruhe, Germany 
PureLink®HiPure Plasmid Filter Midiprep kit  Invitrogen GmbH, Karlsruhe 
PureLink®HiPure Plasmid Midiprep Invitrogen GmbH, Karlsruhe 
QIAEX II Gel Extraction kit Qiagen GmbH, Hilden 
QuantiTect SYBR Green RT-PCR Qiagen GmbH, Hilden 
Quikchange II Site-Directed Mutagenesis kit Agilent Technologies, Santa Clara, CA, USA 
Quikchange II XL Site-Directed Mutagenesis kit Agilent Technologies, Santa Clara, CA, USA 
RNeasy Fibrous Tissue kit Qiagen GmbH, Hilden 
Roti-Fect transfection reagent Carl Roth GmbH & Co. KG, Karlsruhe 
SuperScriptII® Reverse Transcriptase Invitrogen GmbH, Karlsruhe 
MolTaq Taq-Polymerase Molzym GmbH & Co. KG, Bremen 
TRIzol reagent Life Technologies GmbH, Darmstadt 
 
4.5. Buffers and solutions 
Unless mentioned otherwise, all solutions were prepared using double distilled water 
(ddH2O). 
Table 5: List of buffers and solution and their composition 
Buffer Composition 
6 x SDS loading buffer 
35 % (v/v) Glycerol 
9 % (w/v) SDS 
8.5 % (w/v) DTT 
0.1 % (w/v) Bromphenolblue 
in Upper gel buffer 
Blotting buffer 
6 % (w/v) tris  
3 % (w/v) glycin 
0.075 % (w/v) SDS 
20 % (v/v) methanol 
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Buffer Composition 
Citric Acid buffer, pH6 10 mM sodium citrate pH 6.0 
Cresol 
0.1 % (w/v) Cresol 
Saturated sucrose solution 
Eosin, 1% 
1 % (w/v) Eosin y (water soluble) 
80 % (v/v) ethanol 
LB-agar 
LB-medium 
1.5 % (w/v) agar 
Lysis buffer 
30 mM tris/HCl, pH 8.8 
150 mM NaCl 
1 % (v/v) triton X-100 
10 % (v/v) glycerol 
Protease and phosphatase inhibitors (1 tablet/50 ml) 
500 µM PMSF (added before use) 
2 mM DTT (added before use) 
Lysogeny broth medium (LB-
medium) 
1 % (w/v) bacto-tryptone 
0.5 % (w/v) yeast extract 
1% (w/v) NaCl (pH7.0) 
Paraformaldehyde 
4 % (w/v) paraformaldehyde 
1 x PBS 
PBS (cell culture) 1 PBS tablet ad 500 ml ddH2O 
Phosphate buffered saline solution, 
10x, pH 7,4 (PBS, stock solution) 
1.4 M NaCl 
27 mM KCl 
15 mM KH2PO4 
65 mM Na2HPO4 
Proteinase K 
50 mM tris/HCl pH 8.0 
5 mM EDTA 
40 μg/ml proteinase K 
RIPA-buffer (modified) 
50 mM tris/HCl, pH7.4 
150 mM NaCl 
1 mM EDTA 
1 % (v/v) Nonidet NP-40  
0.25 % (w/v) Na-deoxycholate 
Protease and phosphatase inhibitors (1 tablet/10 ml) 
STE-Buffer 
50 mM tris/HCl pH 8.0 
100 mM NaCl 
1 mM EDTA 
1% (w/v) SDS 
Tris-boric acid-EDTA solution, 
10x (TBE; stock solution) 
890 mM tris/HCl pH 8.0 
730 mM boric acid 
12.5 mM EDTA 
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Buffer Composition 
Tris-buffered saline solution, 10x 
(TBS; stock solution) 
0.5 M tris/HCl pH 7.4 
1.5 M NaCl 
Upper gel buffer 
6 % (w/v) tris , pH 6.8 
4 % (v/v) SDS 
 
4.6. Media 
4.6.1. Media and agar plates for culture of prokaryotic cells 
LB medium and LB agar plates were prepared as described in table 5. After 
autoclaving and cooling to 55°C either 50 µg/ml ampicillin (Carl Roth GmbH, Karlsruhe) or 
25 µg/ml kanamycin (Carl Roth GmbH) were added. Both, media and plates, were stored at 
4°C. 
 
4.6.2. Media and reagents for culture of eukaryotic cells 
Cell culture media and supplements for culture of eukaryotic cell lines are listed in 
table 6. 
Table 6: Cell culture media and supplements for culture of eukaryotic cell lines 
Medium or reagent Supplier 
154CF medium Gibco, Invitrogen GmbH, Karlsruhe 
Blasticidin S hydrochloride (3 mg/ml) Sigma-Aldrich Chemistry GmbH, Steinheim 
DMEM phenol-red free Gibco, Invitrogen GmbH, Karlsruhe 
Dulbecco's Modified Eagle Medium (DMEM) Gibco, Invitrogen GmbH, Karlsruhe 
F12 Nutrient Mix(Ham) Gibco, Invitrogen GmbH, Karlsruhe 
Fetal calf serum (FCS) PAN Biotech GmbH, Aidenbach 
G 418 disulfate salt solution (50 mg/ml) Sigma-Aldrich Chemistry GmbH, Steinheim 
Penicillin (10.000 U/ml)/streptomycin (10 mg/ml) (P/S) PAN Biotech GmbH, Aidenbach 
Puromycin dihydrochloride (10 mg/ml) Sigma-Aldrich Chemistry GmbH, Steinheim 
S.O.C. medium Invitrogen GmbH, Karlsruhe 
Sodium butyrate (100 mg/ml) Invitrogen GmbH, Karlsruhe 
Tetracycline (10 mg/ml) Invitrogen GmbH, Karlsruhe 
Trypsin/EDTA and TrypLE Express Gibco, Invitrogen GmbH, Karlsruhe 
Zeocin™ Selection Antibiotic (100 mg/ml) Life Technologies GmbH, Darmstadt 
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4.7. Biological material 
4.7.1. Bacterial strains and growth 
For transformation and amplification of plasmid DNA chemical competent 
Escherichia coli (E. coli) strain DH5α (Invitrogen GmbH, Karlsruhe) was used. For 
transformation after site-directed mutagenesis (see chapter 5.1.3.6) E. coli XL-10 gold were 
used (Agilent technologies, included in the Quikchange II and Quikchange II XL-site directed 
mutagenesis kits). 
 
4.7.2. Eukaryotic cell lines 
The cell lines used in this thesis are listed in table 7. 





ASZ001 Murine BCC cell line 154CF 
2 % chelexed FCS, 1 % PS, 0.05 mM 
CaCl2 
(So et al. 
2006) 
Gli1-/- Gli2-/- MEF 
DMEM 
(+++) 













kidney cell line 
DMEM 
(+++) 










10 % FCS, 1 % PS, 2µg/ml G418, 








10 % FCS, 1 % PS, 0.4 mg/ml G418 




fibroblast cell line 
DMEM 
(+++) 










10 % FCS, 1 % PS, 10 µg/ml 








10 % FCS, 1 % PS 
(Uhmann et 
al. 2011a) 







10 % FCS, 1 % PS, 0.4 µg/ml G418, 
0.15 mg/ml Zeocin 
(Chen et al. 
2002b) 





Shh light II 
DMEM 
(+++) 
10 % FCS, 1 % PS, 0.4 µg/ml G418, 















Shh light II 
DMEM 
(+++) 
10 % FCS, 1 % PS, 0.4 µg/ml G418, 
0.15 mg/ml Zeocin, 2 µg/ml 
puromycin 
this work 
Smo-/- Smo-deficient MEFs 
DMEM 
(+++) 
10 % FCS, 1 % PS 



















10 % FCS, 1 % PS, 2 µg/ml 
puromycin 
this work 
wt Ptch  
Adult, murine 
fibroblast; parental 
cell line of Ptch-/- 
DMEM 
(+++) 
10 % FCS, 1 % PS 
(Nitzki et al. 
2010) 
*: 1:1 mixture of DMEM (+++) and F12 nutrient mixture (Ham), FCS: fetal calf serum, PS: 
penicillin/streptomycin. (+++): supplemented with 4.5g/l D-Glucose, L-glutamine and Sodium pyruvate; MEF: 
murine embryonic fibroblasts 
 
4.7.3. Mouse lines 
The inbred C57BL/6N mice were bred in-house or purchased from Charles River 
Laboratories, Sulzfeld. Nude mice (NMRI-Foxn1nu) were bred in-house or purchased from the 
department hematology and oncology, University medical center, Göttingen. Ptchflox/flox 
CreERT2+/- mice were bred as described in (Uhmann et al. 2007). Ptchflox/flox mice have loxP 
sites in Ptch introns 8 and 9 that can be recognized by Cre-recombinase (Uhmann et al. 2007). 
R26RCreERT2 mice express a tamoxifen-inducible Cre-recombinase under the control of the 
ubiquitous Rosa26-promoter (Soriano 1999). Initially, the mice were on mixed C57BL/6N x 
BALB/c background (Uhmann et al. 2007; Uhmann et al. 2011a), but backcrossed to a more 
pure C57BL/6N background (this thesis). 
 
4.8. Synthetic DNA-oligonucleotides 
Synthetic DNA-oligonucleotides were purchased from Eurofins MWG Operon, 
Ebersberg and a 100 µM stock solution in ddH2O was prepared for long-term storage at -
80°C. Unless mentioned otherwise 10 µM working solution were used for PCR methods. 
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The following oligonucleotides were used for the genotyping of transgenic mice (table 
8). The specific PCR-protocols are listed in chapter 5.1.2.2. 
Table 8: Gene-specific DNA-oligonucleotides (primers) for mouse genotyping 
Genotype Primer name 
Amplification 
product 





(Uhmann et al. 






AGGAAGTATATGCATTGGCAGGAG (Uhmann et al. 




CCAGGCTAAGTGCCTTCTCTACA (Uhmann et al. 
2007) Ella-Cre-R AATGCTTCTGTCCGTTTGCCGGT 
flox: floxed Ptch-locus, del:Ptch locus after after Cre-mediated recombination, wt: wildtype allele. 
The following primer pair was used to amplify the Gapdh gene as a quality control 
after cDNA synthesis. 
Table 9: List of primers used for semiquantitative RT-PCR 
Application Primer name 
Primer sequence  
(5'-3' orientation) 
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The following oligonucleotides were used for quantification of gene expression levels 
by qRT-PCR (quantitative real-time PCR). 
Table 10: List of primers used for qRT-PCR 
cDNA Primer name Primer sequence (5'-3' orientation) Reference 
murine Gli1  
mGli1-tq-f TACATGCTGGTGGTGCACATG (Ecke et al. 
2008) mGli1-tq-r ACCGAAGGTGCGTCTTGAGG 
murine 18S-rRNA  
18S-fwd CGCAAATTACCCACTCCCG (Nitzki et al. 
2010) 18S-rev2 TTCCAATTACAGGGCCTCGAA 
murine Cyp24a1  
Cyp24a1-F GTGTGGCAAGCGCACACGCT (Uhmann et al. 
2011a) Cyp24a1-R CCGTGACAGCAGCGTACAGT 
murine Gli2  
Gli2-RT-PCR-F GGTCATCTACGAGACCAACTGC (Uhmann et al. 
2011b) Gli2-RT-PCR-R GTGTCTTCAGGTTCTCCAGGC 
murine Gli3  
Gli3F2 GAAGGAACAACCCTAGTCAAGGAGGA 
(Fritsch 2014) 
Gli3-sybrgree R CCAGCGGCACACGAACTCCTTCT 
murine Vdr  
Vdr-F AGAACATGTGCTGCTCATGGC (Uhmann et al. 
2011a) Vdr-R2 TCATCTTGGCGTAGAGCTGGTTGGCT 




murine K1  
mK1-F TCAACGTTGAGGTTGACCCTC (Nitzki et al. 
2010) mK1-R ACCTTCCTTCTGAGGATGCTG 
murine K10  
mK10-F GGATGCTGAAGAGTGGTTCAA (Nitzki et al. 
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The following oligonucleotides were used to generate and verify the plasmids 
pMSCVmSmowt and pMSCVmSmoΔCRD via Sanger sequencing. The primer mSmo_D54_F has 
been described in (Nedelcu et al. 2013). 
Table 11: Primers used to generate and sequence the pMSCV mSmo plasmids 
Application Primer name Primer Sequence (5'-3' orientation) 
amplification of mSmo from 
pHAGE mSmo mCherry 
overlap-extension PCR  
SmoKlon1AF CGCCATCCACGCTGTTTTGACCTCCATTC 
PCR-based amplification of 
mSmo from pHAGE mSmo 
mCherry 
overlap-extension PCR  
SmoKlon 1BF GTACTGCTGGGCCAAACGAGGTAC 
Mutagenesis of pMSCV 
mSmoW113Y to mSmowt 
CRD_mut_F2 CGGCAAGCTCGTGCTCTGGTCCGGCCTC 
CRD_mut_R2 GAGGCCGGACCAGAGCACGAGCTTGCCG 
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4.9. Plasmids 
The following plasmids were either used for transfection of eukaryotic cells or served 
as basis for new plasmids. For details see respective chapters. 
Table 12: Plasmids  
Name Application Supplier/Reference 








(Jacobs et al. 2013) 
pCR 3.1-mGli1 Overexpression of Gli1 (Fritsch 2014) 
pCR 3.1-mGli3 Overexpression of Gli3 (Fritsch 2014) 
pCR3.1 Control plasmid 
Invitrogen GmbH, 
Karlsruhe 
pEGFP-N1 Transfection efficiency 





Agilent Technologies, Santa 
Clara, USA 
pGL-TK 
Positive control for transient 
luciferase-assays 
Promega GmbH, Mannheim 
pHAGEmSmo(W113Y) mCherry Subcloning of mSmo-cherry (Nedelcu et al. 2013) 
pMSCV mSmoW113Y Basis of mSmo variants this work 
pMSCV mSmowt 








Backbone for pMSCV mSmo 
variants 
Clontech Laboratories, Inc., 
Mountain View, USA 
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4.10. Antibodies 
All antibodies were stored as described in the manufacturer’s instruction and diluted as 
described in the following table. 
Table 13: List of antibodies, application and appropriate dilutions 
Immunohistochemistry 
primary antibody dilution (diluent) antigen retrieval 
mAb mouse anti-Ki-67, BD Pharmingen 1:50 (TBS) citric acid pH 6; heat mediated 
   
secondary antibody dilution (diluent)   
En vision+ anti- rabbit/mouse/HRP*; Dako K5007 undiluted   
Western Blot 
primary antibody dilution blocking reagent 
mouse anti-HSC70, Santa Cruz (B-6, sc-7298) 1:10,000 
5 % (w/v) milkpowder in TBS-
tween  
Rabbit anti-c-myc, Santa Cruz (A14) 1:100 
5 % (w/v) milkpowder in TBS-
tween 
    
secondary anitbody dilution diluent 
goat anti-rabbit IgG, HRP-conjugated, Sigma-
Aldrich (A0545,) 
1:5,000 
5 % (w/v) milkpowder in TBS-
tween  
Sheep anti-mouse/HRP, GE Healthcare (NA931) 1:5,000  
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4.11. Software 
The following softwares were licensed and, if possible, used in the most recent 
version. 
Table 14: List of used software 
Name Developer/Reference 
Adobe Photoshop CS5 Adobe Systems Incorporated, San Jose, USA 
Analyst 1.6 AB SCIEX, Framingham, USA 
BD FACSDiva Becton Dickinson GmbH, Heidelberg 
BioEdit Ibis Biosciences, Carlsbad, USA 
Cell F Olympus Europa GmbH, Hamburg, Germany 
CompuSyn (Chou 2005) 
Endnote X5 Thomson ISI ResearchSoft , California, USA 
Fiji (Schindelin et al. 2012) 
FlowJo Tree Star Inc., Oregon, USA 
GraphPad Prism 6 GraphPad Software, Inc., La Jolla, CA, USA 
Intas GDS Intas Science Imaging Instruments GmbH, Göttingen 
Gen5 1.11 BioTek Instruments, Inc., Bad Friedrichshall 
MatInspector (Quandt et al. 1995) 
Microsoft Office Microsoft Co., Redmont, USA 
SDS 2.2 Applied Biosystems, Darmstadt 
Sequencing Analysis Software v5.4 Applied Biosystems, Darmstadt 
SnapGene Viewer GSL Biotech (snapgene.com) 
 
4.12. Databases 
The following databases were used to retrieve data. 
Table 15: List of databases 
MGI_3.43-mouse genome informatics http://www.informatics.jax.org/ 
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5. Methods 
5.1. Molecular biology methods 
5.1.1. Nucleic acid isolation 
5.1.1.1. Small-scale plasmid purification 
For small-scale plasmid purification the buffer system of the PureLink®HiPure 
Plasmid Midiprep or PureLink®HiPure Plasmid Filter Midiprep kits was used. 1.5 ml of a 
bacterial overnight (O/N) culture was transferred to a 1.5 ml reaction tube and the cells were 
pelleted by centrifugation for 30’’ at 13,000 rpm. The supernatant was discarded, the pellet 
was resuspended in 200 µl buffer R3 supplemented with RNase (see chapter 5.1.1.3) and 
vortexed in short pulses until it was visibly homogeneous. After the addition of 200 µl buffer 
L7 the sample was incubated for 5’ at room temperature (RT). Hereafter, 200 µl buffer N3 
were added and the sample was inverted until the solution was homogeneous. The cell debris 
was pelleted by centrifugation at 13,000 rpm for 10’ and 500 µl of the supernatant was 
transferred to a new 1.5 ml reaction tube containing 1 ml 99 % EtOH. The DNA was 
precipitated at -20°C for 1 h and pelleted by centrifugation for 30’ at 13,000 rpm at 4°C. The 
pellet was washed with 70 % ethanol (EtOH), centrifuged for 10’ at 13,000 rpm and dried at 
55°C for 10’ and finally resuspended in sterile-filtered DNase-free ddH2O in an appropriate 
volume (50-100 µl) for 10’ at 42°C and 1,400 rpm on a heating block. 
 
5.1.1.2. Medium-Scale Plasmid Purification 
Medium-scale plasmid purifications were performed using the PureLink®HiPure 
Plasmid Midiprep or PureLink®HiPure Plasmid Filter Midiprep kit according to the 
manufacturer’s instructions. The plasmid DNA was solved in sterile-filtered DNase-free 
ddH2O. To increase plasmid purity an additional precipitation step was performed. Hence, the 
plasmid DNA was diluted to a final volume of 500 µl and either 1 volume-unit isopropyl-
alcohol or 2.5 volume units 99 % EtOH were added. After thorough mixing by inverting, the 
DNA was precipitated O/N at -20°C and pelleted by centrifugation at 13,000 rpm for 30’. The 
pellet was washed, dried and resuspended as described in chapter 5.1.1.1. Plasmid stocks were 
stored at -20°C. 
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5.1.1.3. Isolation of genomic DNA 
For isolation of genomic DNA (gDNA) mouse tail biopsies (see chapter 5.5.2) were 
incubated overnight (O/N) in 400 µl STE-buffer supplemented with 25 µl of proteinase K 
(10 mg/ml). Thereafter, the samples were briefly vortexed and centrifuged for 10’ at 
13,000 rpm to remove tissue debris. 400 µl of the supernatant were transferred into a fresh 
reaction tube containing 1 ml cold 99 % EtOH. The samples were briefly vortexed and the 
DNA was precipitated for 10’ at -20°C, pelleted for 25’ at 13,000 rpm, washed with 500 µl 
70 % EtOH and centrifuged again for 10’ at 13,000 rpm. Finally, the DNA was dried for 10’ 
at 55°C and resuspended in 125 µl ddH2O on a heating block for 10’ at 42°C and 1,400 rpm. 
 
5.1.1.4. Isolation of total RNA from cell culture 
Total RNA from cells was isolated using TRIzol-reagent according to the 
manufacturer’s instructions. In short, the cells were washed with cold sterile 1 x PBS and 1 ml 
TRIzol was added to the cells. To ensure the integrity of RNA the following steps were 
performed on ice unless stated otherwise. The samples were first transferred into 2 ml reaction 
tubes and vortexed for 2’ on the highest setting. Afterwards the samples were kept at RT for 
5’. After the addition of 200 µl chloroform the samples were vortexed for 15’’ and incubated 
for another 3’ at RT. The solution was centrifuged for 10’ at 13,000-14,000 rpm and 4°C. The 
upper phase was transferred to a fresh 1.5 ml reaction tube containing 1 ml 99 % 
DNAse/RNAse-free EtOH and inverted several times to ensure proper mixing. Subsequently, 
the RNA was precipitated O/N at -20°C, pelleted by centrifugation at 13,000 rpm for 30’ and 
4°C and washed two times with 500 µl 70 % DNase/RNase-free EtOH. Finally, the pellet was 
dried for 10’ at 55°C, resuspended in 20 µl DNase/RNase-free H2O and solved for 10’ at 
56°C on a heating block. Until further use the RNA was stored at -80°C. 
 
5.1.1.5. Isolation of total RNA from murine skin samples 
The isolation of RNA from mouse skin, skin biopsies and nude mice allografts (see 
chapters 5.2.11, 5.5.7 and 5.5.8) was performed using the RNeasy Fibrous Tissue kit 
according to the manufacturer’s instructions, with some modifications. In brief, a maximum 
of 30 mg tissue was minced using sterile scalpels and transferred into a 1.5 ml reaction tube 
containing 300 µl buffer RLT supplemented with 3 µl of the supplied β-mercapto-EtOH. The 
tissue was homogenized on ice using a tissue homogenizer for 90’’. After each sample the 
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tissue homogenizer was cleaned and rinsed in sterile, RNase-free ddH2O two times and once 
with RLT-buffer. The homogenate was processed as stated in the manufacturer’s instructions. 
After the elution of the RNA a second DNase-treatment was included. For this purpose, the 
eluate was supplemented with 3.22 µl RDD-buffer and 1.4 µl DNase I and subsequently 
incubated for 1 h at 37°C. To inactivate the DNase the solution was incubated for 5’ at 65°C. 
Afterwards 500 µl 99 % DNase/RNase-free EtOH was added to the solution and the RNA 
was precipitated at -20°C O/N. Finally, the RNA was pelleted and solved (see chapter 
5.1.1.4). Until further use the RNA was stored at -80°C. 
 
5.1.1.6. Reverse transcription of RNA (cDNA-synthesis) 
For cDNA synthesis 2 µg RNA in a final reaction volume of 20 µl were reversely 
transcribed using the SuperScript II Reverse Transcriptase System. 250 ng hexamers were 
incubated with the RNA for 10’ at 70°C. Afterwards 1 x 1st Strand Buffer, 10 mM 
dithiothreitol (DTT) and 0.5 mM deoxynucleotides (dNTPs) were added and the mixture was 
incubated for 10’ at RT. After pre-warming to 42°C for 2’, 1 µl of SuperScript II (200 U/µl) 
was added and the mixture was incubated for 1 h at 42°C. Finally, the reaction was stopped at 
70°C for 10’. Assuming the reverse transcription reaction is 50 % efficient the final 
concentration of cDNA was 50 ng/µl. 
 
5.1.1.7. Photometric quantification of nucleic acids 
To quantify the concentration of DNA or RNA, 1 µl of the sample solution was diluted 
with 200 µl DNase/RNase-free ddH2O. The concentration was measured on a photometer by 
determination of the optical density (OD) at A260. The final concentration was calculated 
according to the formula:  = 260	 × 50	( )	 	40	( ) 
with c being the concentration (ng/µl). Additionally, the OD at A280 was measured to 
determine the amount of protein. With these values the purity was calculated as the ratio of 
OD260 and OD280. A ratio between 1.8 and 2.0 was considered sufficiently pure. 
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5.1.2. Polymerase-Chain-Reaction (PCR) 
5.1.2.1. PCR-based genotyping of mouse tail gDNA and semiquantification of cDNA 
For PCR-based amplification of gDNA or cDNA the following reactions were carried 
out in a 10 or 20 µl reaction volume.  For the primer combinations 
mPTCNx_f/mPTCNx_R/mPTCwt_R.2, EIIa-Cre-F/EIIa-Cre-R and Exon7-F/Neo-R the 
following conditions were applied: 
1x 10 x reaction buffer 5‘ 95°C   
10-100 ng template DNA 1‘ 95°C 
35 cycles 0.5 µM forward primer 1‘ 62°C 
0.5 µM reverse primer 3‘ 68°C 
0.2 mM dNTP Mix  5‘ 68°C 
1 µl Cresol solution (10x) ∞ 8°C   
0.1 U Taq polymerase (Moltaq) 
Amplification of Gapdh transcripts was conducted using the following settings, but the 
same reaction mixture: 
Denaturation 5’ 95°C   
Denaturation 30 95°C 
30-40 cycles Annealing 1’ 58°C 
Elongation 1‘ 72°C 
Elongation 5‘ 72 °C 
  ∞ 8°C   
The resulting amplification products were separated and visualized by agarose gel 
electrophoresis. 
 
5.1.2.2. Quantitative Real-Time PCR (qRT-PCR) 
Differential gene expression was analyzed by SYBR-green based quantitative real-
time PCR (qRT-PCR). Primer combinations are listed in table 10. The following reagents 
were used in a total reaction volume of 10 µl. 
2.5 ng template cDNA 
1 x SYBR-green 
0.4 µM forward primer 
0.4 µM reverse primer 
Gene expression values were calculated using the standard curve method. For this 
purpose, 5-fold serial dilutions from tissue or cells known to express the target gene, starting 
with 20 ng cDNA, were prepared and amplified by qRT-PCR. The experimental Ct values 
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were interpolated from the standard curve by nonlinear-regression using the semilog-line 
model of the GraphPad Prism 6. Afterwards, the expression values of each sample were 
normalized to the respective expression of the housekeeper genes 18S rRNA or TBP. For 
housekeeper quantification 0.8 pg or 0.25 ng cDNA, respectively, were used as template in 
the qRT-PCR reaction. The first dilution standard-series of the standard-curve contained 
20 ng cDNA obtained from a tissue that was known to express the gene of interest. The first 
dilution for 18S rRNA expression measurement contained 80 pg cDNA. The samples were 
measured in triplicates and the data was analyzed using SDS 2.2 (and higher) and GraphPad 
Prism 6. 
 
5.1.2.3. Agarose gel electrophoresis 
To separate DNA by its size, agarose gel electrophoreses were performed. For this, 
agarose gels containing 0.5 to 2 % (w/v) agarose in 1 x TBE buffer were prepared by boiling 
for 2-3 min at 1,000 W in a microwave. After cooling down, the still liquid gels were 
supplemented with 5-7 drops of a 0.07 % ethidiumbromide solution. The electrophoresis 
chamber was filled with 1 x TBE buffer. To ease the gel-loading, the samples were either 
diluted with 10 x cresol solution or 6 x loading dye to obtain a final concentration of 1 x. In 
parallel to the samples an appropriate DNA ladder was loaded. The gels were run at a constant 
voltage of 80 to 150 V. For documentation a UV transilluminator was used. 
 
5.1.3. Cloning techniques 
5.1.3.1. Transformation of E.coli with plasmid DNA 
Competent E. coli DH5α were thawed on ice and 50-100 µl of the cells were mixed 
with 50-100 ng of plasmid DNA. The remaining cells were immediately frozen and stored at  
-80°C. After two freeze-thaw-cycles the bacteria were discarded. The plasmid/bacteria 
mixture was incubated on ice for 20’ and subsequently subjected to a heat shock at 42°C for 
45’’. Afterwards, the cells were incubated again on ice for 2’. After the addition of 500 µl 
super optimal broth with catabolite repression (SOC) medium the cells were incubated for 1 h 
at 37°C and 900 rpm. Finally, an appropriate volume of the cell suspension (usually 20 to 
200 µl) was plated onto lysogeny broth (LB) agar plates containing the adequate antibiotic as 
a selection marker. The plates were incubated in an incubator O/N at 37°C. The next day 
single colonies were chosen for further applications. 
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5.1.3.2. Restriction hydrolysis 
Restriction endonucleases cut DNA on specific sites according to their sequence. The 
recognition site usually consists of 4-8 palindromic nucleotides. In this work test-restriction 
hydrolysis and preparative restriction hydrolysis were performed. For the test restriction the 
following mixture was prepared, in which the buffer was chosen according to the 
manufacturer’s instructions:  
100-250 ng plasmid DNA 
0.1 U restriction enzyme 
1 x buffer 
ad 10 µl ddH2O 
If necessary and possible, a double restriction was performed. If not, a sequential 
restriction was performed by increasing the total volume to adjust for different salt 
concentrations of the different buffer systems of up to 50 µl. If the buffers were not 
compatible the DNA was precipitated after the first restriction reaction and, once solved 
again, subjected to the second restriction reaction. The restriction reaction was usually carried 
out for one hour at the optimal temperature for each enzyme. If possible, enzymes were heat-
inactivated afterwards. Finally, the complete sample was separated by agarose gel 
electrophoresis. 
In case of preparative restrictions the amount of DNA was increased as needed and the 
amount of enzymes used was increased accordingly, following the manufacturer’s 
instructions. Also, the restriction reaction duration was increased to ensure maximal 
restriction to a maximum time of 16 h. All used enzymes were purchased from NEB (Ipswich, 
USA) or Invitrogen (Karlsruhe). 
 
5.1.3.3. Isolation of DNA fragments from agarose Gels 
DNA-fragments were excised from agarose gels with a sterile scalpel under 70 % UV-
light to reduce the risk of UV-induced mutations (e.g. thymidin dimers). The DNA was 
cleaned-up using the QIAEX II Gel extraction kit according to the manufacturer’s instructions 
including all optional washing steps. 
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5.1.3.4. Ligation 
During a ligation reaction two pieces of DNA with compatible restriction ends are 
being connected. The ligation reactions were performed by employing the T4 DNA Ligase 
system. The molar ratio of the respective insert to vector was 3:1. The molar ratio was 
calculated according the following formula:  
	 = 	 × 		 × 	 	( : ) 
A reaction with a total amount of 100 ng DNA was set up according to the ligation 
protocol below.  
X ng vector DNA 
Y ng insert DNA 
4 U T4 DNA Ligase 
1x T4 Ligase buffer 
ad 10 µl ddH2O 
The ligation reaction was conducted at 4°C for at least 48 h, stopped by heat-
inactivation for 10’ at 65°C and transformed into E.coli (see 5.1.3.1). 
 
5.1.3.5. DNA sequencing 
The nucleotide sequence of plasmids was determined by the Sanger sequencing 
method using the BigDye® reagent and an ABI3500XL sequencing device. For sequencing 
the following reagent mixture and conditions were used. 
1x BigDye buffer 1‘ 95°C   
1x BigDye 3.1 30‘‘ 95°C 
30 cycles 
20-200 ng plasmid DNA 2.5‘ 60°C 
100 pmol sequencing primer 5‘ 60°C 
ad 10 µl ddH2O ∞ 8°C   
The primers used for sequencing are listed in table 11. The obtained 
electropherograms were evaluated and the obtained sequences were analyzed using the freely 
available software BioEdit. 
 
5.1.3.6. Site-directed mutagenesis 
The QuikChange II site-directed mutagenesis kit or the QuikChange II XL site-
directed mutagenesis kit were used to induce point mutations in plasmid DNA as described in 
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the manufacturer’s instructions. The specific PCR reagent mixtures and conditions are 
described in the respective chapters. DpnI restriction was performed immediately after the 
respective PCR. For transformation of the E.coli strain XL-10 gold SOC-medium was used. 
 
5.1.3.7. Generation of Smo expression plasmids 
The plasmid pHAGE mSmoW113Y mCherry carrying a point mutation in the Smo CRD 
(W113Y) was a kind gift from Dr. Adrian Salic, Harvard Medical School, USA (Nedelcu et 
al. 2013). To generate the pMSCV mSmoW113Y mCherry plasmid (see Appendix) the mCherry-
tagged mSmo-sequence from pHAGE mSmoW113Y mCherry plasmid was amplified using the 
primer pair SmoKlon1AF/SmoKlon1BR and Phusion High-fidelity polymerase in a 20 µl 
reaction volume according to the following protocol: 
50 ng template plasmidDNA Hotstart 98°C   
0.5 µM SmoKlon1AF (forward Primer) 10‘‘ 98°C 
35 cycles 0.5 µM SmoKlon1BR (reverse Primer) 30‘‘ 60°C 
0.2 mM dNTP mix 2‘ 72°C 
1x HF buffer 10‘ 72°C 
2.5 mM MgCl2 ∞ 8°C   
0.05 U Phusion High-fidelity polymerase 
 
The amplified 3,635 bp fragment was purified by agarose gel extraction (see chapter 
5.1.3.3) and eluted in 30 µl ddH2O. Next, the DNA was restricted by BclI at 50°C O/N and 
NotI at 37°C for 2 h. The DNA was separated on a 0.7 % agarose gel and the 3,559 bp 
fragment was excised, purified and subcloned into the pMSCVpuro vector after BglII/NotI 
digestion (kindly provided by Dr. Michael Engelke). The insertion of the respective fragments 
was verified by Sanger sequencing using the primers given in table 11. 
To generate the pMSCV mSmowt mCherry (see Appendix) plasmid the W113Y 
mutation of the pMSCV mSmoW113Y mCherry plasmid was reversed to the wildtype (wt) 
sequence using the primers CRD_mut_F2/CRD_mut_R2 and the QuikchangeII-XL site-
directed mutagenesis kit in accordance to the manufacturer’s instructions. The following PCR 
settings were used: 
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1x 10 x reaction buffer 1‘ 95°C   
10 ng pMSCV mSmoW113Y mCherry 50‘‘ 95°C 
18 cycles 125 ng CRD_mut_F2 (forward primer) 50‘‘ 60°C 
125 ng CRD_mut_R2 (reverse primer) 9‘ 50‘‘ 68°C 
1 µl dNTP mix (proprietary solution) 7‘ 68°C 
3 µl Quiksolution 2‘ 37°C   
2.5 U PfuUltra HF DNA polymerase 
 
After the PCR reaction the amplification product was restricted by DpnI and 
transformed to E. coli XL-10 Gold bacteria, clones were picked as described above and small-
scale plasmid preparations were performed. The site-directed mutagenesis was verified by 
Sanger sequencing using the primers mSmo_D54F and CRD_R. After medium-scale plasmid 
preparation of one positive clone, the integrity of the Smo sequence was verified by Sanger 
sequencing and the primers given in table 11.  
The plasmid pMSCVpuro mSmoΔCRD mCherry (see Appendix) was generated 
according to the sequence described by Nedelcu et al. (Nedelcu et al. 2013). The CRD-
deletion was achieved by performing a two-step overlap-extension PCR. First, two fragments 
were generated using the primer-combination 1A2F/1AR (206 bp) and 1BF/1BR (2,899 bp) 
using the following conditions in a 20 µl reaction volume for each PCR reaction: 
overlap extension small fragment 
50 ng pMSCV mSmoW113Y mCherry Hotstart 98°C   
0.5 µM SmoKlon 1A2F (forward primer) 30'' 98°C 
0.5 µM SmoKlon 1AR (reverse primer) 8'' 98°C 
35 cycles 0.2 mM dNTP mix 20'' 60°C 
1x HF buffer 15'' 72°C 
0.05 U Phusion High-fidelity polymerase 10' 72°C 
∞ 8°C   
 
overlap extension large fragment 
50 ng pMSCV mSmoW113Y mCherry Hotstart 98°C   
0.5 µM SmoKlon 1BF (forward primer) 30'' 98°C 
0.5 µM SmoKlon 1BR (reverse primer) 8'' 98°C 
35 cycles 0.2 mM dNTP mix 20'' 65°C 
1x HF buffer 50'' 72°C 
0.05 U Phusion High-fidelity polymerase 10' 72°C 
∞ 8°C   
 
The amplification products were validated on a 1 % agarose gel and the overlap-
extension-PCR was performed using the 1A2F/1AR (206 bp) and 1BF/1BR (2,899 bp) 
amplification products as template for the following protocol: 
 Methods 
- 39 - 
 
 
overlap extension PCR 
2 µl small fragment PCR Hotstart 98°C   
2 µl large fragment PCR 30'' 98°C 
0.5 µM SmoKlon 1BF (forward primer) 8'' 98°C 
35 cycles 0.5 µM SmoKlon 1BR (reverse primer) 20'' 65°C 
0.2 mM dNTP mix 1' 72°C 
1x HF buffer 10' 72°C 
2.5 mM MgCl2 ∞ 8°C   
0.05 U Phusion High-fidelity polymerase 
 
 
The amplification products were separated on a 0.5 % agarose gel and the 3,077 bp 
fragment was excised and purified as described in chapter 5.1.3.3. Afterwards, the fragment 
were digested with BclI and NotI and cloned into pMSCVpuro vector linearized with BclI and 
NotI. The CRD deletion was confirmed by Sanger sequencing using the primer CRD_R. A 
deletion at position 1,636 was repaired using the QuikChangeII XL site-directed mutagenesis 
kit and the primers CRD_Ins_1636_F/CRD_Ins_1636_R. 
 
5.2. Cell biology methods 
5.2.1. Culture of eukaryotic cells 
All eukaryotic cell lines were cultured in an incubator with constant 37 °C, 5 % CO2 
and 95 % humidity. The media were refreshed every 3-4 days and the cells were splitted when 
reaching 80 to 90 % confluence. Splitting of the cells was conducted by detaching the cells 
with 1-3 ml of TrypLE express or for ASZ001 cells with 2-3 ml of trypsin/EDTA. After the 
cells started to detach, the reaction was stopped by the addition of FCS-containing medium 
and an appropriate volume was transferred to a new culture plate containing fresh medium. 
The culture media and supplements are listed in table 7. 
 
5.2.2. Cryopreservation of eukaryotic cells 
For long-term storage of eukaryotic cell lines the cells were stored in liquid nitrogen. 
For this purpose, 1-3 10 cm culture plates with 90 % cell confluency were rinsed with  
1 x PBS and detached as described above. The detached cells were transferred into a 15 ml 
reaction tube und pelleted by centrifugation at 300 x g for 5’ and 4°C. Afterwards the cells 
were resuspended in 10 ml culture medium supplemented with 10 % DMSO and appropriate 
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antibiotics. 1 ml aliquots were frozen in Cryovials at -80°C in the freezing device Mr. 
FrostyTM for 16 h. Afterwards, the cells were stored in liquid nitrogen. 
To thaw the cells they were rapidly warmed and transferred to 10 ml 1 x PBS, pelleted 
as described above and resuspended in fresh culture medium. Cells were transferred to a 5 or 
10 cm culture dish and stored in an incubator. The next day the medium was replaced with 
fresh medium to ensure the complete removal of DMSO. 
 
5.2.3. Transfection of eukaryotic cells 
For the transfection of plasmid DNA, the cells were seeded as described in the 
respective experiments at a density of approximately 70 %. The cells were transfected using 
RotiFect® according to the supplier’s instructions. For each cell line a specific ratio of DNA 
to RotiFect® and a specific transfection time was used. In brief, one day after seeding, the 
transfection mixture was prepared by pipetting the appropriate volumes of DNA and RotiFect 
to culture medium without any supplements. This mixture was thoroughly vortexed to allow 
for forming complexes for 40’ at RT. Afterwards an appropriate volume of culture medium 
supplemented with 10 % FCS was added and mixed by gentle pipetting. This solution was 
added to cells, which were rinsed before with 1 x PBS. After the transfection time the solution 
was aspirated, the cells were rinsed with 1 x PBS and normal culture medium was added. If 
the transfection solution was not removed, the same volume of normal culture medium 
(including 1 % Penicillin/Streptomycin) was added to the cells after 6 h to prevent microbial 
contamination. 
Table 16: Transfection conditions 





transfection time  
[h] 
wt Ptch 24-well plate 0.5 2:1 3 h 
Ptch-/- 24-well plate 0.5 2:1 3 h 
Gli1-/-/Gli2-/- 24-well plate 0.5 4:1 6 h 
NIH/3T3 
6-well plate 2 3:1 6 h 
96-well plate 0.1 – 0.12 3:1 6 h 
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5.2.4. Retroviral transduction of eukaryotic cells 
For retroviral transduction of murine cells Platinum-E cells were used as packaging 
cell line. The latter cells were seeded at a confluency of 50-60 % in 5 cm culture dishes one 
day before transfection with the retroviral vectors. For the transfection the following reagents 
were mixed in the given order: 
400 µl medium of the target cell line 
without supplements 
5 µl RotiFect® 
2.5 µg retroviral expression vector 
 
The reagents were mixed by tapping and were incubated at RT for 30’. Hereafter, the 
Platinum-E cells were washed and the medium was replaced with 4 ml fresh medium used for 
the target cell line. The transfection mixture was added drop wise onto the plates and mixed 
by swirling. After 48 h the cell supernatant (Platinum-E conditioned medium; Platinum-E-
CM) containing the viruses was sterile-filtered using a 0.45 µm pore sterile filter. 3 ml 
Platinum-E-CM was supplemented with 1.5 ml fresh medium and 3 µg/ml polybrene and 
applied to a 50 % confluent cell culture dish (5 cm) of the target cell line. The sterile-filtered 
polybrene stock solution (3 mg/ml) was freshly prepared prior to the infection in 1 x PBS. The 
target cells were washed after 24 h and supplied with fresh medium. After additional 24 h the 
culture media were supplemented with the respective selection antibiotics (see table 7). 
 
5.2.5. Dual-Luciferase assay 
Dual-luciferase assays of transiently or stably transfected cells were performed using 
the Dual-Luciferase® reporter assay system according to the manufacturer’s instruction. In 
brief, the washed cells were lysed by addition of 20 µl or 100 µl per well of 1 x passive lysis 
buffer (PLB) for 96- or 24-well-plates, respectively. The plates were incubated on an orbital 
shaker at 250 to 300 rpm for 15’. Afterwards, the plates were frozen at -80°C for at least 15’ 
and measurement was conducted once the lysates were thawed again. LAR II and Stop’n’Glo 
solutions were prepared and stored as described in the manufacturer’s instruction. Prior to the 
measurements the LAR II and Stop’n’Glo solutions were allowed to equilibrate to RT for at 
least 15’. The measurement was conducted on a Synergy MX luminometer. The firefly-
luciferase values were normalized to the respective renilla-luciferase values. 
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5.2.6. Generation of Shh-N conditioned medium 
For generation of Shh-N-conditioned medium (Shh-N-CM) and respective control 
medium (CoM) HEK293Shh and HEK293 at a density of 70 % were incubated with DMEM 
supplemented with 2 % FCS and 1 % PS for 24 h. Afterwards, the media were sterile-filtered 
(0.2 µm pore size) and stored at 4°C for a maximum of 3 months until prior use. If necessary, 
the media were diluted with DMEM supplemented with 2 % FCS and 1 % PS. 
 
5.2.7. Proliferation assay 
Cellular proliferation was assessed using the BrdU Cell proliferation kit according to 
the manufacturer’s instructions. In brief, 8,000 cells were seeded per well of a 96-well plate 
and treatment was conducted as described in the respective experiments. 22 h prior to the 
measurement 10 µM BrdU reagent was added. The cells were fixed for 30’ and peroxidase-
coupled BrdU-antibody (anti-BrdU-POD) was added for 1 h. After thorough washing, BrdU-
incorporation was determined by the addition of peroxidase substrate. The measurement was 
conducted on a Synergy MX luminometer. 
 
5.2.8. BODIPY-replacement assay 
For analyses of a direct competition of Smo modulators with BODIPY-labeled 
cyclopamine (BD-CP) for Smo-binding a replacement assay was performed. The 
displacement of BD-CP from its binding to Smo was measured by decreased fluorescence 
intensity of cells.  
For the experiments 250,000 HEK293S cells per well of a 6-well-plate were seeded in 
the respective culture medium. The next day, Smo overexpression was induced by changing 
the medium to DMEM/F12 supplemented with 10 % FCS, 1 % PS, 1 µg/ml tetracycline and 
5 mM sodium butyrate for 48 h. Afterwards the medium was changed to DMEM/F12 
supplemented with 10 % FCS / 1 % PS and the compounds described in the respective 
experiments. After 4 h incubation the cells were washed, detached using 1 ml TrypLE express 
and transferred to 15 ml reaction tubes containing 2 ml 1 x PBS. The wells were rinsed with 
1 ml 1 x PBS and the solution was transferred to the same reaction tube to increase the total 
cell number. The cells were pelleted by centrifugation for 5-8’ by 300 to 400 x g and washed 
again with 2 ml 1 x PBS and centrifuged again. Finally, the pellet was resuspended in 350 to 
600 µl phenol-red free DMEM supplemented with 0.5 % FCS by brief vortexing and 
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pipetting. The cells were analyzed on a BD LSR II within 2 h. 50,000 cells per sample were 
counted. 
For statistical analysis and generation of bar graphs the mean fluorescence intensity 
values of the respective histograms were exported using FlowJo software. The data are 
represented as the cumulative distribution function (CDF), which denotes the percentage of 
cells with a given fluorescence intensity. For each experiment the fluorescence intensity of 
BD-CP-single treated cells was set to 100 %.  
 
5.2.9. Generation of concentration response curves and determination of half 
maximal effective or inhibitory drug doses 
Concentration response curves (CRC) were generated to determine the half maximal 
effective concentration (ED50) or the half maximal inhibitory concentration (IC50) of Smo 
modulators in Hh signaling inhibition. For this purpose, the Hh signaling activity of Shh 
light II cells was measured after treatment with increasing amounts of one Smo modulator in 
combination with constant concentrations of a second Smo modulator.  
For this assay 5,000 to 6,000 Shh light II were seeded per well of 96-well plates in the 
respective culture medium. The next day, the medium was replaced with Shh-N-CM, if two 
inhibitors were used, or DMEM supplemented with 0.5 % FCS, if an inhibitor and an agonist 
were used. After 24 h the cells were treated with the Smo modulators diluted in the respective 
media as described in the respective experiments for additional 48 h. Afterwards the cells 
were lysed for Dual-luciferase assay as described (see chapter 5.2.5). 
The renilla-normalized firefly values were first normalized to the respective solvent 
value, which was set to 100 % using MS Excel. Employing GraphPad Prism6, the values were 
normalized again to range from 0 % to 100 % and the used concentration was transformed to 
its logarithm. Finally, the curves were fitted by non-linear regression using the function 
“log(inhibitor) vs. response – Variable slope (four parameters)” or the respective log (agonist) 
function. Curve fitting was calculated using 1,000 iterations. For EC50-shift experiments the 
respective solvent-treated control was set to 100 %.  
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5.2.10. Medium transfer experiments 
For medium-transfer experiments 2 to 4 10 cm cell culture dishes of 70-80 % 
confluent wt Ptch or Ptch-/- cells were washed, trypsinized and pelleted by centrifugation at 
300 x g for 5’ at 4°C. The cells were resuspended in culture medium and 2,000,000 cells were 
transferred to a 50 ml reaction tube in a total volume of 10 ml pre-warmed culture medium 
supplemented with 100 nM calcitriol or solvent. The suspensions were incubated rotating in a 
hybridization oven at 37°C for 1 h. Hereafter, the cells were washed two times with 20 ml 
cold 1 x PBS. Each time, the reaction tube was inverted several times to ensure complete 
removal of the calcitriol-supplemented medium. The cells were pelleted by centrifugation and 
resuspended in 9 ml pre-warmed medium. 1 ml of the obtained cell suspension was seeded 
into each well of 6-well plates for conditioning. After 4, 6 and 8 h the medium was sterile-
filtered (0.2 µm pore size). The same procedure was performed using medium in reaction 
tubes und 6-well-plates without cells in order to verify background levels of calcitriol. The 
conditioned media were stored in 2 ml reaction tubes at 4°C for no longer than 1 week. A 
schematic representation of the workflow is presented in Fig. 4. 
 
Figure 4: Workflow of the medium transfer experiment. Trypsinized wt Ptch and Ptch-/- cells were loaded 
with calcitriol in a rotating 50 ml falcon (“loading phase”). After extensive washing, the cells were seeded in  
6-well plates. After for 4, 6 and 8 h (“conditioning phase”) the medium was collected, sterile-filtered and 
transferred to NIH/3T3 cells transfected with the plasmids pFR-Luc, pCMV-BD-RXRα, pCMV-AD-VDR and 
pRL-TK or Shh light II stimulated with Shh-N-CM. After 16 h or 48 h dual-luciferase assays were performed, 
respectively. 
 Methods 
- 45 - 
 
To analyze the rate of VDR/RXRα-heterodimerization after incubation with 
conditioned medium 200,000 NIH/3T3 cells per well of 6-well plates were seeded in the 
normal culture medium. The following day, the cells were transfected with the plasmids pFR-
Luc, pCMV-BD-RXRα, pCMV-AD-VDR and pRL-TK in a ratio of 50:5:5:1. 6 h after the 
transfection, the cells were washed, trypsinized and transferred to 96-well plates at a density 
of approximately 70 %. The next day, the transfected cells were incubated with 100 µl/well of 
the respective conditioned media for 16 h and finally, dual-luciferase assays were performed. 
To analyze the effect on Hh signaling inhibition 5,000 Shh light II cells per well of 96-
well plates were seeded in the respective culture medium. The following day the medium was 
replaced with Shh-N-CM for 48 h. Then, the cells were incubated with 100 µl/well of the 
respective conditioned media for 48 h. Finally, dual-luciferase assays were performed. 
 
5.2.11. Isolation and culture of mouse skin biopsies 
For culture of mouse skin biopsies, 8-10 week old Ptchflox/flox CreERT2+/- mice were 
intramuscularly injected with 10 µl tamoxifen-solution (10 µg/µl, see chapter 5.5.4). After 
60 days the tail skin of the mice was depilated using customary depilatory cream as stated in 
the manufacturer’s instructions and treated with 70 µl nystatin (1.2 mg/ml in EtOH). The 
nystatin treatment was repeated the next day. After one additional day the mice were 
sacrificed, the tail skin was disinfected with 70 % EtOH and removed using a sterile scalpel. 
Afterwards the skin was shortly rinsed in a petri dish containing sterile 1 x PBS and 
transferred into fresh 1 x PBS in a petri dish. All following steps were performed under a 
sterile bench. First, the skin was excised into 1 mm2 large pieces. Then, 4 skin biopsies (with 
the dermis down) were transferred to one micropore filter, which was floating in a 24-well 
plate well filled with 1 ml DMEM supplemented with 10 % FCS and 1 % PS. The next day 
the medium was changed to DMEM supplemented with 1.5 % BSA and 1 % PS. After one 
additional day the medium was changed with DMEM supplemented with 1.5 % BSA, 1 % PS 
and the compounds described in the respective experiments. After 72 h the medium 
containing the compounds was refreshed and after additional 72 h three skin biopsies were 
stored at -80°C for RNA isolation and one biopsy was used for histological analyses. 
 
 Methods 
- 46 - 
 
5.3. Protein chemistry and immunohistochemistry 
5.3.1. Protein isolation from cell culture 
To isolate proteins of cultured cells, the cells were washed and scraped in 1 ml 
1 x PBS using a cell scraper, and pelleted by centrifugation for 5’ at 2,000 rpm. The 
supernatant was discarded and the pellet was resuspended in 700 µl 1 x PBS and transferred 
into a 1.5 ml safelock-tube. After a second washing step the cell pellet was frozen in liquid 
nitrogen and afterwards thawed on ice. The thawed pellet was incubated with 50 - 100 µl lysis 
buffer for 30’ on ice. Afterwards, the mixture was centrifuged for 30’ at 13,000 rpm and the 
supernatant, containing the soluble proteins, was transferred to a new 1.5 ml reaction tube. 
The protein concentration was determined using the Pierce BCA Protein Assay kit according 
to the manufacturer’s instruction. The proteins were stored at -80°C. 
 
5.3.2. Western blot 
For Western blot analyses protein samples were prepared by adding 6 x loading buffer 
to obtain a 1 x concentration. Prior to loading, the proteins were denatured by boiling for 5’, 
450 rpm at 96°C on a shacking heating block. Proteins and 4 µl SeeBlue Plus2 Prestained 
Standard were loaded on NuPAGE® Novex® 4-12 % Bis-Tris Protein Gels in 1 x NuPAGE® 
MES SDS running buffer and separated at 160 mA, 160 V and 100 W for 1.5 to 2 h. 
Afterwards the proteins were transferred from the gel to a nitrocellulose membrane by semi-
dry blotting for 1 h 20’ at 120 mA, 20 V and 100 W. Next, the membrane was washed three 
times for 10’ with 1 x PBS containing 0.1 % Tween (PBS-Tween) and blocked in 5 % (w/v) 
milk powder/PBS-Tween for 1 h at RT. The membrane was washed again and incubated with 
the primary antibody O/N at 4°C on an orbital shaker. The next day, the membrane was 
washed again and incubated with the secondary antibody for 1 h at RT (see table 13). After an 
additional washing step ECL Plus Western Blotting Detection System was used according to 
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5.3.3. Haematoxylin/Eosin staining 
For Haematoxylin/Eosin (HE) staining tissue was fixed in 4 % PFA for 2 weeks and 
embedded in paraffin. Paraffin sections were prepared on a microtome and mounted on glass 
slides. The sections were deparaffinized in xylene for 2 x 10’. Next, the sections were 
hydrated by descending EtOH solutions (99 % to 70 %). After thoroughly washing with 
ddH2O, the hydrated sections were transferred to a hemalaun solution for 20’. Color 
development was achieved by a constant flow of lukewarm tap water for as long as there was 
no more coloring of the water. Subsequently, the slides were transferred to a 1 % eosin 
solution for no longer than 20’’ and extensively washed with ddH2O until the water stayed 
clear. To prepare the mounting with cover slides, the sections were dehydrated with ascending 
EtOH solution (70 % to 99 %) and were left in xylene prior to mounting in Pertex. For 
hardening the mounting medium, the slides were placed in a 55°C warm oven for at least 20’. 
To analyze the tumor area, pictures were taken on an Olympus BX60-microscope 
operated by Cell F software at 100-fold magnification. Next, the tumor area was depicted 
using the “polygon ROI tool” of three pictures per mouse. The mean of these values was used 
for further calculations. 
 
5.3.4. Ki67-staining 
For immunohistochemical visualization of Ki67-positive cells, microtome sections of 
paraffin-embedded tissue were prepared and mounted on Superfrost slides. The sections were 
first rehydrated for two times 10’ in xylene, followed by descending EtOH solution (99 % to 
70 %). After washing in ddH2O antigen-retrieval was conducted by boiling the slides in citric 
acid buffer (pH 6.0) once for 4’ and 4 times for 3’ at 600 W in a microwave. Afterwards the 
sections were allowed to cool down to RT and washed 2 times for 2’ with 1 x TBS. 
Endogenous peroxidases were blocked by incubating the sections for 20’ in 3 % H2O2 on an 
orbital shaker. Afterwards the sections were washed for 5’ in ddH2O and rinsed with 1 x TBS. 
Subsequently, the sections were blocked for 20’ with 5 % FCS / 10 % BSA in 1 x PBS at RT 
in a moist chamber. Prior to the primary antibody incubation the sections were shortly dipped 
in 1 x TBS and antibody incubation was conducted at 4°C O/N in moist chambers. After 
washing with 1 x TBS two times for 2’ the sections were incubated with the secondary 
antibody for 30’ at RT in moist chamber. Subsequently, the sections were washed again and 
the DAB chromogen was added for 10’ in moist chambers at RT. The sections were dipped in 
TBS and washed with ddH2O for 5’. Counterstaining was conducted for 20’’ in hemalaun 
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followed by a 5’ constant flow of lukewarm tap water. Finally, the sections were mounted 
with Glycergel. 
For the counting of Ki67-positive cells at least three images per section were taken at a 
200 x magnification on an Olympus BX 60 microscope operated by Cell F software. The 
pictures were further analyzed using the freely available software Fiji (Fiji.sc; (Schindelin et 
al. 2012)). To do so, the “smooth”-function was applied; the contrast was enhanced (0.4 %) 
and after channel-splitting the pictures were converted to binary. Ki67+ cells as well as all 
nuclei per picture were automatically counted by adjusting the threshold values. The ratio of 
Ki67+ cells/all nuclei per picture was determined and used for further calculations. 
 
5.4. Mass spectrometry 
The methods for the measurements of vitD3 metabolites and itraconazole have been 
developed by Susanne Weber (Helmholtz-Centre Munich, Institute for Experimental 
Genetics, Prof. Dr. Jerzy Adamski). 
5.4.1. Measurement of intracellular vitD3 metabolites  
Cellular uptake and generation of the different vitD3 metabolites calcitriol (1α,25-
dihydroxy vitamin D3), 24,25-dihydroxy vitamin D3 (24,25(OH)2D3), 25(OH)D3 and vitD3 
were analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). 
ASZ001 cells were seeded at a density of 200,000 cells/well, whereas all other cells were 
seeded at densities of 150,000 cells/well in 6-well plates in the respective culture medium. 
After 24 h the medium was removed and culture medium without FCS and 1 % PS was 
added. Next, the cells were treated with the compounds described in the respective 
experiments. Cells were washed with 1 x PBS and harvested by scraping using 750 µl of 60 % 
methanol (MetOH) in water supplemented with 40 ng/ml of internal standard 25-hydroxy 
vitamin D2 [25,26,27-
13C3]. After the transfer of the scraped cells into 1.5 ml safelock reaction 
tubes, the dishes were rinsed again with 500 µl of 40 % MetOH in water. Both cell fractions 
were combined, immediately put on dry ice and stored at -80 °C until analysis.  
Prior to LC-MS/MS analysis, vitD3 metabolites were extracted via offline solid phase 
extraction (SPE) using a nitrogen-driven Positive Pressure-96 Processor coupled with a 96-
Well Tabless Tube Holder. To do so, the harvested samples were thawed at RT and loaded 
onto an SPE cartridge. After three washing steps the metabolites were eluted twice with 2 % 
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formic acid in MetOH. Eluates were evaporated to dryness under constant nitrogen flow and 
reconstituted with an appropriate solvent mixture. 
LC-MS/MS analysis was performed on a system composed of an HTC-xt autosampler, 
a 1260 HPLC System, and a QTrap5500 mass spectrometer which was controlled by Analyst 
1.6 software. The vitD3 metabolites were separated on a reversed phase column using a 
solvent gradient and detected by multiple reaction monitoring (MRM) after electrospray 
ionization (ESI) in positive mode. In case of calcitriol, 24,25(OH)2D3, and 25(OH)D3 three 
MRMs were monitored, whereas only one MRM was monitored for vitamin D3. The peaks of 
the respective vitD3 metabolites (sum of respective MRMs) were integrated by the Analyst 
1.6 software and the areas were normalized by the peak area of the internal standard 25-
hydroxy vitamin D2 [25,26,27-
13C3] which was added within the harvesting process. 
 
5.4.2. Detection of intracellular ITZ by LC/MS-MS-based assay  
LC-MS/MS was also used for the analysis of intracellular ITZ concentrations. Seeding 
and treatment of the cells, as well as sample preparation was conducted as described above. 
For ITZ two MRMs were monitored. The analysis and downstream calculations were 
performed similar to the vitD3 metabolites. 
 
5.4.3. Detection of vitD3 metabolites and ITZ in ASZ001-allografts 
For the detection of vitD3 metabolites and ITZ from transplanted ASZ001 cells (5.5.7) 
by mass spectrometry, approximately 100 mg of tumor tissue was shredded using a sterile 
scalpel. The homogenate was transferred to Precellys ceramic kit 1.4/2.8 mm 2.0 ml tubes and 
500 µl 100 % MetOH was added. Furthermore, 1 µl per 10 mg tumor of internal standard 
solution (1α,25-(OH)2-D2, 1 µg/ml) was added and the tumors were homogenized using a 
Precellys 24 tissue homogenizer by three cycles of 20’’ homogenization at 5,500 rpm and 30’’ 
pausing in between. The temperature was kept at 4°C with a Cryolys temperature controller. 
The homogenate was shortly centrifuged and the supernatant was transferred to Sephadex 
columns containing 400 µl ddH2O. The remaining tissue debris was rinsed with 500 µl 
MetOH, vortexed and centrifuged again to ensure maximal yield. The supernatant was again 
transferred to sephadex columns containing 400 µl ddH2O. All following steps were 
performed as described in chapter 0. To analyze the data, the values obtained were first 
normalized to the IS and then normalized again to the analyzed tumor amount (weight). 
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5.5. Animal experiments 
All experiments using animals were performed in compliance with all relevant legal 
and ethical requirements. 
 
5.5.1. Breeding of mice 
All mouse strains were housed and bred in the animal facility of the Institute of 
Human Genetics, University of Göttingen, Germany. The animals were housed in Makrolon 
cages type II and III, with a twelve-hour light-dark cycle, 20 +/- 2 °C and a relative humidity 
of 50 +/- 10 %. Food pellets (complete diets for mice breeding) and tap water were given ad 
libitum. Immune deficient nude mice were kept under specified pathogen free (SPF) 
conditions and fed with sterilized food pellets and water. For experiments using calcitriol the 
animals received vitD3-free, Ca
2+ and phosphate-reduced food 1 week prior to the 
experiments and throughout the whole experiment (Ssniff Spezialdiäten: E15312-1). 
 
5.5.2. Tail biopsy and genotyping of mice 
Ear marking and tail clipping were done at 4 weeks of age to mark and identify the 
genotype of the respective mouse (see chapter 5.1.2.1). Genotyping was conducted on gDNA 
isolated from tail clipping using the primers and conditions given in table 8. 
 
5.5.3. Anesthesia of mice 
For the anesthesia of mice the animals were injected intraperitoneally (i.p.) with 64 µg 
Ketanest S and 12 µg Rompun per 1 g of body weight. To prevent a drying of the eyes they 
were covered in 0.9 % NaCl for the time of anesthesia. 
 
5.5.4. Intramuscular injection of tamoxifen 
For the induction of Cre-recombinase activity in Ptchflox/flox CreERT2+/- mice, a 
100 mg/ml tamoxifen-solution (in EtOH) was prepared. This solution was diluted 1:10 with 
sterile sunflower seed oil to obtain a final concentration of 10 mg/ml. To induce BCC-
development in Ptchflox/flox CreERT2+/- mice 6-9 week old animals were fixed and 10 µl of the 
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tamoxifen-solution (equating to 100 µg tamoxifen) were injected into the right musculus 
soleus. Macroscopically visible BCC developed from day 30 post-induction on. 
 
5.5.5. Intraperitoneal injection of calcitriol 
Mice were injected daily with 100 ng calcitriol per 1 kg of body weight i.p.. For this 
purpose, a 10 or 20 µM stock solution of calcitriol was diluted in 20 µl EtOH. This solution 
was further diluted in 1.2 ml sterile sun flower seed oil to obtain the final solution. The mice 
were injected with 50 µl (equating 100 ng/kg) of the final solution. The solution was stored 
frozen for no longer than 1 week. As controls, mice were injected with solvent only. 
 
5.5.6. Oral treatment with azoles 
KTZ tablets were pulverized and ITZ capsules were opened and both compounds were 
dissolved at a concentration of 40 mg/ml in 0.25 % xanthan gum by thorough shaking and 
vortexing. Xanthan gum was prepared in sterile 0.9 % NaCl and stored at -20°C. Azole stock 
solutions were also stored at -20°C. For animal treatment the stock solutions were diluted 
with xanthan gum to reach a final concentration of 100 mg/per kg body weight. Oral 
treatment by gavage was conducted by fixing the animals on their neck and tail and injection 
of 200 µl azole solution into the stomach. Control animals received 200 µl xanthan gum 
orally. The mice were weighed twice a week and the treatment was conducted thrice a week. 
 
5.5.7. ASZ001 allografts 
ASZ001 cells were grown until they reached a confluency of 70 – 80 %. The cells 
were trypsinized, pelleted by centrifugation at 300 x g for 5’ and washed for two times with 
154-CF medium supplemented with 1 % PS. Afterwards the cells were resuspended in culture 
medium in an appropriate volume and the number of viable cells was determined by counting 
trypan blue stained cells in a Neubauer counting chamber. Using pre-chilled syringes 1 x 106 
ASZ001 cells in a total volume of 250 µl 20 % matrigel in culture medium were 
subcutaneously transplanted into the right and left flank of 8 to 10 week old anesthetized nude 
mice. Tumor development was monitored thrice a week using a digital caliper. The volume of 
the tumors was calculated using the formula (Tomayko and Reynolds 1989): 
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= 12 × × ×  
At the end of the experiments the animals were sacrificed, the tumors were removed 
and fixed in 4 % paraformaldehyde or stored at -80°C for further analysis. 
 
5.5.8. Perfusion of mice 
In preparation for the perfusion the mice were injected with a lethal dose of a mixture 
of 4 mg Ketanest S and 0.9 mg Rompun. Next, the animals’ chest was opened and the heart 
was exposed. The right atrium was opened for bleeding. Afterwards, the animal’s left 
ventricle was punctured and the animal was infused with Ringer lactate for 10’. 
Simultaneously, the tail was removed and the skin was carefully stripped from the bone. A 
small part of the tail skin was frozen on dry ice for molecular analyses; another part was 
transferred to a biopsy cassette and incubated in 4 % paraformaldehyde for 2 weeks in 
preparation for embedding in paraffin. Subsequently, the animal was infused with 4 % 
paraformaldehyde for 10’ or until the animal was completely fixed. The animals, as well as 
the remaining tail, were stored for 2 weeks at 4°C in 4 % paraformaldehyde. Afterwards the 
animals were stored in 1 x PBS at 4°C. 
 
5.6. Statistics 
All statistical and graphical analyses were conducted with GraphPad Prism6, unless 
mentioned elsewise. For Gli3 overexpression experiments (see 6.1Fehler! Verweisquelle 
konnte nicht gefunden werden.), Vdr-promoter dual-luciferase assays (see 6.1), the 
calcitriol-combination treatment of ASZ001 cells (see 6.2.1.1), BCC-skin biopsies (see 
6.2.1.2), and in vivo experiments (see 0) unpaired, nonparametric one-way ANOVA (Kruskal-
Wallis-Test), followed by Dunn’s multiple comparison tests were performed. For medium-
transfer experiment (see 6.3.1.1) the data were tested for Gaussian distribution using 
D’Agostino-Pearson omnibus reality test followed by an ordinary one-way ANOVA with 
Sidak’s multiple comparisons test. For comparison of reporter system sensitivity (see 6.3.1.1; 
Fig. 34) unpaired t-tests were performed. 
To test for statistically increased concentration compared to solvent-treated cells for 
the 25(OH)D3 and vitD3 timecourse experiments (see 6.3.1.2; Fig. 35 and 36) unpaired t-tests 
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were performed using the function “Multiple t-tests – one per row” of GraphPad Prism 6, 
without assuming consistent standard deviation (SD) and without correcting for multiple 
comparisons. To test for statistically significant concentrations over time, unpaired, 
nonparametric one-way ANOVA (Kruskal-Wallis-Test), followed by Dunn’s multiple 
comparison test was performed against the first (0.5 h) time point. 
Concentration-response-curves (CRC, see 6.3.2.1) were calculated using GraphPad 
Prism 6 by normalizing the renilla-normalized firefly-values to solvent-treated cells (100 %) 
using MS Excel. Afterwards the concentration was transformed to the logarithm and the range 
of the data was normalized by setting the highest and lowest value to 0 and 100 %, 
respectively. The curve was fitted by non-linear regression using the function “log(inhibitor) 
vs. response – variable slope (four parameters)” or the respective log(agonist) function. Curve 
fitting was calculated using 1,000 iterations. 
For generation of Fa-CI-plots (see 6.3.2.1, Fig. 38) the fractional inhibition (Fa) was 
calculated by normalizing to the data from 0 (lowest inhibition, i.e. solvent) to 1 (highest 
inhibition) and the combination index (CI) was calculated by the freely available software 
CompuSyn using the “non-constant ratio” setting (combosyn.com). The values were plotted 
using GraphPad Prism 6 using the linear regression tool. The obtained lines were tested for 
statistically significant different slopes using the built-in compare function in GraphPad Prism 
6. 
For the BD-CP replacement assays (see 6.3.2.2) unpaired, non-parametric t tests 
(Mann-Whitney) against BD-CP single-treated cells were performed. For Smo overexpression 
experiment (see 6.3.2.3) the data were tested for Gaussian distribution using D’Agostino-
Pearson omnibus reality test. For Shh light II ordinary one-way ANOVA and a Sidak’s 
multiple comparisons test were performed. The results from Smo-/- experiments failed the test 
for Gaussian distribution, thus unpaired, non-parametric t tests (Mann-Whitney) against 
solvent-treated cells were performed. 
 
 Results 
- 54 - 
 
6.  Results 
6.1. Regulation of Vdr expression by Gli TFs 
BCCs, which are characterized by active Hh signaling, overexpress the VDR 
(Mitschele et al. 2004). This indicates that Hh signaling may regulate VDR expression. Using 
the software MatInspector (Quandt et al. 1995), we recently discovered a consensus motif for 
binding of Gli transcription factors (Lee et al. 2010; Winklmayr et al. 2010) 312 bp upstream 
of the first exon in the murine Vdr promoter region (unpublished data, see below). Moreover, 
our initial experiments indicated a Gli3-mediated regulation of Vdr expression, since 
overexpression of Gli3 in wt Ptch cells resulted in upregulation of Vdr (Fritsch 2014). Here, 
we assessed if the Gli binding motifs of the Vdr promoter are functional regulatory elements 
by analyzing the activity of Vdr promoter reporter constructs in the presence of Gli3. 
To determine the effect of Gli3 on Vdr expression we overexpressed Gli3 in three 
different cell lines. As a control cell line wt Ptch fibroblasts were chosen since these cells 
display an intact and Shh-inducible Hh signaling pathway (Uhmann et al. 2011a). We also 
used Ptch-/- fibroblasts, because these cells display constitutive activation of the Hh pathway 
due to a biallelic Ptch mutation (Uhmann et al. 2011a) to analyze the effect of Gli3 
independently of Gli1 and Gli2. Finally we employed a Gli1/Gli2 double knockout cell line 
(Gli1-/-/Gli2-/-) (Lipinski et al. 2008). Since Hh signaling activation by Shh promotes the 
processing of the full-length Gli3 repressor form (Gli3rep) to its activator form (Gli3act) (Wang 
et al. 2007a), Gli3-transfected wt Ptch and Gli1-/-/Gli2-/-cells were additionally stimulated 
with Shh-N-CM. Afterwards the Vdr expression levels were determined. The Hh signaling 
activation status and the transfection efficiency were controlled by quantification of the 
expression of Gli transcription factors.  
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In Hh-responsive wt Ptch cells Shh-N-CM stimulation led to a significant increase of 
Gli1 expression with and without Gli3 transfection (Fig. 5 A). Gli2 expression was 
significantly increased after Gli3 transfection and additional stimulation with Shh-N-CM (Fig. 
5 B). Significantly elevated Gli3 expression levels were detected only after Gli3 transfection 
(Fig. 5 C) which confirmed an efficient transfection procedure. However, Vdr expression was 





Figure 5: Vdr expression is not regulated by Gli3 in wt Ptch cells. Relative quantification of (A) Gli1, (B) 
Gli2, (C) Gli3 and (D) Vdr expression levels of wt Ptch fibroblasts after Gli3 overexpression and Shh-N-CM 
treatment. Gene expression levels were normalized to 18S rRNA expression. Expression levels of control vector-
transfected cells (pCR3.1) treated with control medium (CoM) were set to 1. All data are represented as mean +/- 
SEM of at least three experiments. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
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Next, Ptch-/- cells were transfected with Gli3 (Fig. 6). In contrast to the assumption 
that in Ptch-/- cells Hh signaling activity cannot be further enhanced, Gli3 transfection resulted 
in significant induction of Gli1 and Gli2 expression (Fig. 6 A, B). This indicates that Hh 
signaling activity can be further increased by Gli3 in Ptch-/- cells. Efficient Gli3 transfection 
was revealed by significantly elevated Gli3 levels (Fig. 6 C). Nevertheless, overexpression of 


















Figure 6: Vdr expression is not regulated by Gli3 in Ptch-/- cells. Relative quantification of (A) Gli1, (B) Gli2, 
(C) Gli3 and (D) Vdr expression levels of Ptch-/- fibroblasts after Gli3 overexpression. Gene expression levels 
were normalized to 18S rRNA expression. Expression levels of control vector-transfected cells (pCR3.1) were 
set to 1. All data are represented as mean +/- SEM of at least three experiments. **** p<0.0001.  
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Finally, Gli3-transfected and/or Shh-N-CM-stimulated Gli1-/-/Gli2-/-cells were 
analyzed (Fig. 7). These cells are devoid of any endogenous Gli1 and Gli2 expression 
(Lipinski et al. 2008). Thus any Gli1- or Gli2-mediated effect including activation of Hh 
signaling can be excluded in these cells. Gli3 transfection led to significant elevated Gli3 
expression levels which confirmed the efficient transfection procedure (Fig. 7 A). However, 
Gli3 did not induce Vdr expression (Fig. 6 B). Interestingly, irrespective of Gli3 transfection 
Shh-N-CM significantly increased Vdr mRNA levels. 
 
 
Figure 7: Regulation of Vdr expression by Shh in Gli1-/-/Gli2-/- cells. Relative quantification of (A) Gli3 and 
(B) Vdr expression levels of Gli1-/-/Gli2-/-cells after Gli3 overexpression and/or Shh-N-CM treatment. Gene 
expression levels were normalized to 18S rRNA expression. Expression levels of control vector-transfected cells 
(pCR3.1) treated with control medium (CoM) were set to 1. All data are represented as mean +/- SEM of at least 
three experiments, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
Taken together the experiments suggested that the expression of the Vdr gene is not 
regulated by Gli3, but may be regulated by Shh in dependency of the cellular context. 
Using the software Matinspector (Quandt et al. 1995) one putative Gli binding site 
(GliBS) was identified in the vicinity of the Vdr gene. This putative GliBS is located 312 bp 
upstream of the first exon of the Vdr gene in a reverse complement orientation (Fig. 8 and 
Tab. 17). To assess the activation status of the Vdr promoter (pVdrPromwt) in the presence of 
Gli transcription factors, NIH/3T3 cells, which have an intact Hh signaling pathway (Myers et 
al. 2013), were co-transfected with Gli1, Gli2 or Gli3 expression plasmids and a murine Vdr 
promoter reporter plasmid (pVdrPromwt). The pVdrPromwt plasmid consists of a firefly-
luciferase gene under the control of a 481 bp long Vdr promoter fragment that includes the 
GliBS (Jehan and DeLuca 2000) (Fig. 8).  
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Figure 8: Schematic representation of the Vdr promoter region. The Gli binding site (GliBS) is located 
312 bp upstream of the first exon (exon 1) of the Vdr gene. The pVdrPromwt reporter plasmid contains 481 bp of 
the Vdr promoter region, including 46 bp of exon 1. The 9th nucleotide (red) of the GliBS of the Vdr promoter is 
different than the consensus sequence described (Winklmayr et al. 2010)(compare table 17). 
 
Table 17: GliBS of the Vdr promoter 
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* indicates GliBS according to (Winklmayr et al. 2010). Arrows indicate the genomic orientation of the GliBS. 
Differences to the optimal binding site (active GliBS) are indicated in red (according to (Winklmayr et al. 
2010)). The GliBS of the Vdr promoter has a reverse complement orientation. 
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Dual-luciferase assays revealed that the pVdrPromwt reporter (Fig. 9) was not 
stimulated by any of the co-transfected Gli TFs. (Fig. 9). These results strongly suggest that 
the analyzed Vdr promoter fragment is not regulated by Gli TFs and support the findings that 
transfection of Gli3 did not result in upregulation of Vdr gene transcription. 
 
 
Figure 9: Analysis of Vdr promoter reporters in presence of Gli transcription factors. Dual-luciferase based 
analysis of NIH/3T3 co-transfected with pVdrPromwt (endogenous Gli binding motif; wt GliBS) and Gli1, Gli2 
or Gli3 expression plasmids. Transfection of empty vector (pCR3.1) served as a control. Firefly luciferase 
activities were normalized to the respective renilla luciferase activities. All data are represented as mean +/- 
SEM of at least three experiments in triplicates. Values obtained from pCR3.1/pVdrPromwt co-transfected cells 
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6.2. Role of calcitriol as an anticancer agent 
Recently our group showed that calcitriol, the hormonally active form of vitD3, 
effectively inhibits Hh signaling in vitro and in vivo (Uhmann et al. 2011a; Uhmann et al. 
2012). Moreover other labs demonstrated in vitro inhibition of Hh signaling by the calcitriol 
precursor vitD3 (Bijlsma et al. 2006; Tang et al. 2011). Here, the mechanism resulting in 
calcitriol-mediated Hh signaling inhibition was investigated. In addition, calcitriol was 
combined with other drugs to enhance the Hh-inhibitory effect and to potentially increase its 
anti-tumoral properties.  
 
6.2.1. Enhancement of potential antitumoral effects of calcitriol in vitro 
Recently it has been described that the antifungal drugs azoles ITZ and KTZ 
efficiently inhibit Hh signaling and show anti-tumoral potential (Kim et al. 2014; Kim et al. 
2013; Kim et al. 2010). Moreover, azoles have been described as inhibitors of cytochrome 
P450 enzymes, that are, among others, involved in calcitriol metabolism (see chapter 2.3 and 
below). For the azole ITZ has been demonstrated that it acts on the level of Smo via a 
mechanism distinct from that of CP (Kim et al. 2010). Since the efficiencies of anti-cancer 
therapies often are enhanced by combination of drugs that intensify the effects of each other 
(Chou 2010) we hypothesized that azoles might enhance the anti-tumoral potential of 
calcitriol due to the following two mechanism: 1) Azoles may increase the intracellular 
concentrations or increase the stability of calcitriol due to the inhibition of the calcitriol 
degrading 24-hydroxylase (Cyp24a1) (Hansdottir et al. 2008; Muindi et al. 2010; Vanden 
Bossche et al. 2004) and 2) Calcitriol and azoles might inhibit Smo by binding to different 
sites that may result in an enhancement of Hh signaling inhibition superior to that of single 
drug treatments. Moreover, since most BCCs show loss-of-function mutations of the 
tumorsuppressor Ptch and treatment-resistance usually occurs at the levels of Smo (reviewed 
in (Epstein 2008)) we assumed that combination of two distinct Smo inhibitors could be a 
beneficial therapy strategy. Since the effects of calcitriol are best studied in BCCs (Uhmann et 
al. 2011a) we used the murine BCC cell line ASZ001 as an in vitro model. 
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6.2.1.1. Hh-inhibitory effects of calcitriol are specifically enhanced by azoles 
ASZ001 cells were treated with calcitriol in combination with ITZ or KTZ using 
normal culture medium containing 2 % FCS. As expected from our recent studies, single 
calcitriol treatment significantly inhibited Gli1 expression (Fig. 10 A and D), induced 
Cyp24a1 expression (Fig. 10 B and E) and reduced proliferation of ASZ001 cells (Fig. 10 C 
and F). Single KTZ or ITZ treatments had no effects on Gli1 or Cyp24a1 expression or 
proliferation, but the combinations calcitriol/KTZ and calcitriol/ITZ also significantly 
inhibited Gli1 and induced Cyp24a1 expression and reduced proliferation. Only the 
combination calcitriol/KTZ resulted in significantly reduced Gli1 expression compared to 
both single treatments. Only Cyp24a1 expression was significantly lower after calcitriol/ITZ 
treatment compared to calcitriol alone (Fig. 10 E). 
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Figure 10: Combined calcitriol/azole treatment of ASZ001 cells using FCS-containing medium. Relative 
quantification of (A and D) Gli1 or (B and E) Cyp24a1 expression levels and (C and F) BrdU-incorporation 
assays of ASZ001 cells after treatment with 10 nM calcitriol (cal), (A to C) 1 µM ketoconazole (KTZ), (D to F) 
1 µM itraconazole (ITZ) or a combination of both. Gene expression levels were normalized to 18S rRNA 
expression. The respective solvent-treated controls (solvent) for each experiment were set to 1. All experiments 
were performed in 154-CF supplemented with 2 % heat-inactivated, chelexed FCS, 0.05 mM CaCl2 and 1 % PS 
as described in the material and method section. The treatments for gene expression were conducted for 24 h, 
BrdU-incorporation-assays for 48 h. All data represent at least 3 independent experiments measured in 
triplicates, represented as mean +/-SEM; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
Together these results show that ITZ and KTZ do not have an impact on Hh signaling 
activity or cellular proliferation. They also do not enhance the calcitriol-mediated anti-tumoral 
effects if used in FCS-containing medium. 
Because the effectiveness of ITZ-mediated Hh signaling inhibition can be quenched by 
FCS concentration higher than 2 % in the culture medium (Kim et al. 2010), we next 
performed a similar experiment using FCS-free medium. To decrease the colloid-osmotic 
pressure on the cells 1.5 % (w/v) BSA was added to the medium. Using these settings we 
found that single treatments with the azoles significantly inhibited Hh signaling activity as 
measured by reduced Gli1 expression (Fig. 11 A and D). Moreover, the combination of the 
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azoles with calcitriol significantly intensified Hh signaling inhibition compared to either of 
the single treatments. Again Cyp24a1 expression was strongly induced by single calcitriol and 
calcitriol/azole treatments (Fig. 11 B and E). In addition, calcitriol/ITZ, but not 
calcitriol/KTZ-treatment, significantly induced Cyp24a1 expression compared to the 
respective single calcitriol treatments (Fig. 11 E). The combination of calcitriol with the 
azoles also significantly reduced cellular proliferation compared to solvent (ITZ, Fig. 11 F) or 
single-treatments (KTZ, Fig. 11 C). 
Taken together, these experiments reveal that under serum-starved conditions azoles 
significantly intensify the Hh-inhibitory potential of calcitriol. Moreover the data suggest that 
azoles also cooperate with calcitriol in inhibition of cellular proliferation. 
  
 Results 














































































































































Figure 11: Combined calcitriol/azole treatment of ASZ001 cells using FCS-free medium. Relative 
quantification of (A and D) Gli1 or (B and E) Cyp24a1 expression levels and (C and G) BrdU-incorporation 
assays of ASZ001 cells after treatment with 10 nM calcitriol (cal), (A to C) 1 µM ketoconazole (KTZ), (D to F) 
1 µM itraconazole (ITZ) or a combination of both. Gene expression levels were normalized to 18S rRNA 
expression. The respective solvent-controls for each experiment were set to 1. All experiments were performed 
in 154-CF supplemented with 1.5 % BSA, 0.05 mM CaCl2 and 1 % PS as described in the material and method 
section. Prior to the treatment a 24 h starvation step was included. For gene expression analyses the cells were 
treated with the substances for 24 h, for BrdU-incorporation assays 48 h. All data represent at least 3 
independent experiments measured in triplicates, represented as mean +/-SEM. *, p<0.05; **, p<0.01; ***, 
p<0.001; ****, p<0.0001. 
To analyze if the enhancement of calcitriol-mediated inhibition of Hh signaling and 
proliferation is specific for KTZ and ITZ, we next replaced the azoles with the well-known 
Hh inhibitor CP. Since the effectiveness of CP is not altered by FCS (Uhmann et al. 2011a) 
these experiments were conducted in FCS-containing growth medium. As expected single 
treatments with calcitriol and CP significantly reduced Gli1 expression levels compared to 
solvent-treated controls (Fig. 12 A). However, the combination did not intensify this 
inhibition when compared to the single treatments. Cyp24a1 expression was strongly induced 
by calcitriol, both alone or in combination with CP (Fig. 12 B). Furthermore, the cellular 
proliferation was significantly reduced by calcitriol and the combination calcitriol/CP, but not 
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by CP alone (Fig. 12 C). Again, the anti-proliferative effect of the combined treatment was 
not enhanced compared to the single calcitriol treatment. These results suggest that the 
combination of calcitriol and CP, in contrast to azoles, does not enhance Hh inhibition or anti-
proliferative effects in ASZ001 cells. 
 
 
Figure 12: Combined calcitriol/CP treatment of ASZ001 cells does not result in combined antitumoral 
effects. Relative quantification of (A) Gli1 or (B) Cyp24a1 expression levels and (C) BrdU-incorporation assays 
of ASZ001 cells after treatment with 10 nM calcitriol (cal) and 5 µM cyclopamine (CP) alone or in combination. 
Gene expression levels were normalized to 18S rRNA expression levels. The respective solvent-treated controls 
for each experiment were set to 1. Experiments were performed in 154-CF supplemented with 2 % chelexed 
FCS, 0.05 mM CaCl2 and 1 % PS. The treatments for gene expression were conducted for 24 h, the BrdU-
incorporation assays for 48 h. All data represent at least 3 independent experiments measured in triplicates 
represented as mean +/-SEM. *, p<0.05; **, p<0.01; ***, p<0.001. 
Finally, ASZ001 cells were treated with ITZ and CP. These experiments were 
conducted in FCS-free medium supplemented with 1.5 % BSA. Both compounds significantly 
reduced Gli1 expression (Fig. 13 A). However, no cooperative effect was observed. As 
expected none of the treatments altered Cyp24a1 expression (Fig. 13 B). Significant anti-
proliferative effects were observed by the single ITZ and combined CP/ITZ treatment (Fig. 13 
C).  
Taken together these experiments reveal that azoles can significantly intensify the Hh-
inhibitory potential of calcitriol. Moreover these data suggest a cooperative antiproliferative 
effect of the substances. In contrast, neither the combination of calcitriol and CP nor of CP 
and an azole are sufficient to enhance the anti-tumoral effects of the respective other drug. 
Therefore, the observed cooperative effects must be a specific phenomenon for calcitriol and 
azoles. 
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Figure 13: Combined treatment of ASZ001 with CP and ITZ does not result in combined antitumoral 
effects. Relative quantification of (A) Gli1 or (B) Cyp24a1 expression levels and (C) BrdU-incorporation-assays 
of ASZ001 cells after treatment with 5 µM cyclopamine (CP) and 1 µM itraconazole (ITZ) alone or in 
combination. Gene expression levels were normalized to 18S rRNA expression levels. The respective solvent-
controls for each experiment were set to 1. Experiments were performed in 154-CF supplemented with 1.5 % 
BSA, 0.05 mM CaCl2 and 1 % PS. The treatments for gene expression were conducted for 24 h, the BrdU-
incorporation-assays for 48 h. All data represent at least 3 independent experiments measured in triplicates 
represented as mean +/-SEM; *, p<0.05; **, p<0.01. 
 
6.2.1.2. Combined calcitriol/azole treatment of murine BCC biopsies 
To evaluate the effect of a combined calcitriol/azole treatment in a more sophisticated 
cell culture experiment, murine BCC biopsies were isolated from BCC-bearing skin of 
3 Ptchflox/flox CreERT2+/- mice 60 days after tumor induction (see chapter 5.5.4). Since our 
previous analyses on ASZ001 cells showed that FCS quenched the azole-mediated Hh 
signaling inhibition the short-term culture and calcitriol/azole treatment was conducted in 
medium supplemented with 1.5 % BSA for 7 days (for details see chapter 5.2.11).  
Unfortunately, most biopsies showed signs of necrosis (e.g. destructed dermis; 
fragmented nuclei), a fact that was never observed for skin biopsies cultured in FCS-
supplemented medium. Nevertheless, gene expression analyses were still possible. This was 
demonstrated by Cyp24a1 expression that was significantly induced by single calcitriol and 
combined calcitriol/azole treatment (Fig. 14 B and D). Single calcitriol as well as single ITZ 
treatment reduced Gli1 expression (Fig. 14 A and C), whereas single KTZ treatment did not 
(Fig 14 A). However, in contrast to the cell culture experiment using ASZ001 cells, the 
combined calcitriol/azole treatments did not further reduce Gli1 expression, but rather 
increased it in in vitro cultured BCC-bearing skin (Fig 14 A and C). 
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Figure 14: Combined treatment of Ptchflox/flox CreERT2+/- skin biopsies with calcitriol and azoles. Relative 
quantification of (A and C) Gli1 or (B and D) Cyp24a1 expression levels of cultured BCC-biopsies after 
treatment with 10 nM calcitriol (cal) and (A and B) 1 µM ketoconazole (KTZ) or (C and D) 1 µM itraconazole 
(ITZ) alone or in combination. Gene expression levels were normalized to 18S rRNA expression levels. The 
respective solvent-treated controls for each experiment were set to 1. Experiments were performed in 154-CF 
supplemented with 1.5 % BSA, 0.05 mM CaCl2 and 1 % PS. All data were measured in triplicates represented as 
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6.2.2. Evaluation of combined calcitriol/azole treatments in vivo 
Our in vitro analyses showed that azoles intensify calcitriol-mediated Hh signaling 
inhibition and anti-proliferative effects in ASZ001 cells, but not in BCC-biopsies. In a final 
approach we therefore tested the anti-tumoral effects of the calcitriol/azole combination in 
vivo.  
6.2.2.1. Combined calcitriol/azole treatment of BCC-bearing Ptchflox/flox CreERT2+/- 
mice 
Recently our group treated BCC-bearing Ptchflox/flox CreERT2+/- mice with 100 ng/kg/d 
calcitriol. When the drug was applied for 90 days immediately after tumor induction, tumor 
growth was significantly inhibited (Uhmann et al. 2011a). In order to combine calcitriol with 
azoles, we first tested the tolerance of the mice towards azoles in a pilot experiment. The 
amount of azoles was based on literature data (MacCallum and Odds 2002; McCabe et al. 
1987; Rodriguez-Cuesta et al. 2010; Toledo et al. 2003). 12 8 week-old C57BL/6N mice were 
randomized into two cohorts. One group received 100 ng/kg calcitriol i.p. daily (this dose was 
adopted from our previous studies (Uhmann et al. 2011a)) and 100 mg/kg KTZ orally thrice a 
week (n=6), the second group received 100 ng/kg calcitriol i.p. daily and 100 mg/kg ITZ 
orally thrice a week (n=6)(Fig. 15). After 90 days 3 mice of each treatment group were 
sacrificed. The remaining animals were observed for additional 30 days to observe therapy-
induced long-term effects. During the whole experiment and the observation period the 
animals were weighed twice a week as a marker for the animal’s health (Fig. 16). 
 
Figure 15: Schematic representation of the treatment schedule for determination of the tolerated dose of 
the combined calcitriol/azole therapy. 8 week-old C67BL/6N mice were treated with 100 ng/kg calcitriol in 
combination with 50 or 100 mg/kg ketoconazole (KTZ) or itraconazole (ITZ). Calcitriol treatment was 
conducted daily by i.p. injection; azole treatment was conducted thrice a week by oral gavage. After 90 days of 
treatment 3 mice of each treatment cohort were sacrificed and the remaining mice were observed for additional 
30 days.  
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Figure 16: The combined calcitriol/azoles treatment did not impact the general health conditions of 
C57BL/6N mice. Relative weight changes of C75BL/6N mice treated with 100 ng/kg calcitriol (cal) in 
combination with 100 mg/kg ketoconazole (KTZ, n=6) or itraconazole (ITZ, n=6). The weight of each animal at 
the beginning of the treatment was set to 100 % and used to normalize the weight of the respective mouse of the 
following days. The treatment was conducted for 90 days. At the end of the treatment (day 90, red, dashed line) 
3 animals of each treatment group were sacrificed and the remaining mice were observed for additional 30 days. 
Irrespective of the received treatment all animals gained weight within the observation 
period (Fig. 16). No adverse effects or general health problems were determined, indicating 
that a combined treatment of 100 ng/kg/d calcitriol and 100 mg/kg azole thrice a week should 
be tolerated by BCC-bearing Ptchflox/flox CreERT2+/- mice. 
BCC were induced in 42 8 week-old Ptchflox/flox CreERT2+/- mice by i.m. injection of 
100 µg tamoxifen (see chapter 5.5.4) (Zibat et al. 2009). Directly after the tamoxifen injection 
the animals were randomized into 6 groups and treated with calcitriol (n=7), KTZ (n=7) or 
ITZ (n=7) or with the combination calcitriol/KTZ (n=7) or calcitriol/ITZ (n=7). Solvent-
treated tamoxifen-injected Ptchflox/flox CreERT2+/- mice served as controls (n=7). The treatment 
was continued for 90 days (Fig. 17) as described in the material and method section (5.5.5 and 
5.5.6). During the treatment period the animals were weighed twice a week. 5 mice were 
sacrificed within the treatment period: one solvent-treated control mouse developed a 
medulloblastoma, two mice from the calcitriol/KTZ treatment group showed extensive weight 
loss, one mouse from the ITZ treatment cohort developed a hydrocephalus and 1 mouse from 
the calcitriol/ITZ treatment group developed an ulcerous abscess on the right flank. These 
mice were excluded from further analyses. 
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Figure 17: Schematic representation of the schedule of the combined calcitriol/azole treatment of 
Ptchflox/flox CreERT2+/- mice. 42 8 week-old Ptchflox/flox CreERT2+/- were i.m. injected with 100 µg tamoxifen. 
Directly thereafter the treatment was started and continued for 90 days. 6 mice received 100 ng/kg calcitriol 
daily by i.p. injection and 100 mg/kg ketoconazol (KTZ, n= 7) or itraconazole (ITZ, n=7) thrice a week by oral 
gavage or the respective combinations with calcitriol/KTZ (n=7) or calcitriol/ITZ (n=7). 7 mice received the 
respective solvents.  
All remaining mice treated for 90 days gained weight until an age of 12 week (i.e. 
45 days after onset of therapy) irrespective of the received treatment (Fig. 18). Thirty days 
after tamoxifen injection all mice developed macroscopically visible BCC at the tail and ear 
skin. 
 
Figure 18: The combined calcitriol/azoles treatment did not impact the general health conditions of 
Ptchflox/flox CreERT2+/- mice. Relative weight change of tamoxifen-injected Ptchflox/flox CreERT2+/- mice under 
calcitriol/azole therapy as indicated in Fig 17. The weight of each animal at the beginning of the treatment was 
set to 100 % and used to normalize the weight of the respective mouse of the following days. 
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Ninety days after therapy start all animals were narcotized and preserved by perfusion 
as described (Chapter 5.5.3 and 5.5.8). Prior fixation, BCC tissue from the tail skin was 
sampled for gene expression analyses.  
As shown by representative images of HE-stained paraffin section the tumors show 
typical histological features of nodular BCC (Zibat et al. 2009), irrespective of the treatment 
(Fig. 19). 
 
Figure 19: Histological appearance of BCC from calcitriol/azole-treated Ptchflox/floxERT2+/- mice. 
Representative HE-stained paraffin sections of BCC-bearing skin from Ptchflox/flox CreERT2+/- mice 90 days after 
tumor induction. The mice were treated for 90 days with (A and B) solvent (xanthan gum/sun flower seed oil), 
(C and D) 100 ng/kg calcitriol daily (cal), (E and F) 100 mg/kg ketoconazole thrice a week (KTZ), (G and H) 
calcitriol/KTZ, (I and J) 100 mg/kg itraconazole thrice a week (ITZ) or (K and L) calitriol/ITZ. 100 x 
magnification. 
Gene expression analyses of Cyp24a1 expression in the BCC-bearing skin confirmed 
that calcitriol alone or in combination with azoles has reached the tumor tissue (Fig. 20 and 
21, C). Measurement of Gli1 revealed that single calcitriol and single azole treatments only 
slightly inhibited the Gli1 expression (Fig. 20 and 21, A). Surprisingly, and as seen in BCC 
biopsies (see chapter 6.2.1.2) the combination of calcitriol with an azole increased Gli1 
expression levels. 
Similar results were observed for Gli2 expression (Fig. 20 and 21 B). Thus, all single 
treatments slightly decreased Gli2 expression, whereas the combined calcitriol/KTZ treatment 
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did not change, and the calcitriol/ITZ treatment increased Gli2 expression compared to the 
solvent-treated controls. 
Next, the expression levels of several epidermal differentiation markers were 
analyzed. The intermediate differentiation markers Keratin 1 (K1) and 10 (K10) (Bikle 2004; 
Blanpain and Fuchs 2006) are not only regulated by Vdr signaling (Bikle 2004), but also by 
active Hh signaling (Jetten 1990; Regl et al. 2004). Late epidermal differentiation is 
characterized by the expression of Loricirin (Lor) and Involucrin (Ivl) (Sandilands et al. 2009) 
and Transglutaminase (Tgm1) (Bikle 2004; Blanpain and Fuchs 2006). The latter marker is 
also known to be regulated by Vdr signaling (Bikle 2004). 
In contrast to the single calcitriol, ITZ and KTZ treatments, which had no impact K10 
expression levels (Fig. 20 and 21 D), the combined calcitriol/ITZ treatment significantly 
enhanced K10 expression (Fig. 21 D) compared to single calcitriol. The Tgm1 expression 
level was slightly reduced by single calcitriol and combined calcitriol/KTZ treatments (Fig. 
20 and 21, E), whereas application of single azoles did not influence the expression of Tgm1. 
Remarkably, the expression of this differentiation marker was induced in the calcitriol/ITZ 
treated cohort when compared to the calcitriol- and ITZ-treated animals (Fig. 21 E). 
Analyses of the tumor area of HE-stained BCC sections (see chapter 5.3.3) revealed 
that none of the treatments significantly inhibited BCC growth (Fig 20 and 21 F) although a 
tendency was seen in animals that have been treated with ITZ or calcitriol/ITZ  
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Figure 20: Combined calcitriol/KTZ treatment of BCC-bearing Ptchflox/flox CreERT2+/- mice. Relative 
quantification of (A) Gli1, (B) Gli2, (C) Cyp24a1, (D) K10 and (E) Tgm1 expression levels and (F) relative 
tumor area after 90 days of treatment of tamoxifen-injected Ptchflox/flox CreERT2+/- mice with 100 ng/kg calcitriol 
(cal) or 100 mg/kg ketoconazole (KTZ) or a combined therapy in comparison to solvent-treated controls. (A-E) 
Gene expression levels were normalized to 18S rRNA expression and the solvent-treated controls of each 
experiment were set to 1. (F) Tumor areas were assessed from at least three vision fields of HE-stained BCC 
sections and the solvent-treated controls were set to 100 %. The data are represented as mean +/-SEM. *, p<0.05. 
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Figure 21: Combined calcitriol/ITZ treatment of BCC-bearing Ptchflox/flox CreERT2+/- mice. Relative 
quantification of (A) Gli1, (B) Gli2, (C) Cyp24a1, (D) K10 and (E) Tgm1, and (F) relative tumor area after 
90 days of treatment of tamoxifen-injected Ptchflox/flox CreERT2+/- mice with 100 ng/kg calcitriol (cal) or 
100 mg/kg itraconazole (ITZ) or a combined therapy in comparison to solvent-treated controls. (A-E) Gene 
expression levels were normalized to 18S rRNA expression and the solvent-treated controls of each experiment 
were set to 1. (G) Tumor areas were assessed from at least three vision fields of HE-stained BCC sections and 
the solvent-treated controls were set to 100 %. The data are represented as mean +/-SEM. *, p<0.05; **, p<0.01; 
***, p<0.001. 
In summary these data show that the in vivo application of calcitriol in combination with an 
azole neither inhibits Hh signaling nor reduces BCC size of Ptchflox/flox CreERT2+/- mice, 
despite the fact that calcitriol has reached the tumor. Paradoxically, the combinations rather 
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6.2.2.2. Combined calcitriol/ITZ treatment of ASZ001-transplanted nude mice 
In parallel, we investigated the combined treatment of calcitriol/ITZ on ASZ001-
allografted nude mice. To test if ASZ001 can form tumors 1 x 106 ASZ001 cells transplanted 
into the right and the left flank of 3 8 week-old nude mice (see chapter 5.5.7) gave rise to 
slow-growing tumors which were macroscopically visible and palpable after one week (Fig. 
22). The growth of the grafted tumors was determined by measuring height, width and length 
of the tumors thrice weekly until one of the parameters exceeded 20 mm (Fig. 22). Since 6 to 
7 weeks after the transplantation the tumors grew larger than 20 mm in one dimension the 
experiment was stopped and the mice were sacrificed. Histological examination of the tumors 
revealed that they displayed BCC-like features (Fig. 23). 
 
 
Figure 22: Tumor growth of subcutaneously transplanted ASZ001 cells in nude mice. (A) Tumor volume, 
(B) length, (C) width and (D) height of tumors from subcutaneously transplanted ASZ001 cells in nude mice. 
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Figure 23: Representative images of ASZ001-allografts of nude mice. (A to C) HE-stained paraffin sections 
of ASZ001-allografts of nude mice 37 days after transplantation. Some tumors show areas of high keratinization 
(K in A) in the center of each nodule. T: tumor, S: stroma. 100 x magnification. 
In the treatment cohort the mice were randomly grouped into 4 cohorts of 6 mice one 
week after the transplantation. The animals were treated with 100 ng/kg calcitriol, 
100 mg/kg ITZ or a combination of both drugs for 30 days according to the treatment scheme 
shown in figure 24. Solvent-treated animals served as controls. One mouse from the solvent-
treated control cohort was removed from the study due to an injury. 
 
 
Figure 24: Schematic representation of the treatment schedule of the combined calcitriol/azole therapy of 
ASZ001-allografted nude mice. 8 week-old nude mice were transplanted with 1 x 106 ASZ001 in each flank 
(see chapter 5.5.7). 1 week after the transplantation the treatment was started and continued for 30 days. 6 mice 
received 100 ng/kg calcitriol daily by i.p. injection and 100 mg/kg itraconazole (ITZ) thrice a week by oral 
gavage or a combination of both (n=6) or respective solvent (n=5). 
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Throughout the experiment the tumor growth was determined thrice per week by 
measuring the length, width and height of the tumors and the volume was calculated (for 
details see chapter 5.5.7). Thereafter the mice were sacrificed; the tumors were weighed and 
preserved for histological and molecular analyses. Irrespectively of the treatment all grafted 
tumors grew similar to an approximate volume of 400 mm3 until therapy end (Fig. 25 A). 
Only at day 16 after transplantation the solvent-treated tumors were significantly larger than 
those treated with calcitriol/ITZ. The tumor weight at the end of the study was not 
significantly altered after any treatment (Fig. 25 B). 
 
Figure 25: Growth and weight of subcutaneously transplanted ASZ001 tumors during a combined 
calcitriol/ITZ treatment. (A) Tumor volume and (B) weight of subcutaneously transplanted ASZ001 cells in 
nude mice (A) during and (B) after 30 day treatment with 100 ng/kg calcitriol (cal) and 100 mg/kg itraconazole 
(ITZ) or a combination of both. Solvent-treated ASZ001 transplanted mice served as controls. The tumor 
volumes were calculated by measuring the length, width and the height using a digital caliper (see chapter 5.5.9). 
At the end of the experiments the excised tumors were weighed. * p<0.05 
In contrast to the BCC of Ptchflox/flox CreERT2+/- mice, the single calcitriol and ITZ, as 
well as the combined calcitriol/ITZ treatment, led to significant changes at the molecular 
levels (Fig. 26). Significantly reduced Gli1 expression was observed after single calcitriol and 
ITZ treatment, with calcitriol being slightly more potent than ITZ (Fig. 26 A). The combined 
calcitriol/ITZ treatment only slightly decreased Gli1 expression, which was not statistically 
significant. Cyp24a1 expression analyses revealed that single calcitriol as well as combined 
calcitriol/ITZ therapy led to significantly increased Vdr signaling activity (Fig. 26 B) 
indicating the successful delivery and accumulation of calcitriol to the tumor. Nevertheless, 
the Vdr signaling induction after combined calcitriol/ITZ therapy was significantly lower than 
after single calcitriol treatment. When the proliferative activity of the tumors was analyzed by 
immunohistochemical stainings of Ki67, the amount of Ki67+ cells was significantly 
increased in calcitriol- and calcitriol/ITZ-treated tumors (Fig. 26 C). Moreover, the 
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combination of calcitriol and ITZ significantly elevated the proliferative activity compared to 
single calcitriol-treated tumors. The single ITZ therapy did not change the proliferative 
activity of the tumors compared to solvent-treated tumors. 
 
 
Figure 26: Molecular analyses of subcutaneously transplanted ASZ001 tumors after a combined 
calcitriol/ITZ treatment. Relative quantification of (A) Gli1 or (B) Cyp24a1 expression levels and (C) relative 
Ki67-positive (Ki67+) cells of subcutaneously transplanted ASZ001 cells in nude mice after 30 day therapy with 
100 ng/kg calcitriol (cal) and 100 mg/kg itraconazole (ITZ) or the drugs alone. Solvent-treated ASZ001-
transplanted mice served as controls. Gene expression levels were normalized to TBP expression. Gli1 and 
Cyp24a1 expression levels of the solvent-treated controls were set to 1. Anti-Ki67 stainings and analyses were 
performed as described in the material and method section. The data are represented as mean +/-SEM. *, p<0.05; 
**, p<0.01; ***, p<0.001; ****, p<0.0001. 
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The analyses of the intermediate epidermal differentiation marker K1 and K10, as well 
as late epidermal differentiation marker Lor, Ivl and Tgm1 revealed that none of the 
treatments significantly altered the expression levels of these genes (Fig. 27). 
 
 
Figure 27: Expression analyses of epidermal differentiation markers of subcutaneously transplanted 
ASZ001 tumors after a combined calcitriol/ITZ treatment. Relative quantification of (A) K1 or (B) K10 (C) 
Loricrin (D) Involucrin and (E) Tgm1 expression levels of subcutaneously transplanted ASZ001 cells in nude 
mice after 30 day therapy with 100 ng/kg calcitriol (cal) and 100 mg/kg itraconazole (ITZ) or the drugs alone. 
Solvent-treated ASZ001 transplanted mice served as controls. Gene expression levels were normalized to TBP 
expression. The respective solvent-treated controls were set to 1. The data are represented as mean +/-SEM. *, 
p<0.05; **, p<0.01. 
Together these data show that in contrast to their anti-tumoral effects in cell culture 
(see chapter 6.2.1.1) calcitriol, ITZ as well as a combination of both drugs were not sufficient 
to inhibit proliferation or to induce differentiation of ASZ001 cells in vivo, despite their 
potential for simultaneous inhibition of Hh signaling and activation of Vdr signaling.  
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An ineffective anti-tumoral response can be explained by the absence of drug 
accumulation in the tumor. However, activation of Vdr signaling (Fig. 26 B) showed that 
calcitriol accumulated in the tumors. In order to determine intra-tumoral accumulation of ITZ 
we measured the ITZ levels directly in tumor tissue by mass spectrometry (see chapter 5.4.3). 
As shown in figure 28, ITZ was detected in transplanted ASZ001 tumors both after single ITZ 
and combined calcitriol/ITZ treatment. These data suggest that calcitriol as well as ITZ have 
entered the tumor cells. 
 
Figure 28: LC-MS/MS-based determination of intra-tumoral ITZ in transplanted ASZ001 tumors. LC-
MS/MS-based determination of intraconazole (ITZ) of subcutaneously transplanted ASZ001 cells in nude mice 
after 30 day treatment with 100 ng/kg calcitriol (cal) and 100 mg/kg ITZ or the combination of both. Solvent-
treated ASZ001 transplanted mice served as controls. **** p<0.0001; n.s.: not significant; AU: arbitrary units. 
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Finally we analyzed if the in vivo treatment with these drugs might have induced the 
expression of multidrug resistance proteins (Mdr). Mdrs are P-glycoproteins (P-gp) of the cell 
membrane, which belong to the superfamily of ATP-binding cassette transporters and are 
known transporters of xenobiotic compounds like anti-cancer drugs (Breier et al. 2013; Zhou 
2008). However, irrespective of the therapy none of the analyzed Mdr transcripts (Mdr1a, 
Mdr1b and Mdr2) significantly differed in their expression level compared to the solvent-
treated tumors (Fig. 29). 
 
 
Figure 29: Mdr expression of subcutaneously transplanted ASZ001 tumors after a combined calcitriol/ITZ 
therapy. Relative quantification of (A) Mdr1a or (B) Mdr1b and (C) Mdr2 expression levels of subcutaneously 
transplanted ASZ001 cells in nude mice after 30 day therapy with 100 ng/kg calcitriol (cal) and 100 mg/kg 
itraconazole (ITZ) or the drugs alone. Solvent-treated ASZ001 transplanted mice served as controls. Gene 
expression levels were normalized to Hprt expression. The respective solvent-treated controls were set to 1. The 
data are represented as mean +/-SEM. 
Taken together these data suggest that the ineffective anti-tumoral response of 
transplanted ASZ001 cells can be explained neither by the absence of drug accumulation in 
the tumor cells nor by intra-tumoral activation of Mdr genes. 
 
6.2.3. Analysis of the influence of ITZ on calcitriol-metabolism 
The in vitro studies showed that ITZ significantly cooperates with calcitriol in Hh 
signaling inhibition and Vdr pathway activation (compare Figs 10 and 11, chapter 6.2.1.1). 
Moreover, comparison of the effects of combined calcitriol/ITZ and calcitriol/KTZ treatments 
revealed that KTZ is less effective than ITZ. Based on these findings and the fact that azoles 
have been described as general inhibitor of cytochrome P450 enzymes (Kota et al. 
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2011Muindi, 2010 #4234) we investigated if ITZ might prevent calcitriol synthesis or 
degradation by inhibition of 25-hydroxylase or 24-hydroxylase, respectively (Chen et al. 
2012; Christakos et al. 2010).  
In order to measure a potential alteration of calcitriol metabolism, we incubated 
ASZ001 cells for 6 h with 2 µM ITZ in combination with 2 µM 25(OH)D3. Afterwards, the 
intracellular amounts of 25(OH)D3, the 25(OH)D3 degradation product 24,25(OH)2D3, and 
calcitriol (compare Fig. 3) were quantified by LC/MS-MS-based assays (see 0). The detection 
of the calcitriol degradation product 1α,24,25(OH)3D3 was not possible in our hands. But 
since the degradation of 25(OH)D3 is catalyzed by 24-hydroxylase that also catalyzes the 
degradation of calcitriol (compare Fig. 3, (Chen et al. 2012; Christakos et al. 2010)) 
24,25(OH)2D3 was used as a surrogate marker for 24-hydroxylase-activity and a marker for 
calcitriol degradation. HaCaT cells were simultaneously analyzed as a control, because this 
cell line has been described to convert 25(OH)D3 to calcitriol (Lehmann 1997). 
In both, ASZ001 and HaCaT cells, the intracellular amount of 25(OH)D3 was 
significantly elevated after single 25(OH)D3 or 25(OH)D3/ITZ treatment compared to the 
solvent-treated controls (Fig. 30 A and D). However, the difference between the 25(OH)D3 
and the 25(OH)D3/ITZ-treated cells was not significant. Similarly, the levels of 
24,25(OH)2D3 were significantly elevated in single 25(OH)D3 and 25(OH)D3/ITZ-treated 
cells compared to the control, but did not significantly differ from each other (Fig. 30B and 
E). An enhanced synthesis of calcitriol upon any treatment was not measurable in ASZ001 
cells (Fig. 30 C) whereas in HaCaT cells significantly elevated calcitriol levels were observed 
after 25(OH)D3 and 25(OH)D3/ITZ treatment (Fig. 30 F), that again did not significantly 
differ from each other (Fig. 30 F). 
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Figure 30: ITZ did not inhibit the enzymatic activity of the 1α-hydroxylase and 24-hydroxylase in ASZ001 
and HaCaT cells. LC/MS-MS-based intracellular quantification of the vitD3 metabolites (A and D) 25(OH)D3, 
(B and E) 24,25(OH)2D3 and (C and F) calcitriol in (A to C) ASZ001 or (D to F) HaCaT cells after 6 h 
incubation with 2 µM 25(OH)D3 or 2 µM itraconazole (ITZ) alone or in combination of both drugs. Solvent-
treated cells served as controls. The data were normalized to the respective solvent-treated controls (100 %). The 
experiments were performed at least three times in triplicates. Each point represents the mean +/- SEM of all 
experiments. * p<0.05, ** p<0.01 compared to solvent control, n.s.: not significant. 
Based on these data we conclude that ITZ does not influence the enzymatic activity of 
the 25-hydroxylase or the 24-hydroxylase and thus calcitriol synthesis from 25(OH)D3 or on 
calcitriol degradation. Since the degradation of calcitriol was only measured indirectly by 
hydroxylation of 25(OH)D3 to 24,25(OH)2D3 we next investigated if ITZ directly influences 
the intracellular amount of calcitriol. For this purpose ASZ001 and HaCaT cells were treated 
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In both cell lines single calcitriol and combined calcitriol/ITZ treatment significantly 
elevated the intracellular levels of calcitriol (Fig. 31 A and B). However, no significant 
differences between the calcitriol or calcitriol/ITZ-treated cells were found (Fig. 31 A and C). 
Analyses of the intracellular ITZ levels revealed that both cell lines have accumulated ITZ 
after ITZ and calcitriol/ITZ treatment (Fig. 31 C and D). Significantly different ITZ amounts 
between single ITZ and combined calcitriol/ITZ-treated cells were not observed. 
Taken together these experiments suggest that ITZ neither affects the synthesis of 
calcitriol from its precursor 25(OH)D3 nor the calcitriol degradation in the analyzed cell lines. 
 
 
Figure 31: ITZ did not inhibit the enzymatic activity of the 24-hydroxylase in ASZ001 or HaCaT cells. 
LC/MS-MS-based intracellular quantification of (A and B) calcitriol (cal) or (C and D) itraconazole (ITZ) in (A 
and C) ASZ001 and (B and D) HaCaT cells after 6 h incubation with 100 nM cal or 2 µM ITZ alone or in 
combination of both drugs. Solvent-treated cells served as controls. The data were normalized to the respective 
solvent-treated control (100 %). The experiments were performed at least three times in triplicates. Each point 
represents the mean +/- SEM of all experiments. * p<0.05, ** p<0.01, *** p<0.001 compared to solvent control, 
n.s.: not significant. 
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6.3. Role	of	calcitriol	in	Hh	signaling	
6.3.1. Analyses of the synthesis and secretion of calcitriol in Ptch-deficient cells 
One possible scenario of the Ptch/Smo interaction in Hh signaling regulation is the 
Ptch-mediated secretion of Smo-inhibitory molecules (see introduction and (Bidet et al. 2011; 
Bijlsma et al. 2006; Corcoran and Scott 2006; Myers et al. 2013)). To validate the hypothesis 
that calcitriol is released by Ptch to inhibit Smo, we analyzed if Ptch is sufficient for the 
calcitriol secretion and if loss of Ptch impairs calcitriol synthesis. 
 
6.3.1.1. Ptch is essential for calcitriol secretion from the cell 
As mentioned in the introduction (chapter 2.4), calcitriol is an excellent inhibitor of 
Hh signaling. Since Ptch shows similarities to RND transporters (Taipale et al. 2002) and 
harbors an essential SSD (Strutt et al. 2001) we asked if Ptch is required for calcitriol 
secretion. This would strengthen our model in which calcitriol acts as the endogenous 
inhibitor released by Ptch to inhibit Smo. An elegant way to answer this question would have 
been the quantification of calcitriol in cell culture medium derived from wt Ptch and Ptch-/- 
cells. Unfortunately, the detection of calcitriol in the medium was not possible by non-
derivatized MS methods in our hands. 
We first asked whether media obtained from wt Ptch or Ptch-/- cells are capable to 
inhibit Hh signaling. To answer this question the cell line Shh light II that is stably tranfected 
with a Gli-responsive firefly luciferase reporter gene and a constitutively active renilla-
luciferase gene (Chen et al. 2002b) was used. Hh signaling activity in Shh light II cells was 
induced by Shh-N-CM treatment for 48 h.  
The conditioned medium (CM) was generated by loading wt Ptch and Ptch-/- cells with 
calcitriol or the respective solvent for 1 h. Thereafter the cells were plated in calcitriol-free 
culture medium. After 4, 6 or 8 h the CM was transferred to Shh-N-CM pre-treated  
Shh light II (for details see chapter 5.2.10 and Fig. 4). As a background control the same 
procedure was performed without cells (no cell control). After additional 48 h, dual-luciferase 
assays were performed.  
  
 Results 
- 86 - 
 
Irrespectively of the incubation time of 4 (Fig. 32 A), 6 (Fig. 32 B) or 8 h (Fig. 32 C) 
neither conditioned medium from wt Ptch nor from Ptch-/- cells significantly inhibited Hh 
signaling activity. 10 nM calcitriol or 5 µM CP (Fig. 32 D) served as positive controls.  
 
Figure 32: Conditioned medium from wt Ptch and Ptch-/- cells does not inhibit Hh signaling in Shh light II 
cells. Dual-luciferase based determination of Hh pathway activity using Shh light II after incubation with 
medium conditioned from wt Ptch, Ptch-/- or empty wells (no cell control) for (A) 4, (B) 6, (C) 8 h or (D). The 
conditioned medium (CM) and the treatment with 10 nM calcitriol (cal) or 5 µM cyclopamine (CP) as positive 
controls was conducted for 48 h. As a background-control calcitriol-loading was carried out using culture media 
without cells (no cell control). The conditioned medium was prepared in triplicates, the medium from empty 
wells in duplicates. The treatment of the transfected cells was conducted in duplicates for each medium. Data 
represent normalized firefly/renilla luciferase activity. The solvent-loaded control for each cell line and time-
point was set to 100 %; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
Since the possibility remained that Shh light II cells were not sensitive enough to 
detect small amounts of calcitriol in the media, a calcitriol-mediated VDR/RXR 
heterodimerization assay was established using a mammalian-two-hybrid system (M2H-
assay). For this purpose, NIH/3T3 cells were transfected with a firefly luciferase reporter 
vector (pFR-Luc) and plasmids for the expression of RXRα coupled to a GAL4 binding 
domain (BD-RXRα; bait) as well as a GAL4 activation domain fused to a VDR (AD-VDR; 
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prey). The activation of VDR/RXR heterodimerization by calcitriol then leads to the 
expression of the luciferase gene of the pFR-Luc plasmid under the control of the GAL4 
promoter ((Jacobs et al. 2013); calcitriol-sensitive M2H reporter system).  
As shown in figure 33, the calcitriol treatment induced high luciferase activity in pFR-
Luc, bait and prey transfected cells. In the absence of calcitriol only a low background 
induction was detectable. Also pFR-Luc alone or in combination with the bait did not induce 
background luciferase activity (Fig. 33 A). Treatment with a concentration series showed that 
the assay was highly sensitive towards calcitriol, but not 25(OH)D3. Thus, 0.01 nM calcitriol 
was sufficient to induce luciferase activity and maximal pathway activation was achieved 
using 10 nM calcitriol (Fig. 33 B, orange curve). In contrast, the highest amount used for 
25(OH)D3 (1 µM) was needed for an induction level similar to the half-maximal activation of 
calcitriol (Fig. 33 B, blue curve). 
 
 
Figure 33: Establishment of the calcitriol-sensitive M2H reporter system. Determination of the (A) 
specificity and (B) sensitivity of calcitriol-sensitive M2H reporter system. (A) Normalized firefly luciferase 
activity of 10 nM calcitriol (cal) or solvent-treated (solv) NIH/3T3 cells transfected with the plasmids pFR-Luc 
(reporter), pCMV-BD-RXR (bait) and/or pCMV-AD-VDR (prey) as indicated. The transfection with the 
constitutively active pGL-TK plasmid or pEGFP served as positive or negative control, respectively. Solvent-
treated reporter, bait and prey transfected were set to 1. (B) Normalized firefly luciferase activity of NIH/3T3 
transfected with the same as in (A) and treated with increasing amounts of calcitriol (orange) or 25(OH)D3 
(blue). The data were normalized to solvent (set to 1) for each drug and curve fitting was achieved using the 
“log(agonist) vs response (three parameter)”-function of GraphPad Prism 6. The experiments were performed 
once for establishment purposes. Each point represents the mean +/- SEM of biological triplicates. * p<0.05, ** 
p<0.01, *** p<0.001 compared to solvent control; AU: arbitrary units.  
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After establishment of the highly calcitriol-sensitive M2H reporter system we 
analyzed whether Ptch is essential for the release of calcitriol into the extracellular space (i.e. 
cell culture medium). The experiments revealed that after 4 (Fig. 34 A), 6 (Fig. 34 B) and 8 h 
(Fig. 34 C) the medium from calcitriol-loaded wt Ptch cells significantly activated 
VDR/RXR heterodimerization, whereas the medium from Ptch-/- cells only weakly induced 
the reporter. 
 
Figure 34: Ptch is necessary for the release of calcitriol. Calcitriol-sensitive M2H reporter assay of NIH/3T3 
transfected with the plasmids pFR-Luc, pCMV-BD-RXR (bait) and pCMV-AD-VDR (prey) after incubation with 
conditioned media from calcitriol or solvent-loaded wt Ptch and Ptch-/- fibroblasts . The media were conditioned 
for (A) 4, (B) 6 and (C) 8 h. The cells were loaded as described in chapter 5.2.11. As a background control 
calcitriol-loading was carried out using culture media without cells (no cell control). The conditioned medium 
was prepared in triplicates, the medium from empty wells in duplicates. The treatment of the transfected cells 
was conducted in duplicates for each medium. Data represent normalized firefly/renilla luciferase activity. The 
solvent-loaded control for each cell line and time-point was set to 1. All data represent at least 3 independent 
experiments represented as mean +/-SEM. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to 
solvent-treated control; AU: arbitrary units. 
 Results 
- 89 - 
 
Together, these experiments show that loss of Ptch perturbs the release of calcitriol 
into the medium. The minimal activation of the reporter by media from Ptch-/- fibroblasts (for 
comparison see empty-well control) can be explained by unspecific membrane shuttling of 
calcitriol rather than active transport through the cell membrane of Ptch-/- cells.  
We reasoned that Shh light II cells are probably not as sensitive to calcitriol treatment 
as the assay for measuring the activation of the VDR/RXR heterodimerization (calcitriol-
sensitive M2H reporter system). To validate this assumption we directly compared the 
sensitivities of the two assays by treating Shh-N-CoM-induced Shh light II cells and pFR-Luc, 
pCMV-BD-RXR, pCMV-AD-VDR transfected NIH/3T3 cells with increasing amounts of 
calcitriol. As shown in figure 35, inhibition of Hh signaling activity in Shh light II cells was 
first detectable after treatment with 1 nM calcitriol (Fig. 35 grey bars). In contrast, a 
significant activation of VDR/RXR heterodimerization was already observed after treatment 
with 0.1 nM calcitriol (Fig. 34 white bars; 21-fold induction of baseline). Moreover in the 




Figure 35: Sensitivity of luciferase-based reporter systems to assay the effects of calcitriol on Hh signaling 
and VDR/RXRα heterodimerization. Sensitivity of the reporter systems used to assess calcitriol-mediated Hh 
pathway inhibition (gray bars, left y-axis) and calcitriol-stimulated VDR/RXR interaction (white bars, right y-
axis). Data is representative for one individual experiment conducted in triplicates. For each reporter system 
values of solvent-treated cells were set to 1 (dashed line). Data are represented as mean +/- SEM. * p<0.05, 
***p<0.001, ****p>0.0001, AU: arbitrary units. 
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Taken together the medium transfer experiments using the VDR/RXRα 
heterodimerization assay demonstrates that Ptch-/-, in contrast to wt Ptch, cells lost their 
ability to release calcitriol to the extracellular space. Thus, we conclude that Ptch is essential 
for the release of calcitriol. Moreover these data strengthen our hypothesis that calcitriol is the 
endogenous transmitter of the Ptch/Smo-axis. 
 
6.3.1.2. Ptch is dispensable for the synthesis of calcitriol from its precursor 
25(OH)D3 
Because the lack of calcitriol in the medium of Ptch-/- cells may have resulted from a 
defective synthesis of calcitriol we analyzed if wt Ptch, Ptch-/- and Ptch-deficient ASZ001 
cells (So et al. 2006) were able to synthetize calcitriol from its direct precursor 25(OH)D3. 
Hence, the cells were incubated with 2 µM 25(OH)D3 and the intracellular amounts of 
25(OH)D3, its degradation product 24,25(OH)2D3 and calcitriol were measured by LC-
MS/MS-based assays. The occurrence of a specific metabolite was tested either by comparing 
to solvent-treated cells (marked by asterisks) or by comparing the values at time points 2, 4 
and 6 hour with that obtained after the 0.5 h incubation period (marked by plus-signs). For 
details see chapter 5.6. 
These analyses revealed that the intracellular levels of 25(OH)D3 in all analyzed cell 
lines increased rapidly (Fig. 36, solid lines) and compared to solvent-treated cells, high 
amounts of 25(OH)D3 were detected after 0.5 h in all cell lines. In wt Ptch and Ptch
-/- cells the 
25(OH)D3 levels slightly declined thereafter (1 h) but increased again in both cell lines after 
2 h. In ASZ001 cells a 25(OH)D3 peak was reached after 1 h which decreased thereafter (Fig. 
36 C, solid line). In contrast to wt Ptch cells, in which the 25(OH)D3 levels reached a plateau 
after 4 h (Fig. 36 A, solid line) in Ptch-/- cells the 25(OH)D3 levels decreased after 4 and 6 h 
similarly to ASZ001 cells (Fig. 36 B, solid line).  
Furthermore, the amount of the degradation product of 25(OH)D3, 24,25(OH)2D3, also 
significantly increased in all cell lines 0.5 h after 25(OH)D3 supplementation (Fig. 36, dashed 
lines). In wt Ptch and ASZ001 cells the 24,25(OH)2D3 levels decreased after 1 h to baseline 
but increased again thereafter (Fig. 36 A and C, dashed lines). In contrast to wt Ptch and  
Ptch-/- cells in which the amounts of 24,25(OH)2D3 did not change significantly over time 
(Fig. 36 B, dashed lines), the levels of 24,25(OH)2D3 significantly increased after 4 and 6 h in 
ASZ001 cells when compared to the 0.5 h value (Fig. 36 C, dashed line).  
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Calcitriol was first detectable after 4 h in wt Ptch cells (Fig. 36 A, dotted line) and 
after 0.5 h in Ptch-/- (Fig. 36 B, dotted line) and ASZ001 cells (Fig. 36 C, dotted line). 
Calcitriol levels of wt Ptch cells significantly increased after 4 or 6 h (Fig. 36 A, dotted line). 
Compared to the 0.5 h time point, significantly increased amounts of calcitriol were measured 
in Ptch-/- (Fig. 36 B, dotted line) after 4 and 6 h and in ASZ001 cells (Fig. 36 C, dotted line) 
after 6 h.  
 
Figure 36: Ptch is dispensable for calcitriol synthesis from 25(OH)D3. LC-MS/MS based intracellular 
quantification of 25(OH)D3 (solid line), 24,25(OH)2D3 (dashed line) and calcitriol (dotted line) levels in (A) wt 
Ptch , (B) Ptch-/- and (C) in AZ001 cells 0.5, 1, 2, 4 and 6 h after incubation with 2 µM 25(OH)D3. The data 
were normalized to the respective solvent-treated controls for each time point. The solvent-treated control for 
each cell line and time-point was set to 1. All data represent at least 3 independent experiments performed in 
triplicates represented as mean +/-SEM. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to solvent 
control; ++ p<0.01, +++ p<0.001, ++++ p<0.0001 compared to the value 0.5 h after onset of treatment; AU: 
arbitrary units. 
These data show that independently of their Ptch-status all cell lines are able to 
degrade excess intracellular 25(OH)D3 to 24,25(OH)2D3 and to synthesize calcitriol from 
exogenously supplied 25(OH)D3. Therefore, the data suggest that the last hydroxylation step 
from 25(OH)D3 to calcitriol is not disturbed in Ptch-deficient cells.  
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We next investigated if the Ptch mutation disturbs the conversion of vitD3 to 
25(OH)D3. For this purpose, wt Ptch, Ptch
-/- and ASZ001 cells were treated with 10 µM vitD3 
and the intracellular amounts of vitD3, 25(OH)D3, 24,25(OH)2D3 and calcitriol were measured 
by LC-MS/MS based assays. In all cell lines highly increased vitD3 levels were already 
observed 0.5 h after vitD3 treatment compared to solvent-treated cells (Fig. 37 A to C, solid 
lines, significances compared to the solvent are marked by * in the figures). It peaked after 1 h 
and slightly declined thereafter in all cell lines, without reaching statistical significance 
compared to the 0.5 h time point.  
25(OH)D3 was significantly elevated 1 h after vitD3 supplementation in wt Ptch cells 
(Fig. 37 A, dashed line) and after 0.5 h in Ptch-/- (Fig. 37 B, dashed line) and ASZ001 cells 
(Fig. 37 C, dashed line). Thereafter, a further increase in 25(OH)D3 was detected, which was 
was significant after 2 or 4 h in wt Ptch and ASZ001 or Ptch-/- cells, respectively, compared 
to the 0.5 h value (Fig. 37 A to C, dashed lines, marked by +).  
The 25(OH)D3 degradation product 24,25(OH)2D3 was first detectable 1 h after vitD3 
supplementation in wt Ptch (Fig. 37 A, dotted line) and after 2 h in Ptch-/- (Fig. 37 B, dotted 
line) and ASZ001 cells (Fig. 37 C, dotted line). Thereafter it increased continuously and, 
compared to the 0.5 h value, was significantly elevated after 6 h in wt Ptch (Fig. 37 A, dotted 
line) and after 4 and 6 h in ASZ001 cells (Fig. 37, C dotted line). A slight increase was also 
detectable in Ptch-/- cells which, however, did not reach statistical significance (Fig. 37 B, 
dotted line). 
Similar to the 25(OH)D3 treatment, vitD3 supplementation induced calcitriol synthesis 
with continuously increasing calcitriol amounts over time in all cell lines (Fig. 37 D to F, 
dotted lines). In wt Ptch cells the increase was significant 4 and 6 h after vitD3 treatment. At 
the latter time point the increase was also significant compared to the 0.5 h value (Fig. 37 D, 
dotted line). In Ptch-/- (Fig. 37 E, dotted line) and ASZ001 cells (Fig. 37 F, dotted line) 
significantly increased calcitriol levels were detectable 2 h after vitD3 supplementation that 
further increased after 4 h and 6 h. 
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Figure 37: Ptch is dispensable for calcitriol synthesis from vitamin D3. LC-MS/MS-based intracellular 
quantification of (A to C) vitamin D3 (solid line), 25(OH)D3 (dashed line) and 24,25(OH)2D3 (dotted line) or (D 
to F) calcitriol (dotted line) levels in (A and D) wt Ptch, (B and E) Ptch-/- and (C and F) ASZ001 cells 0.5, 1, 2, 
4 and 6 h after incubation with 10 µM vitamin D3. The data were normalized to the respective solvent-treated 
controls for each time point. The solvent-treated control for each cell line and time-point was set to 1. All data 
represent at least 3 independent experiments represented as mean +/-SEM. * p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.0001 compared to solvent control; + p<0.05, ++ p<0.01, +++ p<0.001, ++++ p<0.0001 compared to 
the 0.5 h value; AU: arbitrary units. 
Taken together, these analyses show that wt Ptch, Ptch-/- and ASZ001 cells synthetize 
25(OH)D3 and also calcitriol from exogenously supplied vitD3. Moreover, since all three cell 
lines degraded 25(OH)D3 to 24,25(OH)2D3 in comparable amounts, it is likely that calcitriol 
was degraded as well, because degradation of 25(OH)D3 and calcitriol is catalyzed by the 
same enzyme (24-hydroxylase, Cyp24a1) (Chen et al. 2012; Christakos et al. 2010). 
Therefore the data suggest that Ptch is dispensable for calcitriol synthesis from vitD3 and for 
calcitriol degradation. 
 Results 
- 94 - 
 
 
6.3.2. Functional analyses of calcitriol-mediated Hh signaling inhibition  
Previously, our group demonstrated that calcitriol-mediated inhibition of Hh signaling 
occurs downstream of Ptch at the level of Smo (Uhmann et al. 2011a). Our novel data now 
revealed that calcitriol is released from cells in a Ptch-dependent manner (compare chapter 
6.3.1.1) and cooperates with the Smo-binder ITZ in Hh signaling inhibition (chapter 6.2.2.1) 
in vitro. It has been reported that Smo contains at least two distinct binding sites for small 
molecules (7TM and CRD). In addition, Smo probably possesses a distinct ITZ binding 
pocket (Myers et al. 2013; Nachtergaele et al. 2012; Nachtergaele et al. 2013; Nedelcu et al. 
2013). In order to see whether calcitriol equally suppresses Smo activity by direct binding to 
these binding domains we generated and analyzed concentration-response-curves (CRCs). For 
this purpose, calcitriol was combined with ITZ and other known Smo modulators. 
Subsequently, competition assays for Smo binding were performed and we made use of a 
CRD-deleted Smo variant or the SMO-M2 oncogene and analyzed the effects of calcitriol on 
suppression of Hh signaling activity and cellular proliferation. 
 
6.3.2.1. Synergistic interaction of calcitriol and ITZ in Smo inhibition 
In order to generate concentration-response-curves (CRC) Shh light II cells were 
stimulated with Shh-N-CoM and simultaneously incubated with increasing amounts of 
calcitriol and a constant concentration of ITZ or another Smo modulator. The same 
experiments were also conducted by keeping the doses of ITZ or other Smo modulators 
constant and increasing those of calcitriol. Afterwards dual-luciferase assays were performed 
and the half-maximal effective (EC50) or inhibitory (IC50) concentration for activating or 
inhibitory Smo modulators, respectively, were calculated in the presence of a stable 
concentration of a second Smo modulator. Significant changes were calculated using an extra 
sum-of-squares F test by comparing the CRC for a single substance with the CRC in the 
presence of a second substance. 
First, we generated CRCs for calcitriol in the presence of the Smo inhibitors CP, ITZ 
and vismodegib as well as CRCs for CP, ITZ and vismodegib in the presence of calcitriol. 
The binding sites of CP and vismodegib have been mapped previously to the 7TM (Chen et 
al. 2002a; Nachtergaele et al. 2013) and, in case of CP, also with low affinity to the CRD 
 Results 
- 95 - 
 
(Nachtergaele et al. 2013). The binding site of ITZ is not known, but it does not map to any 
known binding site (Kim et al. 2010; Nachtergaele et al. 2012).  
The data show that all Smo inhibitors efficiently inhibit Hh signaling in a 
concentration-dependent manner (black lines in Fig. 38). The combination of calcitriol with 
CP (Fig. 38 A and B) or vismodegib (Fig. 38 E and F) resulted in downward-shifts of the 
respective CRC without changing its IC50 (table 20 and 21). This shows that neither CP nor 
vismodegib cooperated with calcitriol in Hh signaling inhibition. In contrast, increasing 
concentrations of ITZ shifted the CRC of calcitriol to lower calcitriol concentration (left-shift) 
(Fig. 38 C and D) which demonstrates that in the presence of ITZ lower amounts of calcitriol 
are necessary to inhibit Hh signaling. This finding was validated by significantly decreased 
IC50 of calcitriol from ~1.02 nM without ITZ (table 20, Fig. 38 A, black line) to ~0.13 nM 
with 2 µM ITZ (table 20, Fig. 38, blue line). Vice versa, increasing concentrations of calcitriol 
caused a significantly decreased IC50 of ITZ from ~0.81 µM without calcitriol (table 21, Fig. 
38 B, black line) to ~0.32 µM with 1 nM calcitriol (table 21, Fig. 38 B, green line) and 
~0.6 µM with 10 nM calcitriol (Table 21, Fig. 38 D, blue line). These data confirm that ITZ 
and calcitriol cooperate in Hh signaling inhibition and thus confirm the results using ASZ001 
cells (see chapter 6.2.1.1). 
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Figure 38: Concentration-response-curves (CRC) of calcitriol and Smo-inhibitors. Concentration-response 
curves of calcitriol in the presence of the Hh-inhibitor (A) cyclopamine (CP), (C) itraconazole (ITZ) or (E) 
vismodegib (vismo) or (B) CP, (D) ITZ or (F) vismo in the presence of calcitriol. To activate Hh signaling Shh 
light II cells were pre-induced with Shh-N-CM for 24 h. Afterwards, the cells were incubated with the respective 
compounds for additional 48 h in Shh-N-CM. The data were transformed, normalized and fitted using GraphPad 
Prism 6 (see material and method section). Data represents normalized firefly/renilla luciferase activity. All data 
represents at least 3 independent experiments measured in triplicates represented as mean +/-SEM. 
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Using the software CompuSyn (Chou 1976; Chou 2006; Chou 2010; Chou and Talalay 
1984; Chou 2005) (combosyn.com, see chapter 5.6 for details) we next determined whether 
calcitriol and ITZ synergize in Hh signaling inhibition by a computational analyses of the data 
according to the median-effect principle of the mass-action law and its combination index 
theorem (Chou 1976; Chou 2010; Chou and Talalay 1984; Chou 2005). Thus, we generated a 
Fa-Ci-Plot by plotting the combination index (CI) over the range of the fractional inhibition 
(Fa) of the experimental data shown in figure 38 (C). In accordance to Chou et al. CI>1 
indicates antagonism, CI=1 additivity, CI<0.7 synergism and CI<0.3 strong synergism (Chou 
2005). The respective slopes of each calcitriol concentration were furthermore tested for 
statistically significant differences. As shown in figure 39 low dosages of calcitriol (0.1, 0.5, 1 
and 2.5 nM, Fig. 38, light and dark green, blue and violet line) combined with different 
amounts of ITZ synergistically inhibited Hh signaling activity. Moreover, the lower the 
calcitriol concentration the higher was the degree of synergism of calcitriol and ITZ (Fig. 39, 
e.g., 0.5 nM vs. 2.5 nM; compare table 18). In contrast, increasing concentrations of calcitriol 
led to increased antagonistic effects when combined with intermediate or low ITZ 
concentrations. This antagonism disappeared when high ITZ concentrations (5 nM calcitriol 
Fig 39, orange line) were used. However, high calcitriol and high ITZ concentrations again 
resulted in antagonism (10 nM, Fig. 39 red line). In fact, the CI slope of 2.5 nM calcitriol 
(Fig. 39 violet line) was significantly lower than that of 10 nM calcitriol (Fig. 39 red line, 
table 18). These data show that low to intermediate calcitriol amounts combined with ITZ act 
synergistically on Hh signaling inhibition whereas high calcitriol concentrations combined 
with ITZ result in antagonistic effects.  
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Figure 39: Dual mode of action of calcitriol and ITZ on Hh signaling inhibition. Fa-CI plot of the 
combination of calcitriol and ITZ. The Fa-CI-Plot was generated by calculating the combination index (CI) over 
the range of fractional inhibition (Fa) of the experimental data shown in Fig. 38 C. Shown are the CI-values and 
linear regression of Hh signaling inhibition triggered by 0.1, 0.5, 1, 2.5, 5 and 10 nM calcitriol (circles, squares, 
upward triangles, downward triangles, rhombs and hexagons, respectively) combined with 0.1, 0.5 or 2 µM ITZ 
plotted against the respective Fa. Slopes of 0.5 nM and 2.5 nM (p=0.044) as well as 0.5 nM and 5.0 nM calcitriol 
(p=0.023) are significantly different (compare table 18). CI>1, antagonism; C=1, additivity CI<0.7, synergism; 
CI<0.3, strong synergism (Chou 2005). 
Table 18: Statistical determination of the Fa-CI-Plot 
comparison significant p-value 
0.1 nM cal vs 0.5 nM cal n.s. 0.63 
0.5 nM cal vs 1 nM cal n.s. 0.893 
0.5 nM cal vs 2.5 nM cal * 0.044 
0.5 nM cal vs 5 nM cal * 0.023 
1 nM cal vs. 2.5 nM cal n.s. 0.648 
2.5 nM cal vs 5 nM cal n.s. 0.067 
2.5 nM cal vs 10 nM cal * 0.033 
5 nM cal vs. 10 nM cal n.s. 0.068 
n.s.: not significant; * p<0.05 
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Kim et al. have shown that CP and ITZ cooperate in Hh signaling inhibition (Kim et 
al. 2010). However, we did not see such a cooperation in our in vitro experiments using 
ASZ001 cells (compare chapter 6.2.1.1). We therefore also generated CRCs for CP and ITZ. 
As already observed in ASZ001 cells (see chapter 6.2.1.1) both CP (Fig. 40 B) and ITZ (Fig. 
40 A) efficiently inhibited Hh signaling activity in Shh light II cells. However, the presence of 
CP (Fig. 40 A) did not change the IC50 of ITZ or vice versa (Fig. 40 B; table 19) supporting 
our observation that CP and ITZ do not cooperate in Hh signaling inhibition. 
 
Figure 40: Concentration-response-curves (CRC) of CP and ITZ. CRC of (A) itraconazole (ITZ) in the 
presence cyclopamine (CP) or (B) CP in the presence of ITZ. Shh light II cells were pre-induced with Shh-N-
CM for 24 h. Afterwards, the cells were incubated with the respective compounds for additional 48 h in Shh-N-
CM. The data were transformed, normalized and fitted using GraphPad Prism 6 (see material and method 
section). Data represents normalized firefly/renilla luciferase activity. All data represents at least 3 independent 
experiments measured in triplicates represented as mean +/-SEM. 
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ITZ 0.1 µM 0.3904
ITZ 0.5 µM 0.3525






0.8492CP 0.1 µM 0.4276
CP 0.2 µM 0.3177
 
The half maximal inhibitory concentration (IC50) of cyclopamine (CP) and itraconazole (ITZ) in combination 
with each other on Hh signaling activity were calculated from the experiments shown in Fig. 40 as described in 
the material and method section. To detect significant differences of the IC50 of single and combined treatments 
extra sum-of-squares F tests were conducted. 
We also generated CRCs for calcitriol and the Smo agonists (activators) SAG or 
20(S)OHC using Shh light II cells. Since Smo agonists induce Hh signaling activity by 
themselves, incubation with Shh-N-CM was not necessary. Moreover the Smo binding sites 
for SAG and 20(S)OHC have already been mapped to the 7TM and the CRD, respectively 
(Chen et al. 2002b; Nachtergaele et al. 2013). Thus, if calcitriol indeed occupies the 7TM or 
CRD a competitive inhibitory effect on Hh signaling activity would be expected. 
In the absence of calcitriol both Smo agonists led to concentration-dependent 
activation of Hh signaling (Fig. 41) although 20(S)OHC-induced Hh signaling activation was 
much lower (Fig. 41 C and D) compared to SAG treatment (Fig. 41 A and B). Additionally, 
both SAG as well as 20(S)OHC-induced activation of Hh signaling was inhibited by 
increasing amounts of calcitriol (Fig. 41). However, the ED50 of calcitriol was not 
significantly changed by increasing amounts of SAG or 20(S)OHC or vice versa (tables 20 
and 21). Additionally, the maximal activation of Hh signaling induced by SAG- (Fig. 41 B) or 
20(S)OHC (Fig. 41 D) was clearly reduced by increasing amounts of calcitriol. These data 
suggest that calcitriol acts as a non-competetive inhibitor of SAG (7TM-binder) and 
20(S)OHC (CRD-binder)-induced Hh signaling by binding to a distinct, so far unidentified, 
Smo binding site. 
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Figure 41: Concentration response curves (CRC) of calcitriol and Smo-agonists. CRC of calcitriol in the 
presence of the Hh-agonists (A) SAG or (C) 20(S)-hydroxycholesterol (20(S)OHC) and CRC of (B) SAG or (D) 
20(S)OHC in the presence of calcitriol. Shh light II cells were starved with DMEM supplemented with 0.5 % 
FCS and 1 % PS for 24 h. Afterwards, the cells were incubated with the respective compounds for additional 
48 h in DMEM supplemented with 0.5 % FCS and 1 % PS. The data were transformed, normalized and fitted 
using GraphPad Prism 6 (see material and method section). Data represents normalized firefly/renilla luciferase 
activity. All data represents at least 3 independent experiments measured in triplicates represented as mean +/-
SEM; AU: arbitrary units. 
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CP 0.1 µM 0.771
CP 0.2 µM 1.183
CP 0.3 µM 0.449
CP 0.5 µM 1.008
solvent 1.017
0.0004
ITZ 0.1 µM 0.438
ITZ 0.5 µM 0.273
ITZ 2 µM 0.126
solvent 0.460
0.0739
vismo 2.5 nM 0.185
vismo 10 nM 0.673
vismo 40 nM 0.917
solvent n.d.
0.7716
SAG 5 nM 1.375
SAG 50 nM 1.495
SAG 100 nM 1.139
solvent n.d.
0.3725
20(S)OHC 2 µM 0.129
20(S)OHC 5 µM 1.355
20(S)OHC 10 µM 1.113
 
The half maximal inhibitory concentration (IC50) of calcitriol in the combination with cyclopamine (CP), 
itraconazole (ITZ), vismodegib (vismo), Smo-agonist (SAG) or 20(S)-hydroxycholesterol (20(S)OHC) on Hh 
signaling activity were calculated from the experiments shown in Fig. 38 and 41 as described in the material and 
method section. To detect significant differences of the IC50 or EC50 of single and combined treatments extra 
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solvent 0.3322 0.8083 6.395 5.424 5.158 
calcitriol 0.1 nM 0.5875 0.4276 3.565 6.459 4.978 
calcitriol 1 nM 0.4587 0.3177 4.133 6.071 4.546 
calcitriol 10 nM 0.687 0.5924 4.204 5.028 4.663 
p-value 0.1043 0.0075 0.1788 0.6268 0.3725 
 
The half maximal inhibitory concentration (IC50) of cyclopamine (CP), itraconazole (ITZ) vismodegib (vismo) 
and half maximal effective concentration (EC50) of Smo-agonist (SAG) or 20(S)-hydroxycholesterol 
(20(S)OHC) in combination with calcitriol on Hh signaling activity were calculated from the experiments shown 
in Fig. 38 and 41 as described in the material and method section. To detect significant differences of the IC50 or 
EC50 of single and combined treatments extra sum-of-squares F tests were conducted. 
Taken together these results show that calcitriol acts synergistically with ITZ but not 
with CP or vismodegib, to inhibit Hh signaling. Additionally, calcitriol inhibits SAG or 
20(S)OHC-induced Smo activation by a non-competitive mechanism. Since we did not find 
any functional competition of calcitriol with 7TM- (CP, vismodegib or SAG) or CRD-binders 
(20(S)OHC and CP) (Chen et al. 2002b; Kim et al. 2010; Myers et al. 2013; Nachtergaele et 
al. 2013; Nedelcu et al. 2013), we propose that calcitriol potentially acts on a so far 
unidentified Smo site. 
 
6.3.2.2. Calcitriol does not bind to the 7TM or the CRD of Smo 
In order to validate that calcitriol does neither bind to the 7TM nor the CRD of Smo 
we next performed a BODIPY-CP replacement assay (for details see chapter 5.2.8). For this 
purpose, Smo was overexpressed in HEK293S cells by treating the cells with tetracycline 
((Dwyer et al. 2007), see Fig. 42). Next the cells were treated with fluorescently-labeled CP 
(BODIPY-labeled CP, BD-CP) in combination with calcitriol or other Smo modulators. The 
replacement of BD-CP from Smo was detected by decreased fluorescence intensity of single 
cells determined by flow cytometry (Fig. 43). The data are presented as cumulative 
distribution function (CDF) which reflects the percentage of fluorescence intensity of cells 
and as bar graphs of the mean fluorescence intensity of each sample. 
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Figure 42: Smo overexpression by tetracycline treatment of HEK293S cells. Western Blot analyses of cell 
lysates from tetracycline-induced (+Tet) HEK293S cells using a primary anti-Myc antibody for detection of 6x-
His, myc-tagged Smo protein. As a negative control uninduced HEK293 cells (-Tet) were used. Detection of 
Hsc70 served as loading control. 
 
Figure 43: Schematic representation of the BD-CP-replacement assay. (A) HEK293S cells endogenously 
express small amount of wt Smo. (B) Upon tetracycline-induction 6 x His, myc-tagged Smo is overexpressed 
(grey circles) and (C) binds BD-CP (red square with yellow circle). This increases the fluorescence intensity of 
the cell. (D) Simultaneous CP treatment (red square) leads to competitive replacement of BD-CP causing 
decreased fluorescence intensity. (E and F) The addition of a putative competitor (green circle or blue circle) 
either leads to (E) competition with BD-CP or (F) simultaneous binding on Smo. 
We first tested the efficiency of BD-CP replacement by CP. As expected without BD-
CP nearly no flourescence signals were detectable (Fig. 44 A and B). BD-CP treatment of 
uninduced HEK293S cells led to a slight increase in fluorescence intensity of the cells (Fig. 
44 A and grey line in B). In contrast, BD-CP treatment of HEK293S cells overexpressing 
Smo resulted in a very strong fluorescence intensity of the cells (Fig. 44 and black line in B) 
which was significantly decreased by combination with CP (Fig. 44 A and red line in B). 
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These results showed that the BD-CP replacement worked in our hands. This setup was 
included as a control experiment in all following experiments. 
We next re-analyzed the already described replacement of BD-CP by ITZ (Kim et al. 
2010) and the exclusive 7TM-binders vismodegib (Nachtergaele et al. 2013) and SAG (Chen 
et al. 2002b; Wang et al. 2014). Accordingly, 0.1 and 1 µM vismodegib and 25 and 100 nM 
SAG significantly reduced BD-CP binding from Smo-overexpressing cells (Fig. 44 C to F) 
(Chen et al. 2002b; Nachtergaele et al. 2013; Wang et al. 2014). However, in contrast to Kim 
et al. who reported no effective competition with BD-CP (Kim et al. 2010) we found a strong 
and significant replacement of BD-CP by ITZ (Fig. 44 G and H) that appeared not to be 
concentration-dependent (Fig. 44 E).  
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Figure 44: Cyclopamine, vismodegib, SAG and ITZ compete with BD-CP for Smo-binding. (A, C, E and 
G) Bar graphs and (B, D, F and H) representative CDF-plots (cumulative distribution function) of direct 
competition-assays of 10 nM BODIPY-labeled cyclopamine (BD-CP) and (A and B) 1 µM unlabeled 
cyclopamine (CP), (C and D) 0.1 and 1 µM vismodegib (vismo) or (E and F) 2 and 5 µM itraconazole (ITZ) (G 
and H) 25 and 100 nM Smo agonist (SAG) of tetracycline-induced conditional Smo-overexpressing HEK293S 
cells (induced) as described (Dwyer et al. 2007). Solvent-, single competitor-, and BD-CP-treated uninduced 
HEK293S cells (not induced) served as negative controls in all experiments. BD-CP-treatment of induced cells 
was set to 100 % and for convenience only the single competitor treatment is shown for the CDF-curves (orange 
curve) representative for all negative controls. Representative CDF-curves are shown for (D) 1 µM vismo, (F) 
2 µM ITZ and (H) 100 nM SAG. Data acquisition was conducted as described in the material and method 
section. All data represent at least 3 independent experiments measured in duplicates represented as mean +/-
SEM. * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
Since it has been reported that CP binds to some extent to the CRD, we next used 
20(S)OHC that exclusively binds to the CRD (Nachtergaele et al. 2013; Nedelcu et al. 2013). 
Indeed, 20(S)OHC significantly reduced the fluorescence intensity of BD-CP-labeled cells 
(Fig. 45) indicating that CP also binds to some extend to the CRD. 
 
 
Figure 45: 20(S)OHC competes with BD-CP for Smo-binding. (A) Bar graph and (B) representative CDF-
plot (cumulative distribution function) of direct competition-assays of 10 nM BODIPY-labeled cyclopamine 
(BD-CP) and 3 or 5 µM 20(S)-hydroxycholesterol (20(S)OHC) of tetracycline-induced conditional Smo-
overexpressing HEK293S cells (induced) as described (Dwyer et al. 2007). Negative controls were the same as 
in Figure 44. Representative CDF-curves are shown for (B) 5 µM 20(S)OHC. Data acquisition was conducted as 
described in the material and method section. All data represent at least 3 independent experiments measured in 
duplicates represented as mean +/-SEM. * p<0.05. 
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Finally, we analyzed whether calcitriol, which synergizes with ITZ in Hh signaling 
inhibition, also replaces BD-CP from Smo overexpressing cells. Hence, HEK293S cells were 
treated with BD-CP and 2, 5 and 20 nM calcitriol that equate the 2, 10 and 20-fold 
concentration of the IC50, respectively (compare table 20). We also used the calcitriol 
precursors vitD3 or 25(OH)D3 at concentrations up to 10 µM and 2 µM, respectively. 
However, neither calcitriol nor its precursors reduced the fluorescence intensity of the BD-
CP-labeled cells (Fig. 46). This shows that calcitriol and its precursors do not bind to the same 
binding pocket/s as CP. 
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Figure 46: Calcitriol and its precursors do not compete with BD-CP for Smo-binding. (A, C and E) Bar 
graphs and (B, D and F) representative CDF-plots (cumulative distribution function) of direct competition-
assays of 10 nM BODIPY-labeled cyclopamine (BD-CP) and (A and B) 2, 5 or 20 nM calcitriol (cal), (C and 
D) 0.5 and 2 µM 25(OH)D3 or (E and F) 1 and 10 µM vitamin D3 (vitD3) of tetracycline-induced conditional 
Smo-overexpressing HEK293S cells (induced) as described (Dwyer et al. 2007). Negative controls were the 
same as in Figure 44. Representative CDF-curve are shown with (B) 20 nM cal, (D) 2 µM 25(OH)D3 and (F) 10 
µM vitD3. Data acquisition was conducted as described in the material and method section. All data represent at 
least 3 independent experiments measured in duplicates represented as mean +/-SEM. 
In summary we were able to reproduce already published data showing the 
replacement of BD-CP from Smo by vismodegib and SAG. In addition, we show that the 
exclusive CRD-binder 20(S)OHC competes with BD-CP in Smo binding. Finally, the data 
demonstrates that calcitriol and its precursors vitD3 and 25(OH)D3 do not compete with BD-
CP in Smo-binding, even at very high concentrations. This indicates that calcitriol binds to a 
Smo site distinct from the binding pocket/s of CP. 
 
6.3.2.3. Calcitriol inhibits Hh signaling in cells expressing CRD-deleted or 
constitutive active Smo Variants 
6.3.2.3.1. Overexpression of Smowt and SmoΔCRD in Shh light II and Smo-/- cells 
To confirm our conclusion that calcitriol does not bind to the CRD of Smo, plasmids 
for the expression of mCherry-tagged wt Smo (Smowt) or a CRD-deleted Smo variant 
(SmoΔCRD) were generated (see chapter 5.1.3.7). These plasmids were transduced in Shh light 
II cells (see chapter 5.2.4). Since Shh light II cells express endogenous wt Smo that may have 
interfered with SmoCRD in calcitriol binding, we furthermore transduced the Smowt or 
SmoCRD-expression plasmids into Smo-/- cells (see chapter 5.2.4) that do not express 
endogenous Smo. Fluorescence microscopy revealed a high mCherry expression in  
Shh light II (Fig. 47) and Smo-/- cells (Fig. 48) demonstrating successful transduction of the 
cells with the plasmids. The images were taken in collaboration with Dr. Nickels Jessen and 
Maria Kamper (Max-Planck-Institute for biophysical chemistry, Department for 
NanoBioPhotonics, Prof. Dr. Stefan Hell, Göttingen) 
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Figure 47: Validation of Smowt and SmoΔCRD expression in transduced Shh light II cells. Visualization of 
the mCherry expression of untransduced (upper panel), Smowt (middle panel) or SmoCRD-transduced (lower 
panel) Shh light II cells by fluorescence microscopy. DAPI staining was conducted for visualization of the 
nuclei. DAPI staining and mCherry are shown in grayscale. Magnification: 200x. 
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Figure 48: Validation of Smowt and SmoΔCRD expression in transduced Smo-/- cells. Visualization of the 
mCherry expression of untransduced (upper panel), Smowt (middle panel) or SmoCRD-transduced (lower panel) 
Smo-/- cells by fluorescence microscopy. DAPI staining was conducted for visualization of the nuclei. DAPI 
staining and mCherry  are shown in grayscale. Magnification: 200x. 
 
6.3.2.3.2. Analyses of the Hh signaling activity of Smowt or SmoΔCRD 
overexpressing cells 
To assess the effect of the CRD-deletion on the Hh signaling regulation by Smo 
modulators we determined the Hh signaling activity of Smowt or SmoCRD-expressing 
Shh light II and Smo-/- cells by dual-luciferase assays or by Gli1 expression analyses, 
respectively. First, we tested if overexpressed Smowt or SmoCRD are functionally active. Next, 
we tested if Smowt or SmoCRD-overexpressing cells are still susceptible to induction of Hh 
signaling by SAG or Shh-N-CM. 
As shown in figure 49 and 50, Smowt or SmoCRD overexpression led to significantly 
higher baseline activity of Hh signaling in both cell lines compared to untransduced cells (Fig. 
49 A and B, white bars; Figure 50 A). In contrast to untransduced cells (Fig. 49 A and B, left 
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column pair) the stimulation with SAG or Shh-N-CM of Smowt or SmoΔCRD-overexpressing 
Shh light II cells did not further increase Hh signaling activity (Fig. 49 A and B, middle and 
right column pair). Similar results were observed in SAG-treated Smowt or SmoΔCRD-
overexpressing Smo-/- cells (Fig. 50 B). These data suggest that Smo overexpression in Shh 
light II and Smo-/- cells induces the maximum of Hh signaling activity and show that the 
deletion of the CRD merely influences Smo function. 
Next, we tested if calcitriol inhibits Hh signaling activity of Smowt or SmoCRD-
overexpressing cells. As a control we used CP that mainly acts with high affinity at the 7TM 
(Chen et al. 2002a; Nachtergaele et al. 2013). As control experiments we additionally 
analyzed Hh signaling activity in SAG or Shh-N-CM-treated untransduced Shh light II after 
calcitriol or CP treatment. Figure 49 shows that calcitriol and CP significantly reduced the Hh 
signaling activity of SAG or Shh-N-CM-treated Shh light II cells (Fig. 49 C). Interestingly, 
calcitriol and CP also significantly inhibited Hh signaling activity in Smowt or SmoCRD-
overexpressing Shh light II (Fig. 49 D) and Smo-/- cells (Fig. 50 C). However, SAG treatment 
of Smowt and SmoCRD-overexpressing cells rendered the cells irresponsive to CP (Fig. 49 E 
and Fig. 50 D) whereas all cell lines, except Smowt-expressing Shh light II cells, stayed 
responsive towards calcitriol (Fig. 49 E and Fig. 50 D). Both, calcitriol and CP can inhibit Hh 
signaling after treatment with Shh-N-CM (Fig. 49 F). 
Taken together these results show that calcitriol efficiently inhibits the activity of 
SmoCRD indicating that calcitriol does not bind Smo’s CRD. Moreover SAG treatment led to 
CP-unresponsiveness, possibly by the occupancy of the 7TM by SAG, whereas calcitriol 
efficiently inhibited the Hh signaling activity in these settings. This again fosters our 
hypothesis that calcitriol does not bind to the 7TM. 
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Figure 49: Calcitriol inhibits the Hh signaling activity of SmoCRD-expressing Shh light II cells. Dual-
luciferase-based analyses to determine the Hh signaling activation of (A) SAG or (B) Shh-N-CM-treated 
untransduced and Smowt or SmoΔCRD-overexpressing Shh light II cells. (C) SAG- or Shh-N-CM-induced 
untransduced Shh light II cells, (D) uninduced, (E) SAG- and (F) Shh-N-CM-treated Smowt or SmoΔCRD-
expressing Shh light II cells after treatment with 10 nM calcitriol or 5 µM CP. Values of SAG or Shh-N-CM-
induced cells in (C) and solvent-treated controls in (D-F) were set to 100 %. Data represent normalized 
firefly/renilla luciferase activity. All data represent at least 3 independent experiments measured in triplicates 
represented as mean +/-SEM. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 50: Calcitriol inhibits the Hh signaling activity of SmoCRD-expressing Smo-/- cells Relative 
quantification of Gli1 expression levels of (A) untransduced, Smowt or SmoΔCRD-overexpressing Smo-/- cells, (B) 
SAG-treated Smowt or SmoΔCRD-overexpressing Smo-/- cells, (C) uninduced and (D) SAG-treated Smowt or 
SmoΔCRD-expressing Smo-/- cells after treatment with 10 nM calcitriol or 5 µM CP. Gli1 expression levels were 
normalized to 18S rRNA expression. Values of untranduced cells in (A), solvent-treated Smowt-expressing cells 
in (B), solvent-treated controls in (C) and SAG-induced cells in (D) were set to 1. All data represent at least 3 
independent experiments measured in triplicates represented as mean +/-SEM. * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. 
Finally, we analyzed whether calcitriol was able to inhibit the activity of the SMO-M2 
oncoprotein that harbors a Trp535 to Leu mutation located at the 7TM (Xie et al. 1998). 
Using the mouse analog SmoA1 it has been shown, that this mutant is partially resistant to 
CP. It is also resistant to physiological concentrations of Ptch, whereas increased amounts of 
Ptch retain the ability to inhibit it (Taipale et al. 2000). Thus, we assumed that our 
experimental concentrations of calcitriol (i.e. higher than physiological) should also be 
capable to inhibit constitutively active SMO-M2. To validate this hypothesis, we transiently 
transfected Smo-/- cells with wt SMO or SMO-M2 expression plasmids. Subsequently, the cells 
were treated with calcitriol or CP and Hh signaling activity was determined by Gli1 
expression analyses. Although SMO-M2 has been reported to be less sensitive to CP-
mediated inhibition, CP treatment led to significantly reduced Gli1 expression levels in wt 
SMO or SMO-M2-expressing cells compared to solvent-treated cells (Fig. 51, blue bars). 
More importantly, this experiment revealed that calcitriol efficiently inhibited Hh signaling in 
wt SMO or SMO-M2 expressing Smo-/- cells (Fig. 51, green bars). This shows that neither the 
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Figure 51: SMO-M2-mediated Hh signaling activation is inhibited by calcitriol. Relative quantification of 
Gli1 expression levels of SMO or SMO-M2-expressing Smo-/- cells treated with 10 nM calcitriol or 5 µM CP. 
Gli1 expression levels were normalized to 18S rRNA expression levels. Solvent treated controls were set to 1. 
All data represent at least 3 independent experiments measured in triplicates represented as mean +/-SEM. ** 
p<0.01, **** p<0.0001. 
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7.  Discussion 
7.1. Regulation of the Vdr expression by Gli TFs 
Previous work of our group indicated that Vdr gene expression is regulated in a Gli3-
dependent manner. This was based on the findings that overexpression of Gli3 in wt Ptch 
fibroblasts led to a significantly increased Vdr expression (Fritsch 2014). Moreover similar 
results were obtained in Gli2-/-/Gli3-/- fibroblasts, which do not show functional expression of 
any Gli TF, since Gli1 is regulated by Gli2 (Ikram et al. 2004; Regl et al. 2002). Gli3 is 
usually proteolitically cleaved and mainly acts as a transcriptional repressor and only as a 
weak activator (Aberger et al. 2012; Roberg-Larsen et al. 2014; Wang et al. 2007b). 
However, Gli3 can be shifted towards its full-length activator form Gli3act by activation of Hh 
signaling. In order to investigate whether Gli3 can activate Vdr expression we overexpressed 
Gli3 in wt Ptch or Ptch-/- cells that show constitutive activation of this pathway (Uhmann et 
al. 2011a) and wt Ptch cells were additionally incubated with Shh-N-CM. We also used Gli1-/-
/Gli2-/- fibroblasts in which the effects of Gli3 can be determined without any crosstalk with 
Gli1 and Gli2. Since the proteolytical processing of Gli3 occurs upstream of the Gli TFs, via 
phosphorylation of protein kinase A, glycogen synthase kinase 3-beta and casein kinase I 
(Aberger et al. 2012), we also stimulated the cells with Shh-N-CM to cause a shift towards 
Gli3act. 
Whereas no significant regulation of Vdr expression was seen in wt Ptch or Ptch-/- 
cells after Gli3 transfection or Shh-N-CM treatment, the incubation of Gli1-/-/Gli2-/- cells with 
Shh-N-CM resulted in an upregulation of Vdr expression (compare Figs. 5 to 7). Thus, the 
data suggest that the expression of the Vdr gene is not regulated by Gli3 but may be regulated 
by Shh in dependency of the cellular context. These results are contradictory to initial 
experiments by A. Fritsch that showed increased Vdr expression in wt Ptch cells after Gli3 
transfection (Fritsch 2014). However, the respective experiments were performed in medium 
supplemented with 10 % FCS (Fritsch 2014) whereas the experiments presented here were 
performed with CM that was generated from medium supplemented with 2% FCS. It is 
known that FCS starvation causes cell cycle arrest (Kronemann et al. 1999) or inhibition of 
proliferation (Oya et al. 2003). Therefore the differential gene expression pattern might be 
more likely the result from differential FCS supply than of the presence of Gli3. Moreover, 
media which are conditioned by cells (e.g. Shh-N-CoM and CM) certainly contain, aside from 
Shh-N, other factors which are not necessarily present in normal (10% FCS containing) 
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media. These factors (e.g. growth factors or soluble ligands) also might affect gene expression 
levels complicating the comparison between the settings even more. 
In Gli1-/-/Gli2-/- cells Gli3 is most likely processed to Gli3rep ((Wang et al. 2007b), 
reviewed in (Briscoe and Therond 2013)) since Gli1 and Gli2 are completely absent, basal Hh 
activity is reduced (Lipinski et al. 2008) and Gli3act is dependent on the Gli1-mediated 
feedback induction (Bai et al. 2004; Roberg-Larsen et al. 2014). However, Vdr expression 
was activated after Shh-stimulation in Gli1-/-/Gli2-/- cells, which was likewise independent of 
Gli3 transfection. Whereas Gli3 and its activator form Gli3act (that should occur after Shh-N-
CoM treatment) probably do not play a role in Vdr expression, Shh seems to be able to induce 
Vdr expression in this cell line. Therefore it is possible that Shh induced a non-canonical 
pathway, resulting in Vdr gene expression. Such non-canonical effects of Shh have been 
reported previously for the expression of the Rho GTPases RacI and RhoA, which are 
regulated in a Shh-dependent, but Gli-independent manner (Polizio et al. 2011). However, 
because Shh did not enhance Vdr expression in wt Ptch and Ptch-/- cells, this effect must be 
specific for Gli1-/-/Gli2-/- cells. 
Our data furthermore showed that the expression of Gli2 is strongly induced by 
simultaneous Gli3 overexpression and Shh-N-CM treatment in wt Ptch cells and in Ptch-/- 
cells after Gli3 transfection. These results suggest that Gli2 expression is induced by Gli3act. 
Although Gli3 is widely known as a transcriptional repressor (Marigo and Tabin 1996), others 
also found that Gli3 can act as an activator of gene expression ( e.g. in the development of the 
sclerotome (Buttitta et al. 2003), the spinal cord (Bai et al. 2004) or the limbs (Bowers et al. 
2012). It is known that Gli3 regulates Gli1 by binding to GliBS in the promoter of Gli1 (Dai et 
al. 1999), whereas no induction of Gli2 expression by Gli3 has been described yet, probaply 
because Gli2 does not contain a GliBS in its promoter (Regl et al. 2002). Additionally, we 
analyzed if the putative GliBS located 312 bp upstream of the first exon of the Vdr gene is 
functionally active. Although this GliBS is the reverse complement of the consensus sequence 
(Hallikas et al. 2006; Winklmayr et al. 2010), TF binding to a reverse consencus sequence has 
been described previously (Scholz et al. 2010). Our analyses of the pmVdrPromwt reporter 
constructs showed that overexpression of any Gli TF does not change luciferase activitiy of 
the pmVdrPromwt reporter. This supports the findings that the Vdr gene is not directly 
regulated by Gli TF binding to the Vdr promoter.  
Together, these experiments strongly suggest that Vdr expression is not regulated by 
Gli TFs. Nevertheless, since the Gli code is strongly dependent on the cellular context and 
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developmental stage (Aberger et al. 2012; Aberger and Ruiz 2014), it is possible that Gli TFs 
may regulate Vdr expression in other cells lines. Thus, it has been shown that Cyclin D2 is 
regulated independently of Hh signaling in embryonic kidney development (Hu et al. 2006) 
but is regulated by Hh signaling during hair follicle development (Mill et al. 2003). 
Strikingly, studies of the development of medulloblastoma in mice showed that the mere 
presence of a GliBS is not sufficient for the expression of the respective gene (Lee et al. 
2010). However, whether this also applies for Vdr expression remains to be analyzed in the 
future. Additionally, a larger proportion of the Vdr promoter and thus more regulatory 
sequences should be employed in the Vdr promotor plasmids. Since it is an established fact 
that gene expression is not only regulated by TF binding at the direct vicinity of a promoter 
(e.g. the Vdr) but also several kb upstream (Hallikas et al. 2006) it is possible that the Vdr 
gene is rather regulated by such distant enhancers. 
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7.2. The potential of calcitriol as an anticancer agent 
The general antitumoral effects of calcitriol are known for several decades (Bikle 
2004; Bikle 2011a; Campbell et al. 2010; Deeb et al. 2007; Garland and Garland 1980; 
Trump et al. 2010). Moreover and as shown by our group, calcitriol has potential as an 
anticancer agent by modulating two distinct pathways simultaneously: First, it inhibits Hh 
signaling due to a inhibition of Smo activity and second, it induces Vdr signaling via its 
cognate receptor (Uhmann et al. 2011a; Uhmann et al. 2012). In this study we therefore tested 
if the combination of calcitriol with azoles enhances the calcitriol-mediated Hh signaling 
inhibition (and maybe Vdr signaling activation) and thus its anti-tumoral effects. This 
approach was chosen since azoles have been described as 1) efficient inhibitors of Hh 
signaling acting on Smo (Kim et al. 2010) and 2) to inhibit P450 enzymes, like the 24-
hydroxylase, (Hansdottir et al. 2008; Vanden Bossche et al. 2004) which are among others 
implicated in calcitriol catabolism. Based on these data we hypothesized that the combination 
of azoles and calcitriol might enhance the inhibition of Hh signaling and activation of Vdr 
signaling due to calcitriol-stabilization and simultaneous inhibition of Smo. 
 
7.2.1. Enhanced antitumorigenic capacity of a combined calcitriol/azole 
treatment in vitro but not in vivo 
The simultaneous treatment of the murine BCC cell line ASZ001 with calcitriol and 
azoles significantly decreased Gli1 expression levels when compared to single drug 
treatments (Fig. 11). Since Cyp24a1 expression was significantly enhanced after combined 
calcitriol/ITZ treatment compared to calcitriol single treatment, ITZ supposedly stabilized 
calcitriol. The inhibition of Hh and activation of Vdr signaling, respectivily by single 
calcitriol is in line with previous findings by us and were also observed by others using the 
precursor of calcitriol, vitD3 (Tang et al. 2011; Uhmann et al. 2011a; Uhmann et al. 2012). 
The combined treatment also resulted in a significant inhibition of proliferation reflecting an 
enhanced antiproliferative capacity of the agents when used simultaneously. However, these 
antitumoral effects were only detectable under serum-starved conditions (i.e. by using BSA-
containing media) but not with FCS-containing media. Similar effects have been previously 
described by Kim et al. who showed that FCS-containing medium suppresses the Smo 
inhibitory properties of ITZ (Kim et al. 2010). Hence it was shown that this suppression is 
possibly mediated by low-density lipoproteins (LDL) that sequester ITZ (Kim et al. 2010). If 
so, this LDL-mediated suppression of ITZ must be specific for some cultured cells, since 
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similar results were not observed in vivo (Kim et al. 2014; Kim et al. 2013; Kim et al. 2010) 
or in other cell culture systems (e.g. human tracheobronchial epithelial cells, A549 cells 
(Hansdottir et al. 2008) or human hepatoma cell lines (Vanden Bossche et al. 2004)). The 
fact, that the antiproliferative effect of the (single) calcitriol treatment was weaker in FCS-free 
than in FCS-containing medium (compare Figs. 10 and 11), can be explained by a generally 
decreased proliferation rate of FCS-starved cells ((Oya et al. 2003) see also (Uhmann et al. 
2011a)). Our results are further strengthened by the current literature which describes the 
potential antitumoral cooperation of calcitriol and azoles, albeit those studies did not focus on 
Hh signaling inhibition but Vdr signaling activation. Thus, it has been shown that calcitriol 
and KTZ displayed combined antitumoral effects in prostate cancer cell lines (Kota et al. 
2011) and respective xenografts (Muindi et al. 2010). Moreover, the combination of calcitriol 
and the azole liarozole significantly decreased the proliferation of the calcitriol-resistant 
prostate cancer cell line DU145. This is due to enhanced calcitriol levels, probably by the 
inhibition of 24-hydroxylase activity (Ly et al. 1999). Besides 24-hydroxylase activity, 1α-
hydroxlase is also inhibited by ITZ (Hansdottir et al. 2008; Vanden Bossche et al. 2004). 
Although the reports mentioned above did not focus on the role of calcitriol in Hh signaling 
inhibition, it is likely that the antitumoral effects of combined calcitriol/azole treatments are 
not only mediated by active Vdr signaling but also by inhibition of Hh signaling, especially 
since Hh signaling is implicated in several tumor types (e.g. prostate, lung or breast cancer 
(Gupta et al. 2010; Wilkinson et al. 2013)). 
This conclusion is furthermore strengthened by our findings that no combined 
inhibition or activation of Hh or Vdr signaling, respectively were observed when calcitriol 
was combined with CP or when CP was combined with ITZ. At the first glance the latter 
result seem to contrast those described by Kim et al. who showed combinatory effects in Hh 
signaling inhibition upon combination of ITZ and KAAD-CP (3-Keto-N-(aminoethyl-N’-
aminocaproyldihydrocinnamoyl)-cyclopamine) (Kim et al. 2010). However, this observation 
can be explained by the fact that KAAD-CP shows a higher affinity to Smo  compared to CP 
(Chen et al. 2002b).  
As already stated above, the azole-suppressing effects of FCS have not been observed 
in vivo and seem to be cell type specific (Hansdottir et al. 2008; Kim et al. 2014; Kim et al. 
2013; Kim et al. 2010; Vanden Bossche et al. 2004). Unfortunately and in contrast to 
observations made by us using 2 % FCS supplemented culture medium (Nitzki et al. 2010; 
Uhmann et al. 2011a), the culture of murine skin biopsies in 1.5 % BSA-supplemented 
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medium led to necrosis (see 6.2.1.2). Nevertheless gene expression analyses of the samples 
were possible. Although the interpretation needs precaution, the analyses revealed that the 
Vdr target gene Cyp24a1 is induced robustly by calcitriol or by the combination of calcitriol 
and an azole. Furthermore, although not reaching significance, Gli1 expression was reduced 
by single treatments with either calcitriol or ITZ. The fact that calcitriol treatment did not 
significantly decrease Gli1 expression levels can be due to necrosis and the associated 
changes in gene expression (Raza et al. 2004; Sato et al. 2008). Those might have altered Gli1 
baseline levels or indirectly affected Gli1 expression. Curiously, the combination 
calcitriol/KTZ led to an (not statistically significant) increase in Gli1 expression whereas the 
combination calcitriol/ITZ did not result in any change compared to solvent. This hints 
towards a functional contradiction, which was also observed in vivo (see below). Thus, the 
lack of response due to (calcitriol) single treatment might be due to the mouse background 
that might have caused a diminished response, whereas the contradiction of the combination 
might result from too high concentration of the drugs, leading to functional antagonism as 
revealed by the Fa-CI Plot (compare Fig. 39 and see below). 
The calcitriol/azole combination was also employed in vivo in BCC-bearing 
Ptchflox/flox CreERT2+/- mice. The dose of 100 ng/kg calcitriol and 100 mg/kg azole was well-
accepted by the mice, since no major adverse effects and no weight loss was observed. 
Unexpectedly, neither of the single treatments led to a significant inhibition of Hh signaling 
(compare Figs. 20 and 21); although a tendency for either single treatment was apparent. 
Surprisingly, Hh signaling was activated when calcitriol was combined with either ITZ or 
KTZ as judged by an increase in Gli1 and Gli2 expression. This increase reached statistical 
significance for calcitriol/ITZ compared to single ITZ treatment but not to solvent-treated 
animals. These findings indicate that the two drugs negatively influence each other in vivo 
with respect to Hh pathway inhibition. 
The weak inhibition of Hh signaling by calcitriol in the mouse model for BCC was 
unexpected and strongly contradicted our previous findings (Uhmann et al. 2011a; Uhmann et 
al. 2012), especially because the same calcitriol treatment scheme was applied. However, the 
differences might have been caused by the background of the animals. Whereas the mice used 
by Uhmann et al., were on a mixed C57BL/6N x BALB/c background (Uhmann et al. 2007; 
Uhmann et al. 2011a), the mice used in this study were C57BL/6N. This might have 
introduced some regulatory sequences or modifier regions that may have caused the tumors to 
be more aggressive or less susceptible towards the treatment. Accordingly, using a mixed 
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C57BL/6N x BALB/c background it takes 45 days for the tumors to be macroscopically 
visible (Nitzki et al. 2010), whereas in this study the tumors were already visible starting from 
day 30 post-induction, indicative for enhanced growth rates. Hence, the effect of modifier 
regions affecting tumor aggressiveness or therapeutic outcome has been described in many 
murine disease models including those of rhabdomyosarcoma (Hahn et al. 2004), kidney 
diseases (Salzler et al. 2007), lung cancer (Manenti et al. 1997), colon carcinoma (Dietrich et 
al. 1993) or mammary tumor metastasis (Hunter et al. 2001). Therefore it is possible that the 
two mouse backgrounds (i.e. C57BL/6N x BALB/c and C57BL/6N) are suitable to map 
genomic regions involved in treatment-susceptibility or aggressiveness of BCCs. 
In contrast to Hh signaling, Cyp24a1 was strongly induced upon calcitriol and 
calcitriol/azole treatment (Figs. 20 and 21). This is in line with our previous findings that 
calcitriol treatment of mice led to increased Cyp24a1 expression levels (Uhmann et al. 2011a; 
Uhmann et al. 2012). Importantly, a tendency for an increased Cyp24a1 expression after 
calcitriol/ITZ treatment compared to single calcitriol (Fig. 21) was detected. This is similar to 
our data obtained in vitro (compare Fig. 11) and strengthened the suggestion that ITZ 
stabilizes calcitriol levels in vivo, especially since similar observations were also made by 
others using in vitro approaches (Hansdottir et al. 2008; Vanden Bossche et al. 2004). 
Furthermore the increased Cyp24a1 expression can be used as a surrogate marker for 
successful tumor penetration of calcitriol, thus excluding an inappropriate treatment 
procedure. 
We furthermore assessed the expression levels of tissue-specific differentiation 
markers. The analyses revealed that K10 and Tgm1 expression levels significantly increased 
upon calcitriol/ITZ treatment, but not by any single treatment or calcitriol/KTZ treatment. 
Since a) ITZ probably stabilizes intracellular calcitriol levels (see above), b) calcitriol/ITZ 
activated Vdr signaling (as seen by increased Cyp24a1 expression) and c) K10 and Tgm1 are 
known to be regulated by active Vdr signaling (Bikle 2004; Blanpain and Fuchs 2006) the 
increased expression of these differentiation markers most likely resulted from increased 
and/or stabilized calcitriol levels after calcitriol/ITZ treatment. Again, the data of the single 
calcitriol treatment contradicted previous findings which showed that K10 and Tgm1 
expression levels were increased upon in vivo application of calcitriol (Uhmann et al. 2011a), 
although neither the amount of calcitriol (100 ng/kg/d) nor the treatment length (90 days) was 
changed. Additionally, the analyses of the tumor area demonstrated that neither calcitriol, nor 
any other treatment, significantly reduced the tumor size. Given the fact that reduction of 
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tumor size is seen upon calcitriol-treatment in the C57BL/6N x BALB/c BCC mouse model 
(Uhmann et al. 2011a) and has been described for ITZ-treated allografts of BCCs from  
K-14CreER;Ptch+/-;p53fl/fl (Kim et al. 2013; Kim et al. 2010) and human BCCs (Kim et al. 
2014), these contradictory data again may reflect differences in the genetic mouse 
backgrounds. Thus, the knowledge about the respective genetic modifiers that may be 
responsible for the decreased treatment susceptibility of BCC from Ptchflox/flox CreERT2+/- on 
a C57BL/6N x BALB/c background may contribute to the establishment of targeted and 
personalized therapy of this kind of tumor. 
We finally tested the efficacy of the calcitriol/ITZ treatment in ASZ001-transplanted 
nude mice. As shown in Fig. 11, cultured ASZ001 cells were sensitive towards the combined 
treatment. After successful establishment of the ASZ001 allograft mouse model (Fig. 22) the 
calcitriol/ITZ combination treatment was evaluated. This approach (Fig. 26) revealed that 
both, calcitriol and ITZ alone, efficiently inhibit Hh signaling This was in line with the in 
vitro data (see Fig. 11) and publications by ours and other labs (Kim et al. 2010; Kota et al. 
2011; Tang et al. 2011; Uhmann et al. 2011a; Uhmann et al. 2012). However, the 
combination of both drugs again negatively influenced each other with respect to Hh pathway 
inhibition, although not as strong as in Ptchflox/flox CreERT2+/- mice. Thus, Gli1 expression 
was higher after the combined treatment in comparison to the single treatments, but lower 
than solvent-treated mice. Besides, calcitriol treatment led to significantly enhanced Cyp24a1 
expression, whereas ITZ alone and the calcitriol/ITZ combination only slightly induced 
Cyp24a1 expression. The latter data again suggest that calcitriol and ITZ counteract their 
respective effects in vivo. However, calcitriol is known to induce the expression of the drug-
transporters Cyp3a23 (Xu et al. 2006) and CYP3A4 which potentiate the activity and interact 
with the other multi-drug transporter (P-gps) in rats and humans, respectively leading to 
increased drug clearance (Chan et al. 2004). Furthermore, ITZ is a known potent inhibitor of 
P-gps (Heiskanen et al. 2008) and other transporter of xenobiotica but is also a target of those 
transporters itself (Miyama et al. 1998). Due to these facts, we hypothesized that calcitriol, 
ITZ or both drugs might have led to the induction of drug transporters in BCC, which finally 
may have decreased the intracellular concentrations of the two drugs. This could explain the 
diminished antitumoral effects in vivo. Indeed, compared to calcitriol-treated tumors, 
calcitriol/ITZ treated tumors showed somewhat diminished intratumoral ITZ concentrations 
by LC-MS/MS. Similarly, Cyp24a1 induction in calcitriol/ITZ treated tumors was not as high 
as after single calcitriol treatment. Those observations indicate a decreased tumor penetration 
of the drugs. Due to these data we analyzed the expression levels of different Mdr transcripts 
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(Mdr1a, Mdr1b and Mdr2) but we did not detect any differential expression in the treatment 
cohorts. However, it is possible that other drug transporters are involved in export of 
intracellular ITZ. In addition, we cannot exclude an upregulation of drug transporters in other 
tissues by ITZ for example in the liver (Miyama et al. 1998). 
Like in BCC-bearing Ptchflox/flox CreERT2+/- mice we also analyzed the differentiation 
status of the allografted BCC. However, no significant changes of the K1, K10, Tgm1, Lor or 
Ivl expression were observed by neither single nor the combination treatment. Given the fact 
that 90 day-calcitriol treatment led to enhanced K10 and Tgm1 expression in BCC of 
Ptchflox/flox CreERT2+/- mice on a C57BL/6 x BALB/c background (Uhmann et al. 2011a), it is 
possible that the treatment scheme of 30 days (that has been applied in the allografted 
animals) might have been too short to achieve significant induction of keratinocyte 
differentiation. Since these markers were also not induced in BCC of Ptchflox/flox CreERT2+/- 
mice on the C57BL/6 background (see above), the lack again rather argues for genetic 
background reasons. Moreover, the treatment might have been more effective (concerning 
induction of differentiation and inhibition of tumor growth) by starting drug application 
directly after the transplantation like described by others (Kim et al. 2010), although it is 
common practice to allow the tumors to start growing (Ng and Curran 2011). 
In summary, we showed that our promising findings concerning the combination of 
calcitriol and ITZ obtained in vitro could not be recapitulated in two different animal models 
for BCCs. These observations demonstrate the importance and application of preclinical in 
vivo systems to test new drugs or drug combination before applying them to the clinics. 
Furthermore these findings should be taken into consideration by clinicians, since both, 
calcitriol and ITZ, are already approved drugs for the treatment of non-cancerous diseases like 
psoriasis (calcitriol) (Kircik 2009) as well as fungal infections (ITZ) (Doring et al. 2015) and 
are currently being tested as single drugs in clinical trial for the topical treatment of BCCs 
(NCT02120677; NCT01358045). 
Thus, future research should address the search for the genetic modifier region which 
is responsible for calcitriol insensitivity of Ptchflox/flox CreERT2+/- mice on a C57BL6/N 
background. It also would be of great interest to determine the reason for the counteraction of 
calcitriol and ITZ in vivo and to evaluate the combined calcitriol/ITZ therapy in other Hh-
driven cancers in vitro and in vivo. 
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7.2.2. Analysis of the influence of ITZ on calcitriol-metabolism 
Our in vitro approaches revealed an enhanced antitumorigenic effect of combined 
calcitriol/azole treatment. Azoles are known as general inhibitors of P450 enzyme like 1α-
hydroxylase and 24-hydroxylase, which are involved in calcitriol metabolism (Kota et al. 
2011; Muindi et al. 2010). Hence, we hypothesized that ITZ might mediate, aside from Smo 
inhibition, an additional antitumoral effect by preventing the degradation of calcitriol und thus 
potentiate the calcitriol-mediated effects. In fact, we observed a significant increase of 
Cyp24a1 expression after calcitriol/ITZ treatment compared to calcitriol alone in serum-
starved ASZ001 cells (Fig. 11) and in BCC from calcitriol/ITZ-treated Ptchflox/flox CreERT2+/- 
mice (Fig. 14). However, by LC-MS/MS-based quantification we showed that ITZ did not 
change calcitriol-synthesis or its degradation neither in ASZ001 nor HaCaT cells (Figs. 30 
and 31). These data suggests that ITZ does not have an impact on calcitriol bio-availability. 
However, the treatment with 25(OH)D3 and calcitriol of the MS-based experiments were 
conducted for 6 h and relatively high concentration of 25(OH)D3 (2 µM) and calcitriol 
(100 nM) were used. It is possible that the time of treatment period of 6 h was too short to 
induce efficient inhibition of the hydroxylases, leading to the different amounts of the vitD3-
derivatives or that the high intracellular amounts of 25(OH)D3 or calcitriol (due to the 
treatment) masked measurable differences. This incubation time was chosen because our 
timecourse experiment of 25(OH)D3 and vitD3 supplementation (compare chapter 6.3.1.2) 
showed that calcitriol synthesis is well-measurable within 6 h. Also, we wanted to observe 
ITZ-mediated inhibition of the enzymes 1α- and/or 24-hydroxylase rather than transcriptional 
responses. Beyond that, different cell types are also known to display different susceptibilities 
to inhibition of cytochrome P450 enzymes by azoles. Thus, it has been shown that vitD3 
supplementation in the presence of KTZ leads to the synthesis of significantly higher calcitriol 
levels in dendritic cells but not in monocyte-derived macrophages (Kundu et al. 2014). Thus, 
the proof whether ITZ influences calcitriol-synthesis or its degradation will require more 
experiments with longer vitD3 incubation times and a more sensitive method to detect subtle 
variations in calcitriol levels.  
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7.3. Role	of	calcitriol	in	Hh	signaling	
7.3.1. Ptch is dispensable for calcitriol synthesis, but essential for its release 
Our own research and those of others suggested that Ptch 1) exports vitD3-like and/or 
Hh-inhibitory molecules (Bijlsma et al. 2006; Uhmann et al. 2011a), 2) is involved in sterol-
transport (Bidet et al. 2011) and 3) is a homologue to RND-transporters that transport 
lipophilic molecules across membranes using a proton gradient (Taipale et al. 2002). Due to 
the fact that calcitriol is the only physiological Hh inhibitor that works in low doses (Uhmann 
et al. 2011a; Uhmann et al. 2012), we hypothesized that calcitriol might present an 
endogenous inhibitor of Smo that is released by Ptch in the absence of Hh ligands. Since the 
detection of calcitriol in the cell culture medium by means of underivatized LC-MS/MS 
analyses was not possible in our hands, we established a highly sensitive assay to measure 
calcitriol by induction of luciferase-expression. Using this assay we showed that wt Ptch, but 
not Ptch-/- fibroblast are able to release significant amounts of calcitriol into the cell culture 
medium (Fig. 34). The calcitriol concentration in the medium was likely less than 0.1 nM 
(compare fold-change induction of Figs. 35 and 34) and was not able to inhibit Hh signaling 
in Shh light II cells (Fig. 32). Similar effects were observed by CRC analyses in which 
0.1 nM calcitriol had only little potential to inhibit Hh signaling (Fig. 38). Although calcitriol 
release is difficult to assess, some reported the release of calcitriol in dendritic cells and 
macrophages (Kundu et al. 2014). However, the issue of how this release is mediated has not 
been addressed. It is known that the uptake of DBP-bound 25(OH)D3 is mediated by the 
multi-ligand receptor Megalin (Kaseda et al. 2011), but no reports for the release of vitD3-like 
molecules are available. Interestingly, it has also been described that Megalin mediates the 
Shh response in the nervous system (Ortega et al. 2012). A recent study showed the Ptch-
mediated release of 3β-hydroxysteroids including the calcitriol-precursors 7-DHC and vitD3 
and that those molecules are inhibitors of Hh signaling (Bijlsma et al. 2006). Accordingly, we 
provide evidence that the release of calcitriol is mediated by Ptch. 
Furthermore, we show that the Ptch status of cells does not influence the synthesis of 
calcitriol from its progenitors 25(OH)D3 and vitD3. Both wt Ptch and Ptch
-/-adult fibroblasts 
and the Ptch-deficient BCC cell line ASZ001 were able to synthetize calcitriol from its 
precursors (Fig. 36 and 37). These findings are in line with the plethora of different cell 
systems capable of the extra-renal synthesis of calcitriol like the skin (Vantieghem et al. 2006; 
Zehnder et al. 2001), the lung (Hansdottir et al. 2008) or cells of the immune system (Kundu 
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et al. 2014). Taken together our data demonstrate effective calcitriol synthesis and show that 
Ptch is dispensable for calcitriol synthesis. 
 
7.3.2. Calcitriol does neither bind to the CRD nor the 7TM of Smo 
We previously provided evidence that calcitriol inhibits Hh signaling independently of 
the Vdr presumably at the level of Smo because it cannot inhibit Hh signaling in Smo-/- cells 
but regains this ability upon Smo-overexpression (Uhmann et al. 2011a). This indicates that 
calcitriol might directly bind to and regulate Smo. As already mentioned, the Smo protein 
contains  two known binding sites for small molecules, which are the 7TM and the CRD. The 
7TM resembles the main binding site for (synthetic) modulators (see introduction) and the 
CRD is the exclusive binding site for oxysterols (Nachtergaele et al. 2012; Nachtergaele et al. 
2013; Nedelcu et al. 2013). ITZ, which also inhibits Hh signaling at the level of Smo, is 
thought to bind a site distinct from the 7TM or the CRD (Kim et al. 2010; Nachtergaele et al. 
2012). The fact that the CRD is the binding site for oxysterols led us to the initial assumption 
that calcitriol, as an oxidized distant, derivative of cholesterol, might bind to the CRD as well. 
Thus, we first performed CRCs to detect potential functional competitions of calcitriol with 
other Smo-modulators. We found that none of the 7TM-binders CP (Chen et al. 2002a), 
vismodegib (Nachtergaele et al. 2013) or SAG (Chen et al. 2002b), influenced the IC50 of 
calcitriol or vice versa. These findings indicate that calcitriol does not bind to the 7TM. 
Accordingly, the maximal pathway activation of SAG was reduced by increasing amounts of 
calcitriol. This is suggestive for non-competitive binding of both drugs (Litman et al. 1997). 
Interestingly, we observed a significant decrease of the IC50 of ITZ in the presence of 
calcitriol and vice versa. This potential synergistical modulation of Smo, indicates non-
competitive binding of the two drugs to Smo. In fact, these results are in line with the in vitro 
data obtained in ASZ001 (compare Fig. 11). Moreover, the analyses of the CRC data using a 
Fa-CI-Plot, showing that low to intermediate concentrations of calcitriol and ITZ synergize in 
Hh signaling inhibition, supported our interpretation of the results (Chou 2006; Chou 2010) 
(Fig. 39). Interestingly, the Fa-CI-Plot also revealed that high concentrations of both drugs led 
to antagonism. These findings might explain our results from the in vivo treatment studies, in 
which relatively high amounts of calcitriol and ITZ (100 ng/kg calcitriol and 100 mg/kg ITZ, 
respectively) were applied to the mice. Therefore, it is possible that the drug concentrations 
used in vivo were high enough to cause an antagonistic interplay of calcitriol and ITZ. This 
may have caused the lack or a diminished Hh signaling inhibition, which was seen in BCC 
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from Ptchflox/flox CreERT2+/- and ASZ001-allografted nude mice, respectively. Hence, the 
future in vivo experiments should also be conducted with lower concentrations of both drugs 
to ensure that they are applied in a synergistical concentration. 
Since Kim et al. reported a functional, non-competitive synergism of ITZ and KAAD-
CP (Kim et al. 2010), we also assessed the potential interaction of CP and ITZ. In contrast to 
Kim et al., our data obtained from the CRC analyses (Fig. 40) and the in vitro treatment of 
ASZ001 (Fig. 13) suggests that CP and ITZ do not functionally synergize. However, KAAD-
CP binds Smo with a higher affinity than CP (Chen et al. 2002a; Kim et al. 2010). Therefore, 
it probably interacts differently with ITZ and Smo, which might explain these contrasting 
results. Finally, we showed that calcitriol is a non-competitive inhibitor of 20(S)OHC, which 
binds to the CRD (Nachtergaele et al. 2012; Nachtergaele et al. 2013; Nedelcu et al. 2013). 
This is based on the observation that, similar to SAG, calcitriol does not change the ED50 of 
20(S)OHC but reduces the maximal pathway activation. Together these data suggest that 
calcitriol binds to a site distinct from the CRD or the 7TM. 
In order to verify our interpretation that calcitriol does not directly bind to the 7TM we 
furthermore performed BD-CP replacement assays (Dwyer et al. 2007; Kim et al. 2010) 
(Nachtergaele et al. 2013). CP, vismodegib and SAG significantly competed with BD-CP for 
binding on Smo, indicating that these drugs bind to the 7TM as described previously (Chen et 
al. 2002a; Chen et al. 2002b; Nachtergaele et al. 2013). In accordance to Nachtergaele et al. 
we also observed a competition of 20(S)OHC with BD-CP for Smo binding (Nachtergaele et 
al. 2013). Beyond that, we also observed a competition of ITZ with BD-CP. This observation 
is opposed to results described by Kim et al. (Kim et al. 2010). However, the fact that Kim et 
al. did not perform a statistical evaluation of their data questions their conclusion. Finally and 
in accordance with our hypothesis, we showed that neither calcitriol nor its precursors 
25(OH)D3 and vitD3 compete with BD-CP for Smo-binding. Due to the fact that BD-CP was 
significantly replaced by 7TM binders (i.e. CP, SAG, vismo) and also by the CRD binder 
20(S)OHC we conclude that calcitriol, 25(OH)D3 or vitD3 neither bind to the 7TM nor (at 
least calcitriol) the CRD of Smo. Notably, our observation that vitD3 does not bind to the 
same site as CP, is in contrast to previously published data by Bijlsma et al., who showed that 
Smo binding of vitD3 can be competed with CP (Bijlsma et al. 2006). However, they were 
employing a yeast-expression system and measured residual radioactivity of [3H]-labeled 
vitD3 (Bijlsma et al. 2006), whereas we measured direct changes in fluorescence intensity, 
using an assay that is widely used and also might be the more physiological assay to analyze 
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Smo-binding (Chen et al. 2002b; Dwyer et al. 2007; Kim et al. 2010; Nachtergaele et al. 
2013; Nedelcu et al. 2013). Hence, the observed differences rather relate to the different 
methods applied. 
To verify the assumption that calcitriol does not bind to the CRD of Smo, Shh light II 
overexpressing wt Smo (Smowt) or CRD-deleted Smo (SmoΔCRD) were incubated with calcitriol 
and Hh signaling activity was analyzed. To ensure that endogenous Smo does not interfere 
with our interpretation we also transduced Smo-/- cells with the plasmids (Figs. 49 and 50). 
The overexpression of both Smo variants resulted in strongly enhanced basal pathway activity 
which was in line with data of other labs (Myers et al. 2013; Taipale et al. 2000; Taipale et al. 
2002). This enhanced pathway activity is most likely caused by excessive amounts of Smo, 
that can no longer be inhibited by the endogenous amounts of Ptch (Taipale et al. 2002). 
Accordingly, Myers et al. showed that pathway activation caused by overexpression of Smo 
can be inhibited by cotransfection of Ptch (Myers et al. 2013).  
The pathway inhibition by CP and calcitriol showed that, similar to CP which acts 
mainly at the 7TM (Chen et al. 2002a; Nachtergaele et al. 2013), the calcitriol treatment 
resulted in efficient Hh pathway inhibition in Smowt and SmoΔCRD overexpressing cells, too. 
This demonstrates that calcitriol inhibits Smo in a CRD-independent manner. Since we 
excluded a binding of calcitriol to the 7TM using the BD-CP competition assay these data 
indicate that calcitriol acts independently of the two binding sites. 
Besides, we tested the sensitivity of the Smowt and SmoΔCRD overexpressing cells for 
further pathway activation due to Shh-N-CM or SAG treatment. Others also reported that a 
further enhancement of Hh signaling activity of SmoΔCRD overexpressing cells by Shh-N-CM 
is not possible but that SAG treatment was still possible, whereas Smowt overexpressing cells 
still can be activated by Shh-N-CM and SAG treatment (Myers et al. 2013; Nachtergaele et 
al. 2013; Nedelcu et al. 2013). This lack of response might be caused by the strong 
overexpression of Smo facilitated by our pMSCV-expression system which leads to strong 
gene expression (Andersen et al. 2011) and likely resembles maximal pathway activity upon 
Smo overexpression (Rohatgi and Scott 2007; Taipale et al. 2000). Nevertheless, control 
experiments using untransduced Shh light II cells revealed that SAG and Shh-N-CM 
treatment indeed led to high activation of Hh signaling and that this induction can be 
effectively inhibited by calcitriol or CP. Thus, we conclude that the maximal induced pathway 
activity is reached in Smowt and SmoΔCRD overexpressing cells which enables us to analyze 
pathway inhibition without the presence of any inducer of Smo activity (e.g. SAG) that might 
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interfere with Smo-binding. The fact that calcitriol was able to inhibit Hh signaling in Smowt 
and SmoΔCRD overexpressing Shh light II and Smo-/- cells shows that calcitriol can act 
independently of the CRD. Our additional findings that calcitriol does not compete with BD-
CP, that mainly acts at the 7TM, further strengthens our hypothesis that calcitriol acts at a yet 
unidentified site on Smo. 
Nonetheless, beyond this conclusion we found that SAG-treated Smowt and SmoΔCRD 
overexpressing cells were not susceptible for CP-mediated Hh signaling inhibition. This 
observation might be explained by the fact that the occupancy of the 7TM by SAG 
(Dockendorff et al. 2012; McCabe and Leahy 2015; Wang et al. 2014) prevents the binding of 
CP, that can to a lesser extent also be observed in untransduced SAG-treated Shh light II 
(compare Fig. 49 C). A reduced susceptibility of CP due to SAG-treatment has also been 
described for C3H10T1/2 cells (Dockendorff et al. 2012), another in vitro model for the Hh 
pathway. Intriguingly, SAG-bound Smowt and SmoΔCRD were sensitive towards calcitriol-
mediated Hh signaling inhibition in Smo-/- cells (Fig. 50 D). This supports our hypothesis that 
calcitriol does not bind to the 7TM and exemplifies that calcitriol is a very potent inhibitor of 
Smo. In Smowt overexpressing Shh light II cells calcitriol does not mediate an inhibition of 
Hh signaling inhibition (Fig. 49 E) indicating that SAG-treatment results in an active state of 
Smo that is less prone to inhibition (Dockendorff et al. 2012; Wilson et al. 2009). Whether 
this observation is cell-type specific or due to the endogenous Smo present in Shh light II 
needs to be addressed in future studies. 
In contrast to SAG-treated cells, calcitriol as well as CP efficiently inhibited Shh-N-
CM-treated Smowt and SmoΔCRD overexpressing cells (Fig. 49 F). This, more physiological, 
process of Shh-induced Smo activation, caused by the removal of Shh-bound Ptch from the 
membrane (Rohatgi and Scott 2007), likely removes any Smo-inhibiting endogeneous 
molecules that were previously released by Ptch, thus relieving the binding pockets for 
calcitriol or CP. 
Finally, we made use of the SMO-M2 variant that is less sensitive but not resistant to 
Ptch-mediated inhibition and CP treatment (Taipale et al. 2000; Taipale et al. 2002). 
Remarkably, calcitriol as well as CP inhibit SMO-M2 activity but less efficient than wt SMO. 
But since we used relatively high concentrations of calcitriol and CP the inhibition of SMO-
M2 seems plausible. Especially since both drugs are more efficient in cells expressing wt 
SMO and since KAAD-CP has been previously reported to inhibit the murine equivalent of 
SMO-M2 as well (Taipale et al. 2000). The fact that overexpression of Ptch restores the 
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inhibition of SMO-M2 (Taipale et al. 2002) and assuming that calcitriol might resemble an 
endogeneous inhibitor of Smo, opens the possibility that increased amounts of Ptch result in 
increased amounts of calcitriol to be released. This would resemble our findings that higher 
than physiological concentrations (i.e. 10 nM) of calcitriol can inhibit SMO-M2. Furthermore, 
since the M2-mutation is located at the 7th transmembrane domain (Taipale et al. 2002), these 
observations foster our assumption that calcitriol acts independently of the 7TM. 
Nonetheless, we admit that our experiments do not show a direct binding of calcitriol to Smo. 
Thus, we cannot exclude the unlikely event that a yet unidentified protein/peptide facilitates 
the inhibitory effects on Smo. Our approaches in developing an ELISA to measure Smo-
binding failed due to the lack of specificity and appropriate positive controls. However, 
radioactively or fluorescently labeled calcitriol would be beneficial to perform an assay 
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7.4. Calcitriol	as	a	candidate	molecule	for	the	Ptch/Smo	interaction	
The currently accepted model for the Ptch/Smo interaction is that Ptch releases a small 
molecule that inhibits or activates Smo and thereby limits the presence or absence of this 
putative molecule (Albert and Hahn 2014; Briscoe and Therond 2013; McCabe and Leahy 
2015; Myers et al. 2013; Nachtergaele et al. 2013; Nedelcu et al. 2013; Roberg-Larsen et al. 
2014; Wang et al. 2014). Our data provides evidence that this putative molecule is calcitriol. 
First, this putative molecule needs to be available locally. Indeed, our data show that 
calcitriol can be synthesized in non-renal cells including fibroblasts and a BCC cell line. 
Similar observations were made by other groups who showed calcitriol synthesis in the skin 
(Vantieghem et al. 2006) or the lung (Hansdottir et al. 2008).  
Second, the putative inhibitor needs to be released by Ptch. Accordingly, we show that 
wt Ptch, but not Ptch-/- cells can release calcitriol into the cell culture medium (Fig. 34). This 
indicates that Ptch is indispensable for calcitriol secretion. The released amount of calcitriol is 
extraordinarily low (0.1 nM) which correlates with the low calcitriol concentration in human 
blood serum (38 to 134 pM) (Hollis 2010).  
Third, the putative molecule needs to be able to modulate Smo activity. Here and 
previously (Uhmann et al. 2011a; Uhmann et al. 2012) we show that calcitriol inhibits Smo 
activity by a new, uncharted binding site. Furthermore, this is the first report of a 
physiologically occurring sterol-based molecule with Smo-inhibitory capacity, whereas all 
other reports have identified oxysterols with Smo-activating activity. 
A recent study suggests that neither the CRD nor the 7TM are the major site of Smo 
regulation (Myers et al. 2013). In addition, the CRD is thought to rather function as a site for 
fine-tuning Smo’s activity (Myers et al. 2013; Nedelcu et al. 2013). This is in line with our 
analyses showing that calcitriol does not bind to the 7TM because it does not compete with 
known 7TM-binders (compare Figs. 38, 41 and 46) and also can inhibit mutant SMO-M2 
(compare Fig. 51) that carry a mutation in the 7TM (Taipale et al. 2000). Calcitriol also does 
not bind to the CRD as it inhibits Hh signaling activity in SmoΔCRD-overexpressing Shh light 
II and Smo-/- cells (Figs. 49 and 50) and acts as a non-competetive inhibitor of 20(S)OHC 
(Fig. 41). Recent publications also describe potential candidates for the Ptch/Smo interaction. 
As stated above are oxysterols capable to induce Hh signaling via binding to the Smo CRD 
(Corcoran and Scott 2006; Nachtergaele et al. 2012; Nachtergaele et al. 2013; Nedelcu et al. 
2013), although these have been ruled out as the key effectors of Hh signaling (Myers et al. 
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2013). Other candidates are lipids or other sterols that have been shown to traffic through Ptch 
and to inhibit Smo in D. melanogaster (Khaliullina et al. 2009), as well as endocannabinoids 
that are present in lipoproteins (Khaliullina et al. 2015). Another group proposed that Ptch 
inhibits the generation of phospholipid phosphatidylinositol-4 phosphate (PI4P) that is able to 
activate Smo (Yavari et al. 2010). 
In order to validate our data it would be helpful to use labeled calcitriol and track its 
sub-cellular fate in the presence or absence of Ptch, as described in a recent study using the 
Smo-activating oxysterol 20(S)OHC (Peyrot et al. 2014). In addition, mice defective in 
calcitriol synthesis or degradation could help to analyze if the lack or excess of calcitriol 
mimics phenotypes associated with high or low Hh signaling activity, like the murine model 
systems for SLOS-like diseases (Cooper et al. 2003; Cunniff et al. 1997; Opitz et al. 1987; 
Porter 2006; Tint et al. 1994; Wassif et al. 1998). 
Furthermore it is of importance to unravel the Smo-binding site of calcitriol. This 
could be achieved by competition assays using immobilized calcitriol (e.g. by beads or using 
biotin-tags) and mutant Smo proteins that lack different domains. Similar experiments have 
been performed by Nachtergaele et al. and Necelcu et al. to identify the Smo-binding site of 
20(S)-OHC (Nachtergaele et al. 2013; Nedelcu et al. 2013). The generation of various Smo 
mutants lacking different domains, like the extracellular linker domain connecting the CRD 
and the heptahelical bundle or the intracellular c-terminal tail, will allow for the identification 
of the calcitriol binding pocket of Smo.  
Moreover, it would be interesting to generate the 3D-structure of calcitriol-bound 
Smo. This has already been done for several 7TM-binders such as SANT-1, CP and SAG 
(McCabe and Leahy 2015; Wang et al. 2014; Wang et al. 2013). The results clearly 
demonstrate that they all are bound to the same cavity, with however different orientation and 
penetration depth. This caused either agonistic or antagonistic properties of the compounds 
and also explained the fact that some compounds still can inhibit treatment resistant variants 
of Smo (Wang et al. 2014).  
Finally, it would be interesting to see whether calcitriol is the only endogenous 
inhibitor of Smo or if other endogenous molecules exist that act on Smo and are released from 
Ptch and if this is a conserved mechanism across mammals and during development. 
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9. Abbreviations 
#   number 
%   percent 
‘   minute 
‘’   second 
°   degree 
µ   micro 
µ   micro 
1st   first 
1α,24,25(OH)3D3 1alpha,24,25-trihydroxy vitD3 
24,25(OH)2D3  24,25-dihydroxy vitD3 
25(OH)D3  25-hydroxy vitD3 
7-DHC   7-dehydrocholesterol 
7TM   seven-transmembraneous domain 
∞   unlimited 
A   Ampere 
Ab   antibody 
Ad libitum  lat. at liberty 
AD   activation domain 
AG   stock company (german: Aktiengesellschaft) 
ANOVA  analysis of variance 
AU   arbitrary unit 
Axxx   absorbance at xxx nm 
BCC   basal cell carcinoma 
BCNS   basal cell nevus syndrome 
BD   binding domain 
BD-CP   BODIPY-cyclopamine 
BODIPY  boron-dipyrromethene 
bp   base pair 
BrdU   5-bromo-2’-deoxyuridine 
BSA   bovine serum albumin 
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C   Celsius 
c   centi 
c   concentration 
CA   California 
Ca2+   calcium 
CaCl2   calcium chloride 
cal   calcitriol 
CDF   cumulative distribution function 
CDK   cyclin-dependent kinase 
CDKN1A  cyclin-dependent kinase inhibitor 1A 
cDNA   complementary DNA 
CHIP   chromatin immunoprecipitation 
CI   combination index 
Ci   cubitus interruptus 
CM   conditioned medium 
CMV   cytomegalovirus 
Co   company 
CoM   control medium 
CP   cyclopamine 
CRC   concentration-response curve 
CRD   cysteine rich domain 
Ct   threshold cycle 
CTD   C-terminal domain 
Cyp24a1  cytochrome P450 24a1 
Cyp27a1  cytpchrome P450 27a1 
Cyp27b1  cytochrome P450 27b1 
D   aspartic acid (amino acid) 
DAPI   4′,6-diamidin-2-phenylindol 
DBP   vitamin D binding protein 
ddH2O   double-distilled water 
DHCR24  3β-Hydroxysterol-δ24-reductase 
 Abbreviations 
- 149 - 
 
DHCR7  7-dehydrocholesterolreductase 
Dhh   Dessert hedgehog 
Disp   Dispatched 
DMEM  Dulbecco’s modified eagle medium 
DMSO   dimethylsulfoxid 
DNA   deoxyribonucleic acid 
dNTP   deoxynucleotide 
DTT   dithiothreitol 
E. coli   Escherichia coli 
e.g.   exempli gratia (lat. for example) 
EC50   half-maximal effective concentration 
ED50   half-maximal effective dose 
EDTA   ethylenediaminetetraacetic acid 
EGFP   enhanced GFP 
EMSA   electrophoretic mobility shift assay 
et al.   et alii (lat. and others) 
EtOH   ethanol 
Fa   fractional inhibition 
FCS   fetal calf serum 
FDA   Federal Drug Agency 
Fig   figure 
FITC   fluorescin isothiocyanate 
Fu   Fused 
g   gramm 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
gDNA   genomic DNA 
GFP   green fluorescent protein 
Gli   Glioma-associated oncogene family member 
Gliact   Gli activator form 
GliBS   Gli binding site 
Glirep   Gli repressor form 
 Abbreviations 
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GmbH & Co KG limited partnership with a limited liability company as general partner  
(german: Gesellschaft mit beschränkter Haftung Compagnie und 
Kommanditgesellschaft) 
GmbH   limited liability company (german: Gesellschaft mit beschränkter Haftung) 
GPCR   G-protein coupled receptor 
h   hour 
HCl   hydrochloric acid 
HE   haematoxylen/eosin 
Hh   Hedgehog 
HPLC   high-pressure liquid chromatography 
Hprt   hypoxanthine phosphoribosyltransferase 1 
HRP   horse-raddish peroxidase 
HSC70   heat-shock protein 70 
i.e.   id est (lat. that is) 
i.m.   intramuscular 
i.p.   intraperitonealy 
IC50   half-maximal inhibitory concentration 
IHC   immunohistochemistry 
Ihh   Indian hedgehog 
Inc.   incorporated 
ITZ   itraconazole 
Ivl   Involucrin 
K1   Keratin 1 
K10   Keratin 10 
KAAD-CP 3-Keto-N-(aminoethyl-N’-aminocaproyldihydrocinnamoyl)-cyclopamine 
kb   kilobase 
KCl   potassium chloride 
KH2PO4  monopotassium phosphate 
KTZ   ketoconazole 
L   leucine (amino acid) 
l   liter 
LAR II   Luciferase Assay Reagent II 
 Abbreviations 
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LB   lysogeny broth 
LC   liquid chromatography 
Leu   leucine (amino acid) 
log   logarithm 
LOH   loss-of -heterozygosity 
Lor   Loricrin 
Ltd.   limited 
m   meter 
m   milli 
M   molar 
m   murine 
M2H   mammalian-two-hybrid 
MB   medulloblastoma 
MD   Maryland 
Mdr   multidrug resistance protein 
MEF   mouse embryonic fibroblast 
MetOH   methanol 
min   minute 
MRM   multiple reaction monitoring 
MS   mass spectrometry 
MSCV   murine stem cell virus 
n   nano 
n.s.   not significant 
Na2HPO4  disodium hydrogen phosphate 
NaCl   sodium chloride 
NAD(P)H  nicotinamide adenine dinucleotide phosphate 
NMSC   non-melanoma skin cancer 
NPC1   Niemann-Pick C1 disease protein 
OD   optical density 
O/N   overnight 
p   pico 
 Abbreviations 
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p   plasmid 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
P-gp   P-glycoprotein 
pH   lat. potentia hydrogenii 
PI   propidium iodide 
PLB   passive lysis buffer 
POD   peroxidase 
PS   penicillin/streptomycin 
PSMF   phenylmethanesulfonylfluoride 
Ptch   Patched1 
Ptch2   Patched2 
qRT-PCR  quantitative real-time PCR 
Ras   Rat sarcoma 
RMS   rhabdomyosarcoma 
RNA   ribonucleic acid 
RND   resistance-nodulation-division 
ROI   region of interest 
rpm   rounds-per-minute 
rRNA   ribosomal RNA 
RT   room temperature 
RXRα   retinoid X receptor alpha 
SAG   Smo agonist 
SANT1   Smo antagonist 1 
SC5D   3β-Hydroxysteroid-δ5-desaturase 
SCC   squamous cell carcinoma 
SDS   sodium dodecyl sulfate 
sec   second 
SEM   standard error of the mean 
Shh   Sonic hedgehog 
SLOS   Smith-Lemli-Opitz syndrome 
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Smo   Smoothened 
SOC   super optimal broth with catabolite repression 
SPE   solid phase extraction 
SPF   specified pathogen-free 
SSD   sterol-sensing domain 
Tab   table 
TBP   TATA-binding protein 
TBS   TRIS-buffered saline 
Tet   tetracycline 
TF   transcription factor 
TGF-β   Transforming growth factor beta 
Tgm1   Transglutaminase 1 
TK   thymidine kinase 
TRIS   tris(hydroxymethyl)aminomethane 
Trp   tryptophan (amino acid) 
U   unit 
USA   United States of America 
UV   ultraviolet 
V   Volt 
v   volume 
Vdr   vitamin D3 receptor 
VDRE   vitamin D response element 
vismo   vismodegib 
vitD3   vitamin D3 
vs   versus 
W   tryptophan (amino acid) 
W   Watt 
w   weight 
WHO   World Health Organization 
wk   week 
Wnt   wingless-type MMTV integration site family 
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wt   wildtype 
x g   gravitational force 
x   times 
Y   tyrosine (amino acid) 
α   alpha 
β   beta 
Δ   delta 
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Appendix 01: Plasmid map of pHAGE mSmo cherry plasmid. The plasmid was used to subclone the mSmo 
mCherry (depicted in green) fusion gene into the pMSCVpuro vector (Clontech, see chapter 4.9, table 12). The 
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Appendix 02: Plasmid map of pMSCV mSmowt cherry plasmid. The plasmid was used to generate stably 
Smowt overexpressing Shh light II and Smo-/- cell lines. The map was created using SnapGene Viewer. 
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Appendix 03: Plasmid map of pMSCV mSmoΔCRD cherry plasmid; The plasmid was used to generate stably 
SmoΔCRD overexpressing Shh light II and Smo-/- cell lines. The map was created using SnapGene Viewer. 
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